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Abstract 
Platelets are small anucleate blood cells that plug holes in damage blood vessels.  They do so 
by adhering to exposed extracellular matrix proteins at sites of injury and aggregating 
together.  Platelet responsiveness to injury is controlled by a diverse repertoire of surface 
receptors that can be divided into two broad categories based on how they signal; the tyrosine 
kinased-linked receptors and the G protein-coupled receptors (GPCRs).  There has been much 
work on elucidating the functions of tyrosine kinases in platelets, whereas protein tyrosine 
phosphatases (PTPs) have been under-investigated.  To date, six non-transmembrane PTPs 
(NTPTPs), PTP-1B, Shp1, Shp2, MEG2-PTP, LMW-PTP and HePTP and a single receptor-
like PTP (RPTP), CD148, have been identified in platelets.  The main objective of this thesis 
was to determine the functional role of CD148 in platelets, which had never been studied in 
platelets.  Using a mouse model, I demonstrate that CD148 is a critical positive regulator of 
signalling from the main collagen activation receptor GPVI and the fibrinogen integrin 
αIIbβ3, and also plays a minor role in regulating thrombin and thromboxane A2 (TxA2) 
mediated aggregation and secretion via the PAR-4 and TP receptors, respectively.  The 
molecular mechanism of how CD148 regulates signalling from so many receptors is by 
maintaining a pool of active Src family kinases (SFKs) in platelets, which it does by 
dephosphorylating a tyrosine residue in the C-terminal of all SFKs.  In an attempt to identify 
other PTPs that perform a similar function to CD148 in platelets, I analyzed platelets from 
PTP-1B- and TC-PTP-deficient mouse models for functional and phosphorylation defects.  
PTP-1B-deficient platelets exhibited minor aggregation/secretion and phosphorylation defects 
relative to CD148-deficient platelets; and TC-PTP, which I show to be expressed in human 
and mouse platelets for the first time, is involved in platelet development.  My conclusion is 
that CD148, PTP-1B and TC-PTP have distinct functional roles in platelets. 
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1.1  Platelet Overview 
 
Platelets play a fundamental role in blood clotting and wound repair.  In the event of vascular 
injury, the sub-endothelial extracellular matrix (ECM) becomes exposed. Exposure of 
circulating platelets to the ECM triggers their activation and subsequent formation of a 
haemostatic plug, preventing excessive blood loss.  This process is crucial for normal 
haemostasis.  However, unwanted platelet activation can have severe, adverse affects on 
human health.  Uncontrolled thrombus formation in diseased vessels such as at the sites of 
ruptured atherosclerotic plaques, can lead to occlusion of the vessel resulting in myocardial 
infarction or stroke, which combined are the leading cause of death in the western world.  
Platelets are therefore a major target for current and new anti-thrombotic drugs. 
 
 
1.2  Platelet Formation 
 
Platelets are one of several types of blood cells that exist in the human body.  All blood cells 
are related by a common ancestry, the haematopoietic stem cell (HSC), which resides in the 
bone marrow of adults.  HSCs give rise to all the different types of blood cells and also have 
the capacity to self renew, so that there is always a pool of HSCs at sites of haematopoiesis.  
Blood cells are divided into two broad categories, the myeloid (macrophages, neutrophils, 
basophils, eosinophils, erythrocytes, platelets) and lymphoid (T and B cells) lineages (Figure 
1.1).  It is well established that platelets and erythrocytes (both of which are anucleate) are 
derived from a common progenitor, the colony forming unit-megakaryocyte/erythroid, which 
bifurcates into the megakaryocyte and erythroid lineages.  Megakaryocytes are large polyploid 
cells that reside in the bone marrow and produce platelets, which enter the peripheral 
circulation.  Immature megakaryocytes migrate along a SDF-1α gradient from the bone niche 
to the vascular niche in the bone marrow where they release platelets into the circulation 
(Avecilla et al. 2004).  Megakaryocytes seldom if ever enter the circulation.  The most well 
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established model of how platelets are formed is the proplatelet model (Italiano et al. 2003; 
Battinelli et al. 2007).  At the vascular niche, megakaryocytes extend long, dynamic 
protrusions called ‘proplatelets’ into microvessels and platelets bud off of these protrusions 
(Figure 1.2) (Italiano et al. 2003; Battinelli et al. 2007).  It is unclear how these bud-like 
structures that give rise to platelets are released from the proplatelet extensions.  Platelet 
formation is regulated by the cytokine thrombopoietin, which is synthesized by the liver and 
kidneys and signals through the c-Mpl receptor on megakaryoctyes (Kaushansky 2009).  It is 
estimated that each megakarycoyte produces between 5,000 – 10,000 platelets in its lifetime 
(Italiano et al. 2003).  The physiological concentration range of platelets in the circulation of a 
healthy adult human is 1.5 – 4 × 109/litre, which is approximately 2,000-fold lower than the 
concentration of erythrocytes (A. Michelson, Platelets, 2nd Edition).  The lifespan of a human 
platelet is 7 – 10 days.  Old and defective platelets are removed from the circulation by 
resident phagocytes in the spleen and liver (A. Michelson, Platelets, 2nd Edition).   
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Figure 1.1: Haematopoiesis. A schematic representation of the various blood cell lineages in 
the human body including the pathway of platelet formation. 
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Figure 1.2:  Proplatelet model of platelet formation from megakaryocytes.  A number of 
events occur during the transition of an immature megakaryocyte to the release of platelets. 
Firstly the immature megakaryocyte undergoes endomitosis and transcriptional activation. 
Organelle synthesis and platelet-specific protein amplification then follows before the 
formation of microtubules within the cell, which move towards the cortex. The next stage is 
the initiation of proplatelet formation. Large pseudopodia elongate from the megakaryocyte 
and organelles are moved individually over the microtubules into the proplatelet ends, where 
nascent platelets assemble. The entire cytoplasm of the megakaryocyte is transformed into a 
mass of proplatelets, which bud off into the microcirculation where new platelets are released. 
(figure adapted from A. Michelson, Platelets, 2nd Edition) 
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1.3  Platelet Structure 
Since platelets are sub-cellular fragments of megakaryocytes, they are composed of 
megakaryocyte membranes, cytoplasm, granules and organelles, but lack a nucleus.  Platelets 
are the smallest of the blood cells and have a discoid shape when they are quiescent or 
‘resting’.  The dimensions of a normal resting human platelet are 2 – 5 μm in diameter and 
approximately 0.5 μm in thickness (A. Michelson, Platelets, 2nd Edition).    The small size and 
discoid shape enables platelets to be pushed towards the vessel edge by larger blood cells 
(primarily erythrocytes) in flowing blood, positioning them close to the endothelium, ideally 
placed to detect and rapidly respond to any vascular damage (Ruggeri 2009).  The surface of 
the resting platelet appears featureless and lacks any protrusions.  High-resolution scanning 
electron microscopy shows that the platelet plasma membrane is made up of many tiny folds 
that provides additional membrane needed when platelets spread on surfaces (Hartwig 2006).  
The plasma membrane also has a large network of invaginations called the open canalicular 
system (OCS) that provides a large surface area between the cytoplasm and blood to facilitate 
exchange of small molecules, but restricts entry of larger proteins such as antibodies (Hartwig 
2006). 
            The cytoskeleton system of the platelet is essential for maintaining the discoid shape 
of the platelet as it encounters high fluid shear forces.  The cytoskeleton also mediates the 
morphological changes that a platelet undergoes after it becomes activated or comes into 
contact with a site of vascular injury.  The three layers of the platelet cytoskeletal system 
include: (1) a spectrin-based skeleton that is attached to the cytoplasmic surface of the plasma 
membrane; (2) a microtubule that is rolled into a coil and lines the circumference of the 
platelet; and (3) a rigid actin filament-based network that fills the cytoplasmic space of the 
cell (Italiano et al. 2003; Hartwig 2006).  Actin is the most abundant platelet protein.  Actin 
filaments are directly attached to the spectrin-based skeleton and are interconnected by filamin 
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and actinin (Italiano et al. 2003; Hartwig 2006).  Of importance to the structural organization 
of the resting platelet is the interaction between filamin and one of the most abundant platelet 
surface glycoproteins GPIb-IX-V, which mediates tethering to sites of vascular injury.  The 
microtubule coil beneath the plasma membrane is mainly composed of the β1 isoform of 
tubulin (Italiano et al. 2003; Hartwig 2006).  Platelet activation initiates remodelling of the 
cytoskeleton that is required for formation of filopodia and lamellipodia.  Actin-filament 
cleavage is mediated by gelsolin (Hartwig 2006).  Following platelet aggregation, platelets 
must generate a contractile force that acts to stabilize the aggregate and plug the site of 
inujury.  Platelets express non-muscle myosin IIA and B which are essential for generating the 
contractile force of platelets (Hartwig 2006).     
Since platelets lack a nucleus they have a limited ability to express new proteins and as 
such are equipped with a wide range of pre-synthesized molecules needed to exert their 
physiological responses.  The platelet cytoplasm contains typical cellular organelles such as 
mitochondria, lysosomes and endoplasmic reticulum as well as two types of platelet specific 
granules, α-granules and dense granules.  α-granules are the largest and most abundant 
platelet granules (~80 α-granules/human platelet) with a size of approximately 0.2 - 0.4 μm in 
diameter (Hartwig 2006; Italiano et al. 2009).  These granules store matrix adhesive proteins 
such as fibrinogen, fibronectin and VWF, and also have glycoprotein receptors embedded in 
their membranes, which promote adhesion between platelets and the ECM.  P-selectin, which 
is not expressed on the surface of resting platelets is stored in the membranes of α-granules as 
well as a proportion of the major platelet adherence receptors, GPIb-IX-V and the integrin 
αIIbβ3.  α-granules also contain coagulation factors, including prothrombin, factors V and 
XIII that promote thrombin generation and fibrin formation (Harrison et al. 1993). 
There are approximately 10-fold fewer dense granules than α-granules in platelets.  
Dense granules are also smaller in size than the α-granule with a diameter of approximately 
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0.15 μm.  Dense granules contain high concentrations of small molecules that play important 
roles in cell activation, including ADP, ATP, GDP, GTP, Ca2+ and the vasoconstrictor 
serotonin (Gunay-Aygun et al. 2004).  ADP is necessary for the ‘secondary’ platelet activation 
and platelet recruitment to the growing thrombi.  Dense and lysosomal granules also contain 
glycoproteins embedded in their membranes that are incorporated into the plasma membrane 
following granule fusion, including CD63, LAMP1, LAMP2 and CD68 (Nofer et al. 2004). 
There are a number of additional features which enable the platelet to carry out its 
physiological functions.  Platelets express high levels of glycoprotein receptors and signalling 
proteins in their plasma membrane that allow them to respond rapidly to vascular damage 
(described in detail below).  In addition, the surface of the activated platelet becomes enriched 
with negatively charged phosphatidylserine (PS), following membrane flipping, which 
provides a platform for assembly of clotting factors, thereby initiating increased thrombin 
production at the site of injury and enhancing platelet activation (Zwaal et al. 2004). 
 
1.4  Platelet Function 
 
The main physiological function of platelets is to plug holes in damaged blood vessels, thus 
preventing excessive blood loss.  There is a growing body of evidence that platelets are also 
involved in angiogenesis, inflammation and immunity.  Platelets rapidly adhere to exposed 
ECM, become activated and recruit other platelets from the circulation to form a haemostatic 
plug at a site of vascular injury.  The surface of activated platelets also accelerates thrombin 
generation at the site of injury that acts to consolidate the platelet plug.  The role of platelets 
in thrombus formation can be broken down into several stages described on the next page and 
in  Figure 1.3 (Ruggeri 2002; Auger et al. 2005; Bennett et al. 2009; Ruggeri 2009).  
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1) Tethering, rolling and adhesion.  Under high shear conditions (>500/s), such as 
those found in small arteries, arterioles and stenotic diseased arteries, platelets initially 
tether and role along the site of injury.  Tethering and rolling is mediated by the 
interaction between the high molecular weight plasma glycoprotein VWF that binds to 
exposed collagen at the site of injury, and the platelet surface receptor GPIb-IX-V.  
Platelet tethering and rolling on VWF occurs due to the rapid ‘on/off’ rates of 
association/dissociation and between GPIb-IX-V and immobilized VWF.  This 
interaction also generates a weak activatory signal within the platelets that is believed 
to prime them for further activation.  The VWF/GPIb-IX-V interaction is not required 
for platelet adhesion under low shear (<500/s) conditions, which are found in large 
arteries and veins.  Under these conditions, platelets bind directly to collagen and other 
ECM proteins via the integrins α2β1 (collagen), α5β1 (fibronectin), α6β1 (laminin) 
and αIIbβ3 (fibrinogen, fibronectin, VWF). 
  
2) Integrin activation and stable adhesion.  The initial tethering, rolling and non-firm 
adhesion of platelets with the ECM allows the low affinity collagen receptor GPVI to 
bind to collagen, cluster, and initiate a rapid, sustained activatory signal that triggers 
integrins (αIIbβ3 and α2β1) to undergo a conformational change from a low affinity to 
a high affinity state.  The platelets can then stably adhere to the exposed ECM and 
VWF. 
 
3) Spreading.  Platelet activation induces several dramatic morphological changes in the 
platelets mediated by cytoskeletal remodelling.  Firmly adherent, activated platelets 
extent long finger-like projections call ‘filopodia’ that then fill in with ‘lamellipodia’.  
Filopoida allow platelets to more firmly adhere to the damaged surface and also to trap 
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platelets flowing by in the bloodstream.  Spreading allows the platelets to cover a 
larger surface area of the vascular lesion. 
 
4) Secretion.  Activated platelets rapidly secrete the contents of their α- and dense 
granules, and synthesize and release the potent platelet agonist thromboxane A2 
(TxA2).  ADP and TxA2 released by activated platelets act synergistically to induce 
maximal platelet activation and also to recruit more platelets to the growing platelet 
plug.  The release of adhesion proteins such as fibrinogen and VWF contribute to 
formation and growth of the thrombus.  Released clotting factors (factors V, XIII and 
prothrombin) accelerate the localized generation of thrombin. 
 
5) Aggregation.  Plasma and platelet derived fibrinogen and VWF mediate platelet 
aggregation.  High affinity interactions are formed between αIIbβ3 and fibrinogen, 
and αIIbβ3 and VWF, leading to rapid thrombus growth. 
 
6) Thrombus stabilisation.  PS exposed on the activated platelet surface provides a 
platform for assembly of components of the coagulation cascade (factors V, VIII, XI 
and X) leading to thrombin generation (Figure 1.4).  Tissue factor exposed on 
damaged endothelial cells and smooth muscle cells in the vessel wall binds factor VIIa 
and initiates the extrinsic coagulation pathway, which also culminates in thrombin 
generation.  A high localized concentration of thrombin enhances platelet activation 
and converts fibrinogen to fibrin, stabilizing the thrombus and making it more resistant 
to embolization due to the shear forces. 
 
7) Clot retraction. The thrombus is stabilised by retraction of the platelet-
fibrinogen/fibrin aggregate.  Contractile forces are generated by non-muscule myosin 
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II pulling on the interlocking cytoskeletons of adjactent platelets.  The 
interconnections between platelets are mediated by fibrinogen-αIIbβ3 interactions. 
 
 
 
Figure 1.3: Platelet activation. A schematic representation of the various stages of platelet 
activation including: tethering, integrin activation and stable adhesion, spreading and 
secretion, aggregation and thrombus stability and clot retraction. 
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Figure 1.4: The coagulation cascade and platelet activation. Thrombin plays an essential 
role in both the coagulation cascade and platelet activation. Thrombin is generated on the 
surface of activated platelets. This greatly enhances the localised generation of thrombin. 
Surface thrombin is also protected from degradation and inhibition. 
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1.5  Platelet Receptors 
Platelets express a wide variety of surface receptors that regulate all aspects of platelet 
function.  They can be divided into two broad groups based on their signalling pathways: the 
tyrosine kinase-linked receptors and the G protein-coupled receptors (GPCRs).  A large 
proportion of these receptors have been well characterized, however, novel receptors/receptor-
like proteins continue to be discovered including CLEC-2, CD148 and CEACAM1 (Suzuki-
Inoue et al. 2006; Senis et al. 2009; Wong et al. 2009).  The functional roles and molecular 
functions of some of the most important and best characterized platelet receptors are described 
below. The focus is on tyrosine kinase-linked receptors as tyrosine 
phosphorylation/dephosphorylation is a major subject of investigation in this thesis, however, 
some of the main GPCRs will also be discussed. 
  
1.5.1  Tyrosine kinase-linked receptors 
Tyrosine kinase-linked receptors signal through a series of tyrosine phosphorylation events 
that culminate in specific cellular responses.  Some of the most important and well 
characterized tyrosine kinase-linked receptors in platelets are the collagen activation receptor 
GPVI/FcR γ-chain complex; the collagen adhesion integrin α2β1; the fibrinogen integrin 
αIIbβ3 and the VWF receptor GPIb-IX-V.  The distinguishing features of these receptors and 
their signalling pathways are described in detail in the following sections. 
 
1.5.1.1  Collagen receptors – GPVI and α2β1 
Collagen is the most abundant protein found in animals (Shoulders et al. 2009).  This fibrous 
structural protein is the main component of the ECM, lining all vessel walls.  Blood comes 
into contact with collagen following vessel injury.  There are many different forms of 
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collagen, but the more thrombogenic types are collagen I and III found in the most luminal 
regions of the subendothelial matrix (Shoulders et al. 2009).  Platelets express two receptors 
for collagen: the immunoreceptor GPVI and the integrin α2β1 (Nieswandt et al. 2003).  GPVI 
and α2β1 bind to different regions of collagen fibrils, GPVI binding to the GPO repeat and 
α2β1 binding to the GFOGER repeat with low and high affinities, respectively.  GPVI 
primarily mediates platelet activation through a rapid sustained signal and α2β1 primarily 
mediates firm adhesion (Nieswandt et al. 2003).   The two receptors act in a cooperative 
manner to reinforce each other’s activities, but also have distinct functions in regulating 
platelet adhesion and thrombus formation on collagen (Figure 1.6) (Holtkotter et al. 2002; 
Chen et al. 2003; Massberg et al. 2003; Auger et al. 2005; Sarratt et al. 2005). 
 
1.5.1.1.1  GPVI/FcR γ-chain complex 
GPVI is a 62 kDa type I transmembrane receptor composed of 2 IgG–like domains in its 
extracellular region, a mucin-like stalk, a transmembrane region, and a short 51-aa 
cytoplasmic tail that is expressed exclusively in platelets and megakaryocytes (Clemetson et 
al. 1999).  Resting human platelets express approximately 2,000 – 4,500 copies of GPVI on 
their surface, which does not increase following platelet activation (Best et al. 2003; Samaha 
et al. 2004).  However, it is shed from the surface of activated platelets as a means of 
regulating its signalling (Bergmeier et al. 2004; Gardiner et al. 2007).  Within the 
transmembrane region of GPVI is a positively charged arginine which mediates a constitutive 
noncovalent interaction with the FcR γ-chain (Watson et al. 2005).  The association of GPVI 
with the γ-chain is essential for expression of GPVI on the platelet surface and also critical for 
signalling (Gibbins et al. 1996; Poole et al. 1997).  GPVI exists partly as a dimer on the 
surface of resting platelets and ligand mediated clustering triggers signalling, as described 
below (Herr 2009; Horii et al. 2009; Jung et al. 2009).  Physiological ligands of GPVI include 
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collagen and laminin (Inoue et al. 2006).  Non-physiological ligands commonly used for 
research purposes include: the GPVI-specific collagen-derived synthetic peptide collagen-
related peptide (CRP) (Asselin et al. 1999); the snake toxin convulxin which also binds to 
GPIb-IX-V (Kanaji et al. 2003); and monoclonal antibodies which binds to the extracellular 
region of GPVI triggering signalling and shedding (Nieswandt et al. 2000; Nieswandt et al. 
2001; Boylan et al. 2004). 
The GPVI signalling pathway is essentially a hybrid of the T and B cell receptor 
signalling pathways sharing many of the same signalling molecules (Watson et al. 1998).  A 
critical early GPVI signalling event is phosphorylation of the conserved immunoreceptor 
tyrosine-based activation motif (ITAM) (YXX[L/I]X6-12YXX[L/I]) in the FcR γ-chain 
(Gibbins et al. 1996; Poole et al. 1997).  This is mediated by Fyn and Lyn which are 
constitutively associated with a proline-rich region in the cytoplasmic tail of GPVI via their 
SH3 domains (Figure 1.5) (Ezumi et al. 1998; Briddon et al. 1999).  Genetic evidence using 
Fyn and Lyn single and double-deficient mice demonstrated that Fyn positively regulates 
GPVI signalling; Lyn both positively and negatively regulates GPVI signalling; and other 
SFKs may compensate in the absence of Fyn and Lyn (Quek et al. 2000). 
The tyrosine kinase Syk subsequently binds to the phosphorylated FcR γ-chain ITAM 
via its tandem SH2 domains and undergoes autophosphorylation and phosphorylation by 
SFKs, which renders it maximally activated and also mediates interactions with other 
signalling proteins (Figure 1.5) (Sada et al. 2001; Watson et al. 2005).  Activated Syk, 
propagates the signal in lipid rafts, which involves the formation of the ‘LAT signalosome’ 
consisting of the adaptors LAT, SLP-76, Gads; Vav small GTPases; Tec family kinases; and 
effector proteins, including PI 3-kinase and PLCγ2 (Figure 1.5) (Watson et al. 2005).  PLCγ2 
induces formation of the second messengers 1,2-diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3).  DAG activates PKC and IP3 induces the release of Ca2+ from intracellular 
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stores and subsequent Ca2+ entry.  GPVI signalling culminates in rapid integrin activation, 
secretion of α- and dense-granules, and the release of the secondary mediators ADP and 
TxA2, which play an important role in amplifying primary stimulatory signals and thrombus 
growth (Nieswandt et al. 2003; Offermanns 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: GPVI signalling cascade. Crosslinking of GPVI induces tyrosine 
phosphorylation of the FcRγ-chain ITAM by the Src family kinases, Fyn and Lyn, which are 
constitutively bound to the proline-rich region in the GPVI cytosolic tail. The phosphorylated 
ITAM recruits Syk and initiates a signalling cascade that leads to formation of the LAT 
signalosome and subsequent activation of PLCγ2. PLCγ2 associates directly with LAT, and 
indirectly via the adapters Gads and SLP-76. Members of the Tec and Vav families support 
activation of PLCγ2 (figure reproduced from Watson et al. 2005). 
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Patients with quantitative or qualitative defects in GPVI exhibit a mild bleeding 
tendency due to masking from various compensatory mechanisms.  Several patients have been 
identified with reduced levels of GPVI surface expression due to auto-antibodies which 
induce GPVI shedding (Boylan et al. 2004).  Two recent reports identified patients with 
genetic defects in GPVI resulting in mild bleeding diathesis (Dumont et al. 2009; Hermans et 
al. 2009).  GPVI-deficient mice (genetically modified or GPVI-depleted) phenocopy the 
condition reported in GPVI deficient humans and confirm the essential role of this receptor in 
collagen-induced platelet activation, thrombosis and haemostasis (Konishi et al. 2002; Kato et 
al. 2003; Massberg et al. 2003; Konstantinides et al. 2006; Lockyer et al. 2006). 
 
1.5.1.1.2  Integrin α2β1 
The integrin α2β1 (also known as GPIa/IIa) was the first collagen receptor identified on 
platelets and serves mainly as an adhesion receptor (Figure 1.6) (Holtkotter et al. 2002; 
Nieswandt et al. 2003).  It is widely expressed and binds with high affinity to collagen types I 
– V (Holtkotter et al. 2002; Leitinger et al. 2002).  It is expressed at approximately 2,000 – 
4,000 copies per resting human platelet, which varies considerably between individuals (Best 
et al. 2003; Samaha et al. 2004).  Its level of expression does not change following platelet 
activation.  The integrin α2β1 is normally in a ‘low-affinity’ state on the surface of resting 
platelets and undergoes a conformation change to a ‘high-affinity’ state in response to agonist-
induced ‘inside-out’ signalling (Jung et al. 2000; Lecut et al. 2004).  In addition to mediating 
platelet adhesion, α2β1 also reinforces the low affinity GPVI-collagen interaction and 
mediates weak ‘outside-in’ signalling (Figure 1.6) (Jung et al. 2000; Inoue et al. 2003; 
Nieswandt et al. 2003).  Although the α2β1 signalling pathway contains many of the same 
signalling molecules as the GPVI signalling pathway, including Src, Syk, SLP-76, and PLCγ2, 
α2β1 signalling is much weaker than GPVI signalling, and likely plays little role in thrombus 
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formation (Jung et al. 2000; Inoue et al. 2003; Nieswandt et al. 2003).  Genetic and 
pharmacological studies demonstrate that α2β1 plays a minor role in platelet aggregate 
formation on collagen under flow and has little or no protective effect in arterial thrombosis 
(Nieswandt et al. 2001; Holtkotter et al. 2002; He et al. 2003; Kuijpers et al. 2003; Auger et 
al. 2005; Kuijpers et al. 2007). 
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Figure 1.6:  GPVI and α2β1 act in a cooperative manner to reinforce each other’s 
activity.  Cross-linking of GPVI with the agonists collagen, collagen-related peptide (CRP 
[GPO]10) and the snake toxin convulxin triggers platelet activation via a SFK-mediated 
signalling pathway (‘outside-in’ signalling) and also initiates activation of α2β1 (‘inside-out’ 
signalling) to promote stable adhesion. Binding of collagen to α2β1 reinforces collagen-GPVI 
interactions and also plays a minor role in platelet activation. The synthetic peptide GFOGER 
can also be used to initiate α2β1 ‘outside-in’ signalling. 
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1.5.1.2  Fibrinogen receptor – integrin αIIbβ3 
The integrin αIIbβ3 (also known as GPIIb/IIIa) is the most abundant glycoprotein expressed 
on the platelet surface (60,000 – 80,000 copies per resting human platelet).  This increases by 
30 – 50% following activation as αIIbβ3 stored in the α-granules translocates to the platelet 
surface (Shattil et al. 1998; Shattil et al. 2004).  The αIIb subunit is expressed exclusively in 
the megakaryocyte/platelet lineage, whereas the β3 subunit is expressed in various other cell 
types where it interacts with other α subunits (Shattil et al. 2004).  αIIbβ3 binds several 
ligands including fibrinogen, fibronectin and VWF.  In resting platelets, αIIbβ3 exists 
primarily in a ‘low-affinity’ state and undergoes a conformational change to a ‘high-affinity’ 
state in response to agonist-induced inside-out signalling (Shattil et al. 2004).  Ligand-
mediated clustering of αIIbβ3 triggers outside-in signalling, filopodia and lamellipodia 
formation, secretion and clot retraction (Shattil et al. 1998).  αIIbβ3 is essential for adhesion 
and aggregate formation at sites of vascular injury (Shattil et al. 2004; Coller et al. 2008). 
Many similarities exist between the outside-in signalling events of αIIbβ3 and GPVI 
signalling (Watson et al. 2005; Kasirer-Friede et al. 2007).  Fibrinogen-mediated clustering of 
αIIbβ3 leads to the sequential activation of SFKs, Syk family kinases, recruitment of adapter 
proteins such as SLP-76 and activation of downstream effector enzymes, including PLCγ2, PI 
3-kinase and Vav small GTPases (Watson et al. 2005; Kasirer-Friede et al. 2007).  Similar to 
the GPVI receptor, SFKs (Src and Fyn) are constitutively associated with the β3 subunit and 
Syk gets recruited to the intergrin in response to clustering.  However, it is not clear whether 
Syk interacts directly with the β3 subunit, or whether an ITAM-containing protein mediates 
this interaction (Woodside et al. 2001; Abtahian et al. 2006; Mocsai et al. 2006).  Two 
significant differences between αIIbβ3 and GPVI are that αIIbβ3 is not localized to lipid rafts, 
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whereas GPVI is; and the transmembrane adapter protein LAT is essential for GPVI 
signalling, whereas it is dispensable for αIIbβ3 signalling (Watson et al. 2005). 
            The molecular mechanism that initiates outside-in integrin αIIbβ3 signalling has been 
studied extensively over the past several years (Figure 1.7A).  In resting platelets, integrin 
αIIbβ3-associated Src is maintained in an inactive conformation by Csk which phosphorylates 
an inhibitory tyrosine in the C-terminal tail of Src (Tyr-529) (Obergfell et al. 2002; Arias-
Salgado et al. 2005).  Upon integrin clustering, Csk dissociates from the αIIbβ3-Src complex 
and is replaced by the non-transmembrane protein tyrosine phosphatase, PTP-1B, which 
dephosphorylates the inhibitory tyrosine of Src and initiates the signalling pathway (Arias-
Salgado et al. 2005).  Syk is then recruited to the complex and becomes activated through 
phosphorylation by Src and autophosphorylated (Woodside et al. 2001; Abtahian et al. 2006; 
Mocsai et al. 2006).  Other SFKs including Fyn, Lyn and Yes have been hypothesized or 
shown to play a role in initiating outside-in integrin αIIbβ3 signalling (Obergfell et al. 2002; 
Arias-Salgado et al. 2003; Reddy et al. 2008; Senis et al. 2009).  Deletion of the two 
conserved tyrosines in the β3-tail prevents the interaction with Syk, as does tyrosine 
phosphorylation at these sites (Woodside et al. 2001).  
Phosphorylation of the two conserved tyrosine residues in the β3 subunit has been 
shown to be functionally important (Law et al. 1999).  The N-terminal tyrosine is found 
within a conserved NPXY motif that mediates binding to proteins with phosphotyrosine 
binding (PTB) domains, such as the Dok family of adapter proteins (Figure 1.7B) (Law et al. 
1999; Calderwood et al. 2002; Arias-Salgado et al. 2003; Garcia et al. 2004).  The second 
tyrosine lies within NXXY motif and has been shown to bind a distinct group of PTB domain 
containing proteins, including Shc (Phillips et al. 2001).  Mutation of these tyrosines to 
phenylalanines results in increased bleeding and impairment in clot retraction in a knockin 
mutant mouse model (Law et al. 1999).  The molecular basis of this defect is presently not 
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known, but has been proposed to be due to the loss of binding of myosin to the 
phosphorylated β3 tail (Figure 1.7B) (Jenkins et al. 1998; Phillips et al. 2001). 
Lack or dysfunction of αIIbβ3 gives rise to Glanzmann thrombasthenia, a severe 
bleeding disorder associated with impaired adhesion and abolished aggregation of platelets 
(Nurden 2006).  Similarly, mice lacking the β3 integrin subunit phenocopy Glanzmann 
thrombasthenia (Hodivala-Dilke et al. 1999).  αIIb-deficient mice have also been generated 
and have been used to study haematopoiesis as well as platelet function (Tropel et al. 1997; 
Emambokus et al. 2003; Jacquelin et al. 2005).  β3-deficient mice have markedly prolonged 
tail bleeding times and display spontaneous hemorrhage in all developmental stages.  
Intravital microscopy studies revealed that β3-deficient mice do not form thrombi at sites of 
vascular injury (Ni et al. 2000).  The importance of αIIbβ3 in platelet adhesion and 
aggregation has made it an attractive pharmacological target for the prevention of ischemic 
cardiovascular events.  Strategies to inhibit its function include antibodies (abciximab), 
peptides adapted from snake venom (eptifibitide), and analogues of an RGD peptide 
(lamifiban and tirofiban) that inhibit ligand binding (Coller et al. 2008).  These inhibitors have 
been beneficial in a clinical setting but are not used extensively because of adverse bleeding 
side effects (Quinn et al. 2003). 
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Figure 1.7:  Integrin αIIbβ3 regulates Syk-dependent and -independent cascades. (A) 
Outside-in signalling through ligand engagement and clustering of integrin αIIbβ3 triggers a 
Syk-dependent intracellular signalling cascade. Syk is recruited to the β3-tail where it 
undergoes phosphorylation by Src. Activation of Syk leads to the activation of PLCγ2 through 
a pathway dependent on SLP-76 and Vav. (B) Tyrosine phosphorylation of two conserved 
tyrosines, possibly by Fyn, leads to binding and tyrosine phosphorylation of the adapters Shc 
and Dok2, and also recruitment of myosin.  
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1.5.1.3   VWF receptor – GPIb-IX-V complex 
GPIb-IX-V is an abundant (25,000 copies per platelet) structurally unique receptor complex 
expressed exclusively in platelets and megakaryocytes (Berndt et al. 2001).  Four different 
genes encode the receptor complex which consists of GPIb α- and β-subunits, GPIX, and 
GPV, all of which belong to the leucine-rich repeat protein superfamily (Berndt et al. 2001).  
Historically the receptor has been thought to be comprised of 2 GPIbα subunits, 2 GPIbβ 
subunits, 2 GPIX subunits and 1 GPV subunit (Berndt et al. 2001).  More recent, Luo et. al. 
suggests a molar ratio of 2:4:2:1 of GPIbα,  GPIbβ, GPIX, and GPV subunits, respectively 
(Luo et al. 2007).  
The primary function of GPIb-IX-V is to recruit platelets to the site of injury by 
reducing their velocity to enable the interaction of other, higher affinity receptors with the 
damaged surface.  At the high shear rates found in small arteries, arterioles, and stenosed 
arteries the interaction between GPIbα and VWF immobilized on collagen or on the surface 
of activated platelets is crucial for the initial tethering of the flowing platelets (Savage et al. 
1998).  This interaction on its own is insufficient to support stable adhesion.  The activation of 
integrins is required to mediate stable adhesion. 
The rapid on/off rate between GPIb-IX-V and VWF was first thought to be too short to 
allow sufficient time for a signal to be initiated (Goto et al. 1995; Savage et al. 1996).  It was 
assumed that the GPIb-IX-V/VWF interaction only provides a physical interaction that tethers 
platelets to the sub-endothelial matrix (SEM), allowing sufficient time for collagen to 
associate with the collagen receptors to elicit intracellular activation signals.  However, a 
growing body of evidence is now emerging that suggests GPIb-IX-V mediates intracellular 
signalling through Src family kinase and PLCγ2-related pathways, leading to platelet 
activation and αIIbβ3-mediated aggregate formation (Yap et al. 2002; Mangin et al. 2003).  A 
hypothetical GPIb-IX-V signal transduction pathway was proposed to take place 
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predominantly in lipid rafts (Ozaki et al. 2005).  In line with this model, GPIb-IX-V is 
constitutively associating with the p85 subunit of PI 3-kinase through 14-3-3ζ (Mangin et al. 
2004; Mu et al. 2008).  The interaction between GPIb-IX-V and VWF induces the binding 
between PI 3-kinase and Src, which then elicits downstream signals, leading to PLCγ2 
activation. 
Humans lacking or expressing dysfunctional GPIb-IX-V have a condition known as 
Bernard-Soulier syndrome (Lopez et al. 1998).  This is a congenital bleeding disorder 
characterized by mild thrombocytopenia, giant platelets and the inability of platelets to 
aggregate in response to the antibiotic ristocetin (Lopez et al. 1998).  Interestingly, GPIb-IX-V 
has also been shown to bind several coagulation factors including thrombin and factors XI, 
XII and VII, which may contribute to the severe bleeding defect exhibited by Bernard-Soulier 
syndrome patients (Dumas et al. 2003; Vanhoorelbeke et al. 2007).  
 
1.5.2  G protein–coupled receptors 
Platelets express a variety of GPCRs that play a central role in regulating platelet activation 
and inhibition (Woulfe 2005; Offermanns 2006).  GPCRs signal in a different way to the 
tyrosine kinase-linked receptors described above.  Some of the most important platelet 
activation receptors are: (1) the thrombin protease-activated receptors (PAR)-1 and PAR-4; 
(2) the ADP receptors P2Y1 and P2Y12; and (3) the TxA2 receptor TP.  Interestingly, several 
of these GPCRs also have a SFK signalling component.  Below are brief descriptions of each 
of these receptors and their signalling pathways in platelets. 
 
1.5.2.1  Thrombin receptors - Protease Activated Receptors (PARs) 
Thrombin (also known as factor IIa) is a soluble plasma serine protease generated through a 
series of enzymatic reactions, commonly referred to as the ‘coagulation cascade’ that takes 
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place on the surface of activated platelets (Hoffman et al. 2001).  The inactive zymogen 
prothrombin gets converted to active thrombin, which in turn cleaves soluble fibrinogen to 
form insoluble fibrin polymers (Figure 1.4).  Fibrin forms a mesh like structure that stabilises 
the thrombus (Figure 1.3).  Thrombin is also a powerful platelet agonist and triggers platelet 
activation by cleaving PAR-1 and PAR-4 to expose a short activatory peptide sequence 
known as a tethered ligand (Coughlin 2000).  Human platelets express approximately 1,000 – 
2,000 copies of PAR-1 (Brass et al. 1992; Ramstrom et al. 2008).  PAR-1 and PAR-4 are 
coupled to heterotrimeric G proteins.  Human platelets express PAR-1 and PAR-4 whilst 
mouse platelets express PAR-3 and PAR-4.  PAR-1 and PAR-4 can couple to Gq, G12/13 and Gi 
G protein α-subunits (Coughlin 2000).  The Gq pathway is the main PAR-1 and PAR-4 
activation pathway and leads to activation of PLCβ and generation of IP3 and DAG, which in 
turn activate PKC and Ca2+ mobilization respectively; the G12/13 pathway leads to activation of 
Rho kinase and cytoskeletal rearrangements; and Gi inhibits adenylyl cyclase, which promotes 
platelet activation (Coughlin 2000).  Although G protein-coupled, there is also a minor Src 
kinase component to the signalling pathway downstream of the thrombin receptors (Coughlin 
2000; Murugappan et al. 2005; Harper et al. 2006).  PAR-3 does not signal, but acts as a 
cofactor that binds and localises thrombin in close proximity to PAR-4 receptor in mouse 
platelets (Coughlin 2000).  
 
1.5.2.2  ADP receptors -P2Y1 and P2Y12 
ADP is a platelet agonist that is released from the dense granules upon activation.  ADP is 
also released from damaged endothelial cells at the sites of vascular injury (Gachet 2006).  
The physiological function of ADP is to enhance platelet activation via a positive feedback 
mechanism and is essential for recruitment of platelets to the growing thrombus (Offermanns 
2006).  Platelets express two ADP receptors, P2Y1 and P2Y12 (Gachet 2006).  Human 
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platelets express very few copies of P2Y1 (150 copies) and approximate ten-fold more of 
P2Y12, however, together they induce rapid and strong platelet activation.  P2Y1 couples to Gq 
and G12/13 heterotrimeric G protein α-subunits, whereas P2Y12 couples to the Gi (Gachet 
2006).  PI 3-kinase also contributes to P2Y12 signalling and Src plays a minor role.  P2Y1 
receptor triggers Ca2+ mobilization, platelet shape change and weak, transient aggregation in 
response to ADP (Gachet 2006).  P2Y12 inhibits adenylyl cyclase, causing a decrease in 
intracellular cAMP levels, as well as activating PI3-kinase and Rap-1B (Gachet 2006).  The 
functional outcome of P2Y12 activation is sustained platelet aggregation and amplification of 
signals initiated by other agonists, including collagen, TxA2 and the integrin αIIbβ3 (Gachet 
2006).  Interestingly, although P2Y1 and P2Y12 receptors signal through distinct mechanisms, 
Src kinase has been reported to be activated downstream of both the P2Y1 and P2Y12 
receptors (Hardy et al. 2004; Shankar et al. 2006).  Coactivation of P2Y1 and P2Y12 is 
necessary for normal ADP-induced platelet activation as inhibition of either receptor results in 
a marked decrease in platelet aggregation (Gachet 2006).  
 
1.5.2.3  Thromboxane A2 receptor - TP 
TxA2 is a short-lived lipid mediator that is synthesized by activated platelets to amplify 
activation signals and recruit additional platelets to the site of thrombus formation (FitzGerald 
1991).  TxA2 also acts as a potent vasoconstrictor.  In activated platelets, TxA2 is generated 
from prostaglandin H2 (PGH2) by thromboxane-A synthase (Huang et al. 2004).  Aspirin 
irreversibly inhibits platelet cyclooxygenase-1 (COX1) that converts arachidonic acid (AA) 
into prostaglandin H2 (Huang et al. 2004).  TxA2 is lipid soluble and crosses the plasma 
membrane, exiting the platelet and binding to the TxA2 receptor (TP) on the surface of the 
same platelet or other platelets in the vicinity in a autocrine and paracrine manner, 
respectively (Shen et al. 1998).  Signalling through the TP receptor induces platelet activation 
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and secretion leading to platelet aggregation.  In platelets, the activated TP receptor 
predominantly couples to Gq and G12/13, similar to the thrombin receptors PAR-1 and PAR-4, 
and the P2Y1 ADP receptor (Djellas et al. 1999; Klages et al. 1999).  The TP receptor also has 
a minor Src signalling component (Huang et al. 2004). 
The importance of TxA2 as a positive feedback agonist is demonstrated by patients 
deficient in TxA2 production, which display a mild bleeding disorder (Lagarde et al. 1978) 
and by the TP knockout mouse, which has a prolonged bleeding time (Thomas et al. 1998).  
TxA2 works synergistically with released ADP to amplify platelet activation signals.  
Collagen in particular has a large dependency on the combined effects of TxA2 and ADP to 
enhance the activation signal and promote more powerful aggregation (Figure 1.8). 
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Figure 1.8: Aggregation by collagen is dependent on ADP and TxA2.  Released ADP and 
TxA2 contribute to a positive feedback mechanism that enhances collagen signalling and 
platelet aggregation. TxA2 signals through P2Y12, whilst ADP signals through P2Y1 and TP. 
 
 
1.5.3  ITIM receptors 
Platelets express several immunoreceptor tyrosine-base inhibition motif (ITIM)-containing 
receptors/receptor-like proteins including: PECAM-1 (CD31), TLT-1, G6b-B and 
CEACAM1.  ITIMs are typically defined by the consensus sequence (L/I/V/S)-XY-X-X-
(L/V) and are frequently found in pairs separated by 15 to 30 amino acid residues (Vivier et 
al, 1997; Ravetch et al, 2000).  The SH2 domain containing non-transmembrane protein 
tyrosine phosphatases (PTPs) Shp1 and Shp2 interact with phosphorylated ITIMs.  ITIM-
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containing receptors were originally identified by their ability to inhibit signalling by ITAM 
receptors, as demonstrated by the selective inhibition of the B-cell receptor when cross-linked 
by surface IgG to FcγRIIb (Bijsterbosch et al, 1985; Daeron et al, 1995).  However, this story 
was complicated by more recent evidence generated by studying platelets from PECAM-1-
deficient mice, which demonstrated that ITIM-containing receptors can also inhibit activation 
by G protein-coupled receptors and that PECAM-1 positively regulates integrin-mediated 
responses (Cicmil et al, 2002; Dhanjal et al, 2007; Jones et al, 2001; Newman 2003; Patil et 
al, 2001). 
PECAM-1 was the first ITIM-containing receptor identified in platelets and is the most 
well studied.  It is highly expressed in platelets (~10,000 copies on the surface of resting 
platelets) and endothelial cells (~1,000,000 copies/endothelial cell) (Muller et al. 1992).  
Cross-linking PECAM-1 has been shown to inhibit signalling from the collagen ITAM-
containing receptor GPVI-FcR γ-chain, the G protein-coupled receptor thrombin receptor 
PAR-4 and the VWF receptor GPIb-IX-V (Newman et al. 2003).  The ligand for PECAM-1 is 
itself (homophilic interaction).  It is hypothesised that the physiological function of PECAM-1 
is to maintain platelets in an inactive state in healthy blood vessels and limit thrombus size at 
sites of injury.  Work done using PECAM-1-deficient mice supports this model (Falati et al. 
2006).  However, the magnitude of the inhibitory function of PECAM-1 has been questioned 
by recent studies showing that PECAM-1 had only a minor inhibitory effect on platelet 
activation induced by ITAM signalling and that thrombus formation on collagen was not 
altered if PECAM-1 was absent (Dhanjal et al. 2007).  Furthermore, Wee et al reported 
potentiation of aggregation in PECAM-1-deficient platelets in response to CRP, 
demonstrating the complexity of the functional role of PECAM-1 in platelets (Wee et al. 
2005). 
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Work done on other ITIM-containing receptors in platelets supports their role as both 
activatory and inhibitory receptors and that they also regulate GPCR-mediated responses.  
TLT-1 which is stored in platelet α-granules and translocates to the surface upon platelet 
activation where it binds fibrinogen, positively regulates thrombosis (Washington et al. 2009); 
antibody-mediated cross-linking of G6b-B inhibits both GPVI- and ADP-mediated platelet 
aggregation (Newland et al. 2007); and work done using CEACAM1-deficient mice has 
shown that it negatively regulates most platelet responses mediated by tyroinse-kinase linked 
receptors (Wong et al. 2009). 
 
1.6  Platelet Inhibition 
Platelets must be maintained in a quiescent or ‘resting’ state in the peripheral circulation to 
prevent unwanted thrombus formation.  Three mechanisms that maintain platelets in a resting 
state are: (1) certain ITIM receptors (PECAM-1 and CEACAM1) have been shown to reduce 
platelet activation (described above); (2) PGI2 which is secreted from endothelial cells and (3) 
nitric oxide (NO), which is also released from endothelial cells.  Below I briefly describe the 
later two mechanisms, which are better defined and have a much greater effect on inhibiting 
platelet activation than ITIM-mediated inhibition. 
 
1.6.1  PGI2 receptor 
Prostaglandin I2 (PGI2) is a potent inhibitor of platelet activation, adhesion, aggregation and 
secretion.  PGI2 is synthesized in endothelial cells from PGH2 by prostacyclin synthase and 
constitutively released into the circulation.  PGI2 is released at relatively low concentrations 
and has a short half-life, exerting its effects on platelets in close proximity to the vessel wall 
(Mitchell et al. 2008).  PGI2 binds to and signals through the Gs-coupled PGI2 receptor.  Gs 
activates adenylyl cyclase, which in turn generates cAMP, which activates the cAMP-
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dependent Ser/Thr protein kinase A (PKA).  PKA phosphorylates numerous proteins in 
platelets that may mediate its inhibitory effects.  A major substrate of PKA in platelets is 
vasodilator-stimulated phosphoprotein (VASP), which interacts with various cytoskeletal 
proteins, focal adhesions, stress fibers and cell-cell contacts (Bundschu et al. 2006).  
Phosphorylation of VASP has been correlated with fibrinogen receptor inhibition.  
Phosphorylation of GPIb and the TxA2 receptor may contribute to inhibition of platelet 
activation by PGI2, whereas the effects of phosphorylation of the guanine nucleotide exchange 
factor Rap1B remain unknown.  
 
1.6.2  Nitric oxide 
NO is another potent inhibitor of platelet activation, adhesion, aggregation and secretion.  NO 
is constitutively produced and release by endothelial cells and is important in maintaining 
platelets in a resting state.  NO has a short half-life, having a high localised concentration near 
the vessel wall that drops off rapidly with increasing distance from the wall.  NO freely 
crosses the platelet plasma membrane and enters the cytosol where it exerts its effect on 
platelet function.  The inhibitory effects of NO are considered to be due to activation of 
soluble guanylyl cyclase resulting in production of cGMP.  Increased intracellular levels of 
cGMP activate the Ser/Thr protein kinase G (PKG) as well as increase intracellular levels of 
cAMP which activates PKA (Walter et al. 2009).  Both PKG and PKA phosphorylate VASP 
and inhibit platelet activation.  The intracellular signalling effects of NO are not fully 
understood, but also involves inhibition of phospholipase C and IP3-mediated mobilization of 
intracellular Ca2+. 
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1.7  Platelet Kinases and Phosphatases 
Protein phosphorylation on tyrosine residues is a fundamental cell-signalling mechanism, 
regulated by the combined activities of the protein-tyrosine kinases (PTKs) and protein-
tyrosine phosphatases (PTPs).  The actions of both the PTKs and PTPs are under tight control 
as they regulate important cellular and physiological processes including cell growth and 
proliferation, differentiation, migration, metabolism and signal transduction (Tonks et al. 
2001; Larsen et al. 2003).  Disruption of the fine balance of tyrosine phosphorylation within 
the cell can trigger the onset of several human diseases, including, diabetes, autoimmunity and 
cancer (Blume-Jensen et al. 2001; Tonks et al. 2001; Zhang 2001).  Therefore understanding 
the functional roles of these critically important enzymes has important implications for the 
development of novel therapies to treat disease. 
The human and mouse genomes code for approximately the same number of 
catalytically active PTPs and PTKs (approximately 90 of each).  However, PTPs in general 
are less well characterized and understood (Manning et al. 2002; Alonso et al. 2004).  This is 
in part due to the first PTK being purified (Czernilofsky et al. 1980) and studied almost ten 
years prior to the first PTP (Charbonneau et al. 1989).  In addition, PTPs were initially 
regarded as housekeeping enzymes that were constitutively active and dephosphorylated every 
substrate they encountered.  In recent years however, a large body of evidence has emerged 
demonstrating that PTPs play very specific, precise roles in regulating tyrosine 
phosphorylation and in the regulation of many physiological processes (Fischer et al. 1991; 
Walton et al. 1993; Tonks et al. 1996; Mustelin et al. 2003; Stoker 2005). 
 
1.7.1 Src family kinases  
The most well studied family of PTKs is the Src family kinases (SFKs).  Humans and mice 
express eight structurally-related SFKs (Blk, Fgr, Fyn, Hck, Lck, Lyn, Src and Yes), all of 
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which are between 53 – 61 kDa in size and consist of an N-terminal SH3 domain, followed by 
an SH2 domain, a proline-rich linker region and a kinase domain (Roskoski 2004).  The SH3 
and SH2 domains mediate both intra- and inter-molecular interactions.  SFKs also contain 
myristoylation and/or palmitoylation sequences in their N-terminus, which allow them to 
localize to the inner leaflet of the plasma membrane.  They have been linked to a variety of 
cellular processes.  One of their most well studied and important function is to initiate and 
propagate signals from surface receptors, including immunoreceptors, integrins and to a lesser 
extent G protein-couple receptors.  SFKs have high catalytic activity, so they are tightly 
regulated.  Aberrant SFK activity leads to various disease conditions including cancer and 
autoimmunity.  Regulation of platelet SFKs is a major component of this thesis and is 
discussed below. 
 
1.7.1.1  SFKs expressed in platelets 
Human platelets express five of the eight SFKs, namely Src, Fyn, Lyn, Yes and Fgr (Golden 
et al. 1986; Rendu et al. 1989; Horak et al. 1990; Pestina et al. 1997; Quek et al. 2000; 
Obergfell et al. 2002).  Src is the most abundant SFK in platelets, estimated to constitute 
~0.2% of total platelet protein (Golden et al. 1986).  Work done with cell lines, knockout 
mouse models and pharmacological inhibitors have clearly established SFKs as essential 
mediators of platelet activation, aggregation, adhesion and thrombosis (Ezumi et al. 1998; 
Gross et al. 1999; Quek et al. 2000; Obergfell et al. 2002).  Src is essential for initiating 
integrin αIIbβ3 signalling, whereas Fyn and Lyn are essential for initiating GPVI signalling 
(Ezumi et al. 1998; Obergfell et al. 2002).  The functions of Yes and Fgr in platelets are not 
clear.  Although SFKs are known to play important roles downstream of many other platelet 
receptors, it is presently not known which specific SFKs act downstream of each receptor.  It 
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is also not clear the extent of functional redundancy between the SFKs and unique functions 
performed by each. 
 
1.7.1.2  Regulation of SFK activity  
SFKs are tightly regulated by phosphorylation and intra-molecular interactions.  SFKs are 
maintained in an inactive conformation by two important intra-molecular interactions, one of 
which is between the SH3 domain and the proline-rich linker sequence between the SH2 and 
kinase domains; and the second is between the SH2 domain and the phosphotyrosine residue 
in the C-terminal tail of the kinase (Tyr-529 in Src) (Figure 1.9) (Roskoski 2005).  Both of 
these interactions must be disrupted in order for SFKs to be activated.  This is achieved by 
either dephosphorylation of the C-terminal inhibitory tyrosine, which releases the interaction 
with the SH2 domain and has a knock-on effect that also disrupts the SH3 interaction, or by 
out-competing the SH3 and SH2 interactions through inter-molecular interactions (Roskoski 
2005).  In the latter scenario, the C-terminal inhibitory site does not have to be 
dephosphorylated.  Dephosphorylation of the C-terminal inhibitory phosphotyrosine of SFKs 
‘primes’ the kinase.  Mutation of the C-terminal tyrosine residue of Src to a phenylalanine has 
been shown to increase its catalytic activity relative to wild-type Src (Cooper et al. 1986; 
Kmiecik et al. 1987).  Primed SFKs become fully activated by trans-autophosphorylation of a 
tyrosine residue located within the activation loop of the kinase domain (Tyr-418 in Src) (Su 
et al. 1999). Phosphorylation of the activation loop maintains it in an ‘open’ confirmation, 
such that it does not obstruct the catalytic site of the enzyme (Xu et al. 1999). 
SFKs are maintained in an inactive conformation by the structurally related tyrosine 
kinases Csk and Chk which phosphorylate the C-terminal inhibitory tyrosine of all SFKs 
(Okada et al. 1991; Zrihan-Licht et al. 1997; Cole et al. 2003).  Csk is expressed in all 
mammalian cells, whereas Chk expression is restricted to hematopoietic cells, neurons, breast 
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and testes (Brown et al. 1996).  Csk is maintained at the plasma membrane, in close proximity 
to the SFKs it regulates, by binding to phosphorylated Csk-binding protein also referred to as 
phosphoprotein associated with glycosphingolipid-enriched microdomains or paxillin 
(Roskoski 2004; Rathore et al. 2007).  
Several PTPs have been shown to dephosphorylate the C-terminal inhibitory tyrosine 
residue of SFKs, including the RPTPs CD45, PTPα, PTPε and PTPλ and the NTPTPs PTP-
1B, Shp1 and Shp2, whereas only CD45 and the PTP PTP-BAS have been shown to 
dephosphorylate the activation loop of SFKs (Roskoski 2005).  SFK activity can also be 
reduced by dephosphorylation of the activation loop phosphotyrosine.  CD45 and the NTPTP 
PTP-BL (PTP-BAS mouse homologue) are the only two PTPs to be shown to 
dephosphorylate this site to date.  Interestingly, Palmer et al. demonstrated that PTP-BL 
specifically dephosphorylates Src at Tyr 418 but not Tyr-529; whereas CD45 dephosphorylate 
both the inhibitory and activation loop tyrosines of Lck (Tyr-507 and Tyr-396, respectively) 
downstream of the TCR (McNeill et al. 2007).  CD45 has therefore been proposed to act as a 
switch modulating the sensitivity of cells to TCR signals by differentially regulating the two 
critical Lck tyrosine phosphorylation sites (McNeill et al. 2007).  
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Figure 1.9: Regulation of Src kinase by tyrosine phosphorylation. (A) The inactive 
configuration of Src showing the SH2 domain interacting with the phosphorylated C-terminal 
tyrosine (pY529), the SH3 domain interacting with the polyproline  SH2-linker region (PPP), 
and the dephosphorylated activation loop (Y418) folded back over the substrate binding site. 
(B) The active configuration of Src, showing SH2 and SH3 domains released from the 
intramolecular interactions and available for binding to substrates and regulatory molecules, 
the C-terminal tyrosine is dephosphorylated (Y529). (C) Src undergoes autophopshorylation 
of the activation loop (pY418) to become fully active. 
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1.7.2 Protein Tyrosine Phosphatases 
 
1.7.2.1 Classification of PTPs 
The defining feature of all PTPs is the presence of a PTP catalytic domain (~280 amino acids) 
containing an active-site signature motif HCX5R, where the cysteine functions as a 
nucleophile and is essential for catalysis (Tonks 2006).  Based on this definition, the human 
genome contains 107 genes that encode for PTPs (Alonso et al. 2004).  Mouse orthologs exist 
for essentially all of these genes.  The number of genes in the human genome that encode 
PTPs is surprisingly higher than the number of genes encoding PTKs (107 PTP genes 
compared with 90 PTK genes) (Manning et al. 2002; Alonso et al. 2004).  However, this is 
somewhat misleading as of the 107 PTPs, 11 have no catalytic activity, 2 dephosphorylate 
mRNA and 13 dephosphorylate inositol phospholipids (Alonso et al. 2004).  Consequently, 
only 81 of the PTPs are active protein phosphatases with the ability to dephosphorylate 
phosphotyrosines.  Of the 90 PTK genes, 85 are thought to be catalytically active (Manning et 
al. 2002).  Therefore, the number of active PTPs and PTKs are similar. 
PTPs are classified into four separate groups (Classes I – IV) based on the amino acid 
sequences of their catalytic domains and their substrate specificity (Figure 1.10) (Alonso et al. 
2004).  The largest group is the Class I cysteine-based PTPs of which there are 99.  Class I 
PTPs are divided into two broad categories, the ‘classical’ PTPs (38), which are strictly 
tyrosine-specific, and the ‘dual-specific’ PTPs (61), named for their broad substrate activity.  
The classical PTPs are further subdivided into the receptor-like PTPs (RPTPs) (21), and the 
non-transmembrane (NTPTPs) (17); and the dual-specific PTPs are subdivided into seven 
subgroups based on substrate specificity (Figure 1.10).  Low molecular weight PTP (LMW-
PTP) is the only Class II cysteine-based PTP, which appears to be more ancient than the Class 
I PTPs.  The Class III cysteine-based PTP family contains only three members, all of which 
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are cell cycle regulators.  In contrast to Class I – III cysteine-based PTPs, Class IV PTPs use a 
different catalytic mechanism, requiring a key aspartic acid and are cation-dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Classification and substrate specificity of the PTPs. Class I Cys-based PTPs 
(blue), class II Cys-based PTPs (green), class III Cys-based PTPs (orange), and Asp-based 
PTPs (pink). The substrate specificity of each class of PTP is listed (grey). Figure adapted 
from Alonso et al, 2004. 
 
 
1.7.2.2  The classical PTPs 
The classical PTPs, comprised of 21 RPTPs and 17 NTPTPs, are further divided into 
subgroups based on structural features and the extent of homology between their catalytic 
domains (Figure 1.11).    All members of the classical PTP family have at least one PTP 
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domain with the majority of the RPTP subfamily containing a second pseudo-PTP domain 
within their cytoplasmic region that has little or no catalytic activity (Figure 1.11) (Tonks 
2006).  Nevertheless, the structural integrity of the pseudo-PTP domain is important for the 
activity, specificity and stability of the RPTP as a whole and may provide docking sites for 
substrates and regulatory proteins (Streuli et al. 1990; Felberg et al. 1998; Tonks et al. 2001).  
The pseudo-PTP domain is also important for protein-protein interactions that regulate 
dimerization. 
The prototype and best studied RPTP is CD45.  In general, the cytoplasmic domains of 
the RPTPs are relatively well conserved (~35% sequence identity), however their extracellular 
regions are structurally diverse (Figure 1.11).  Extracellular regions of RPTPs are typically 
large (with the exception of PTPα and PTPε), highly glycosylated and contain domains 
present in receptors that regulate cell-cell and cell-ECM interactions, including fibronectin 
type III, immunoglobulin, MAM (Meprin/A4/µ domain) and carbonic anhydrase domains 
(Alonso et al. 2004).  There is a growing body of evidence that RPTPs regulate cell-cell and 
cell-ECM adhesion.  
The NTPTPs contain a wide variety of structural motifs flanking the catalytic domain 
that are important for regulating PTP activity, either directly by interaction with the active 
site, as shown for Shp2, or by controlling substrate specificity as demonstrated for PTP-PEST 
and p130cas (Figure 1.11) (Garton et al. 1997).  These non-catalytic regions also target 
NTPTPs to subcellular locations within the cell, thereby indirectly regulating activity by 
controlling access to a particular subset of substrates.  For example, Shp2 is targeted to the 
transmembrane protein PECAM-1 via its SH2 domain, following platelet activation and 
aggregation (Jackson et al. 1997). 
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Figure 1.11: The Classical Protein Tyrosine Phosphatases. Schematic representation of the 
classical PTPs showing their varied structural domains. 
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1.7.2.3  Catalytic mechansim of PTPs 
PTP-1B has been the prototype for understanding the reaction catalyzed by all PTPs.  It was 
the first PTP identified and the first to have the crystal structure of its PTP domain solved 
(Tonks et al. 1988; Charbonneau et al. 1989; Barford et al. 1994).  The crystal structures of 
the PTP-1B catalytic domain on its own and in complex with a peptide substrate were 
determined by the Tonks group (Barford et al. 1994).  Sequence alignments of PTP catalytic 
domains revealed several conserved residues.  The structure of PTP-1B illustrated that these 
residues were clustered in and around the active site and were demonstrated through site-
directed mutagenesis to facilitate enzyme-substrate recognition and catalysis (Jia et al. 1995).  
Recently, work by Barr et. al. revealed the PTP domains of the classical PTPs have many 
structural variations which regulate activity and specificity (Barr et al. 2009).  Other major 
findings from this study include: (1) a new atypical conformation for the WPD (Trp-Pro-Asp) 
catalytic loop; (2) a secondary substrate-binding pocket, initially reported for PTP-1B, can 
also be found in most other PTPs; and (3) a new ‘head-to-toe’ model to explain dimerization 
mediated inhibition of RPTP activity.   
The molecular mechanism of all PTP catalyzed reactions is a nucleophilic attack of the 
substrate phosphate by the PTP.  A schematic representation of the reaction catalyzed by PTP-
1B and the key residues involved is shown in Figure 1.12 (Tonks 2006).  Cys-215 in the PTP 
active site is fundamental for initiating catalysis (Figure 1.12A and B).  Asp-181 located on a 
flexible WPD catalytic loop is another key residue of the reaction.  Upon binding of substrate 
to the enzyme, the flexible WPD loop undergoes a conformational change, bringing Asp-181 
into the active site, so that it protonates the tyrosyl leaving group of the substrate (Figure 
1.12A and B).  A phosphoryl-cysteine intermediate (PTP-Cys-PO3) is subsequently formed 
(Figure 1.12C).  The second part of the reaction involves the hydrolysis of the phospho-
enzyme intermediate, which is stabilized within the catalytic cleft by Ser-222 (Figure 1.12D).  
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Hydrolysis is mediated by Asp-181, which now acts as a general base, and a Gln-262, which 
coordinates a water molecule in the active site (Figure 1.12D and E).  The phosphate is 
released from the active site and the enzyme is ready to dephosphorylate another substrate 
molecule (Figure 1.12F).  PTPs generally have a high catalytic activity that have been 
measured to be 3 orders of magnitude higher than PTKs (Zhang 2003). 
 
1.7.2.4  Identification of PTP substrates 
‘Substrate-trapping mutants’ have been important tools in the identification of physiological 
substrates and deciphering signalling pathways that PTPs regulate (Blanchetot et al. 2005; 
Tiganis et al. 2007).  They were developed following the elucidation of the PTP catalytic 
mechanism.  The basic principle of how they function is that they display impaired catalytic 
activity and bind substrates with higher affinity than their wild-type counter-parts (Garton et 
al. 1996; Flint et al. 1997).  The most successful substrate-trapping mutants generated to date 
have either the signature motif cysteine replaced by a serine (C/S), or the aspartatic acid in the 
WPD loop mutated to alanine (D/A).  The C/S mutation in the active site renders the PTP 
catalytically inactive, but still allows binding of the physiological substrate (S) leading to the 
formation of a stable enzyme-substrate interaction (PTP-Ser-PO3-S) (Blanchetot et al. 2005).  
The D/A mutant is generally regarded as the best mutant to pulldown PTP substrates, as in the 
majority of cases it has greater affinity for substrates compared to the C/S mutant (Buist et al. 
2000; Agazie et al. 2003).  This is because the D/A mutant not only has impaired catalytic 
activity, but has the added benefit of the WPD loop flipping over and locking the substrate in 
the catalytic pocket (Blanchetot et al. 2005). 
PTP substrate-trapping approaches have progressed to include double mutations as a 
means to improve trapping efficiency.  Double mutants are effective when single mutants are 
slightly active and do not display sufficiently high binding affinities to trap substrates.  Two 
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examples are the Shp2 C459S-D425A and PTP-1B D181A-Q262A double mutants, both of 
which proved to be much more effective in trapping substrates than either mutant alone (Xie 
et al. 2002; Agazie et al. 2003). 
Although substrate-trapping mutants have been used with great effect to target 
substrates of PTPs, the binding of a phosphoprotein to a substrate-trapping mutant on its own 
is not sufficient to prove that a protein is a physiological substrate of a PTP.  Therefore 
potential substrates are commonly validated by other means.  Typically the criteria that needs 
to be fulfilled include: (i) the substrate must bind to the substrate trapping mutant via the 
catalytic site; (ii) dephosphorylation of the substrate should be visible in vitro; and (iii) an 
increase in tyrosine phosphorylation of the substrate should be detectable in a cell line or 
mouse model where the PTP has been knocked out or knocked down by RNA interference 
(Tiganis et al. 2007). 
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Figure 1.12: PTP-1B catalytic mechanism. (A) The tyrosine-phosphorylated substrate enters 
the PTP active site. (B) Nucleophilic attack occurs between the sulphur atom of the essential 
cysteine (Cys215) and the phosphate on the substrate, coupled with protonation of the tyrosyl 
leaving group by the conserved aspartic acid (Asp181), resulting in the formation of the 
phospho-enzyme intermediate (C). (D) Asp181 then acts as a general base to hydrolyze the 
phospho-enzyme intermediate, culminating in the release of phosphate (E and F).  
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1.7.2.5  Regulation of PTP activity 
Disruption of the fine balance of tyrosine phosphorylation within a cell can severely effect 
functional responses of the cell.  It is therefore essential that both PTKs and PTPs are under 
precise control.  Below are outlined several ways in which PTPs are regulated (den Hertog et 
al. 2008): 
 
1) Expression.  The expression of PTPs is controlled at many different levels including: 
transcriptional regulation of mRNA, alternative mRNA splicing, mRNA stability, translation, 
post-translational modifications and protein stability.   Some PTPs, such as PTP-1B and Shp2, 
are widely expressed in almost all cell types, whilst others are more selectively expressed, 
such as HePTP and CD45 which are expressed exclusively in hematopoietic cells (Pao et al. 
2007).  Some cell types appear to express many of the 38 classical PTP genes such as 
endothelial cells, whereas other cell types such as neurons and platelets appear to express only 
a select few (Kappert et al. 2005).  The expression of certain PTPs can also be increased 
during development, such as PTPRO which is up-regulated during megakaryocyte 
differentiation (Taniguchi et al. 1999).  Expression of CD148, LAR and RPTPµ are increased 
with increasing cell density (Longo et al. 1993; Ostman et al. 1994; Campan et al. 1996). 
 
2)  Subcellular localisation.  The correct location within the cell is critical for a PTP to exert 
its physiological function.  PTPs are targeted to their required subcellular locations by 
compartment-specific targeting domains and protein-protein interactions (Tonks 2006).  
Several RPTPs have been shown to regulate tyrosine phosporylation at the plasma membrane 
in response to a cell-cell or cell-ECM contact (Ostman et al. 2001; Burridge et al. 2006; Sallee 
et al. 2006).  CD45 is expressed in the plasma membrane of lymphocytes where it regulates B- 
and T-cell receptor proximal signalling events (Hermiston et al. 2003).  Some cytoplasmic 
Chapter 1  Introduction 
  46 
NTPTPs are recruited to the plasma membrane in response to cell stimulation, such as Shp1 
and Shp2 which bind to phoshorylated ITIM receptors via their SH2 domains (Pao et al. 
2007).  PTP-1B is normally anchored to the cytosolic surface of the endoplasmic reticulum 
(ER) by a hydrophobic sequence in its C-terminus (Tonks 2003).  Cleavage of this sequence 
by calpain releases PTP-1B from the ER allowing it to access substrates in other parts of the 
cell and also increases its specific activity (Frangioni et al. 1993). 
 
3) Phosphorylation.  Several PTPs are known to be phosphorylated on Ser and Tyr residues, 
including RPTPα, CD45, PTP-1B, PTP-PEST, Shp1 and Shp2, however, relatively little is 
known about how phosphorylation regulates PTPs.  Phosphorylation of RPTPα at Ser-180 and 
Ser-204 increases catalytic activity, by a mechanism that is thought to inhibit dimer formation 
(den Hertog et al. 1995).  Phosphorylation of RPTPα at Tyr-789 has a completely different 
function, mediating activation of Src and also recruitment of Grb-2, which antagonizes Src 
activation (Su et al. 1999).  There is also evidence that PTPs can dephosphorylate other PTPs.  
For example, CD45 has been shown to dephosphorylate RPTPα at Tyr-789 in vitro and in T 
cells, implying that RPTPα is a direct substrate of CD45 (Maksumova et al. 2007).  This 
suggests the possibility of PTP signalling cascades similar to the well documented, much 
studied kinase cascades. 
 
4) Oxidation.  It is well established that PTPs are reversibly inhibited by reactive oxygen 
species (ROS) that transiently oxidize the active site cysteine (Salmeen et al. 2005; Rhee 
2006).  Many PTPs have been shown to be oxidized following activation of tyrosine kinase-
linked and G protein-coupled receptors, that elevate intracellular levels of ROS (Tonks 2005).  
Cell density, adhesion and migration also transiently affect levels of PTP oxidation (den 
Hertog et al. 2008).  The major sources of ROS appear to be the mitochondria or NADPH 
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oxidases.  The molecular mechanisms of PTP oxidation has been elucidated for some PTPs 
and involves formation of a covalent bond between the sulphur of the catalytic site cysteine 
and the nitrogen of the neighbouring serine (Salmeen et al. 2003; van Montfort et al. 2003; 
Yang et al. 2007).  There is some variability in the sensitivity of PTPs to oxidation, which 
correlates with the conformation of the active site arginine (Groen et al. 2005; Ross et al. 
2007).  For example, Shp2 becomes oxidized following T cell stimulation with H2O2, whereas 
Shp1 does not (Kwon et al. 2005).  Two commonly used general PTP inhibitors, vanadate and 
pervanadate, used throughout this thesis, work by oxidizing the active site cysteine of all 
classical PTPs (Huyer et al. 1997).  Vanadate is a reversible inhibitor of PTPs whilst 
pervanadate is irreversible (Figure 1.13) (Huyer et al. 1997). 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. : Vanadate and pervanadate inhibition of PTPs. Figure adapted from Huyer et 
al. 1996. Inhibition by pervanadate is irreversible whilst inhibition by vanadate is reversible. 
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5) Ligands.  The extracellular regions of RPTPs are typically large, highly glycosylated, 
structurally diverse and evolutionarily conserved, implying that they regulate PTP function.  
However, very few ligands of RPTPs have been identified to date.  Table 1.1 summarizes our 
current knowledge of RPTP ligands.  Interestingly, several RPTPs display homophilic 
interactions and/or interact with ECM proteins, suggesting that they regulate cell adhesion 
(den Hertog et al. 2008).  The only RPTP extracellular region crystallized to date is that of 
RPTPµ, which was shown to form extended, rigid homophilic trans (anti-parallel) dimers 
through a ‘spacer-clamp’ mechanism (Aricescu et al. 2007).  RPTPµ dimers are hypothesized 
to act as a distance gauge between adjacent cells and maintain the phosphatase in the 
appropriate functional location.  RPTPζ is one of the best characterised RPTPs regulated by 
ligand binding.  RPTPζ is inhibited following binding of the growth factor pleiotrophin 
(PTN), leading to an increase in tyrosine phosphorylation of proteins that regulate cell 
adhesion and cytoskeletal function (Meng et al. 2000).  A size exclusion model predicts that 
some RPTPs are regulated by steric hinderance (Lin et al. 2003; Choudhuri et al. 2005).  
CD45 and CD148 are excluded from the tight immunological synapse between a lymphocyte 
and an antigen presenting cell due to the large size of their extracellular regions. 
 
6) Dimerisation.  Unlike receptor tyrosine kinases and tyrosine kinase-linked receptors which 
are activated by homodimerzation, several RPTPs have been shown to be inactivated 
following dimerzation.  The long held, yet controversial ‘inhibitory wedge’ model proposes 
that an helix-turn-helix wedge domain in the membrane-proximal region of one RPTP 
obstructs the active site of the partner RPTP (Bilwes et al. 1996) (Figure 1.14).  The prototype 
of this model is RPTPα.  CD45 has also been proposed to be inactivated by the same 
mechanism (Majeti et al. 1998).  However, recent work by Barr et. al. rejects the existence of 
an inhibitory wedge domain (Barr et al. 2009).  The crystal structure of the complete 
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intracellular region of RPTPγ reveals a different mode of homodimer-mediated inhibition that 
involves the interaction between the D1 catalytic domain of one of the partners in the dimer 
with the D2 catalytic domain of the other partner.  Barr et. al. recognize that the membrane-
proximal region where the inhibitory wedge is thought to lie acts as a linker region that 
provides sufficient flexibility to allow the head-to-toe interaction to occur (Barr et al. 2009). 
 
 
Figure 1.14.  Models of homodimer-mediated inhibition of receptor-like protein tyrosine 
phosphatases.  On the left is a schematic representation of a monomeric active R5 receptor-
like protein tyrosine phosphatase (RPTP) (either RPTPγ or RPTPζ).  The extracellular region 
consists of a carbonic anhydrase (CA) domain and a fibronectin type III (FN) domain.  The 
‘wedge’ model, based on studies of RPTPα and CD45, predicts that inhibition results from the 
wedge of one RPTP obstructing the catalytic domain (D1) of the partner RPTP.  The ‘head-to-
toe’ model, based on the crystal structure of the entire cytoplasmic region of RPTPγ (Barr et. 
al. Cell 2009), demonstrates that the D2 catalytic domain of one RPTP obstructs the D1 
catalytic domain of the partner RPTP.  (Figure from Tremblay et al, Cell 2009) 
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   Table 1.1: Ligands of receptor-like protein tyrosine phosphatases (RPTPs) 
 
RPTP Class Ligand(s) Effect on 
activity 
Comments References 
CD45 R1 - galectin-1 - inhibition - interaction based on 
recognition of CD45 
carbohydrates 
(Walzel et al. 
1999; Chen 
et al. 2007) 
RPTPδ R2A - homophilic - not known - promotes adhesion and 
neurite outgrowth 
(Wang et al. 
1999; 
Gonzalez-
Brito et al. 
2006) 
LAR R2A - LARFN5C 
 
 
- laminin- 
nidogen 
- activation 
 
 
- not known 
- homophilic interaction with 
LAR isoform 
- specific for LAR splice 
variant 
(O'Grady et 
al. 1998; 
Yang et al. 
2005) 
dLAR R2A - syndecan 
- dallylike 
- activation 
- inhibition 
- dLAR ligand 
- competitive binding with 
snydecan 
(Fox et al. 
2005; 
Johnson et al. 
2006) 
LAR2 R2A - homophilic - not known - induces repulsive responses 
in comb cells 
(Johnson et 
al. 2006) 
RPTPσ R2A - heparin sulphate 
proteoglycans 
(collagen XVIII, 
agrin) 
- nucleophilin 
- α-latrotoxin 
- unidentified 
component of 
developing muscle) 
- not known - ligand binding requires PTP 
dimerization 
(Aricescu et 
al. 2002; 
Sajnani-
Perez et al. 
2003; Alete 
et al. 2006; 
Lee et al. 
2007) 
RPTPκ R2B - homophilic - not known  (Sap et al. 
1994) 
RPTPµ R2B - homophilic - not known - ‘spacer-clamp’ mechanism in 
cell-cell adhesions; induces 
RPTPµ signalling in neurites 
(Ensslen-
Craig et al. 
2005; 
Aricescu et 
al. 2007) 
RPTPl R2B - homophilic - not known  (Cheng et al. 
1997) 
CD148 R3 - components in 
matrigel 
- activation - identity of ligand(s) not 
known 
(Sorby et al. 
2001) 
RPTPβ/ζ R5 - pleiotrophin 
 
 
 
 
- tenascin 
- contactin 
- TAG-1/axonin-1 
- inhibition 
 
 
 
 
- not known 
- not known 
- not known 
- may activate several 
signalling pathways; not 
known whether inhibition 
occurs by induction of dimer 
formation 
(Barnea et al. 
1994; Peles 
et al. 1995; 
Milev et al. 
1996) 
  dLAR, Drosophila LAR 
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1.7.2.6  PTPs in platelets 
Although it has been known for many years that PTPs play important roles in regulating cell 
functions in both health and disease, they have been under-investigated in megakaryocytes, 
platelets and thrombosis.  Significantly more emphasis has been placed on investigating PTKs 
in platelets.  To date, five NTPTPs (PTP-1B, Shp1, Shp2, MEG-2 and LMW-PTP) and a 
single RPTP (CD148) have been conclusively demonstrated to be expressed in platelets 
(Table 1.2).  However, this list is unlikely to be exhaustive as there are several PTPs which are 
widely expressed, such as PTP-PEST and TC-PTP.  PTP-1B was the first PTP identified in 
platelets and is the most well studied.  Far less is known about the other four NTPTPs in 
platelets.  Prior to starting this thesis, there had been no studies investigating the functional 
role of any RPTP in platelets, including CD148.  Below I provide a summary of each of the 
PTPs identified in platelets to date and what is known about their functions in platelets. 
 
1.7.2.6.1  Receptor like PTPs expressed in platelets 
1.7.2.6.1.1  CD148 
CD148, also commonly referred to as DEP-1, PTPRJ or rPTPη (rat homologue), is a member 
of the R3 group of RPTPs (Figure 1.11).  It is a large (180 – 250 kDa), surface glycoprotein 
consisting of an extracellular region containing 8 fibronectin type III (FNIII) repeats (~90 
amino acids each), a single transmembrane domain and a cytoplasmic region containing a 
single PTP domain (~280 amino acids).  It is expressed in hematopoietic cells, fibroblasts, 
endothelial cells, epithelial cells and smooth muscle cells (Borges et al. 1996; Autschbach et 
al. 1999).  At the start of this thesis, only two studies had reported expression of CD148 in 
platelets, but neither had addressed its functional role (Borges et al. 1996; de la Fuente-Garcia 
et al. 1998).  CD148 was also the only RPTP identified in platelets by multiple peptide hits 
using a proteomics-based approach (Senis et al. 2007; Lewandrowski et al. 2009).  
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Table 1.2:  Protein tyrosine phosphatases expressed in platelets 
 
Category/ 
Name 
Subcellular 
localization 
Function References 
Non-transmembrane PTPs 
MEG2 binds to PIP2 and 
PIP3 
modulates secretory vesicle 
genesis 
Wang et. al. JEM 2005 
PTP-1B - tethered to the 
cytosolic surface of 
the ER 
 
- calpain-mediated 
shedding from the ER 
and translocation to 
the PM upon platelet 
activation 
- first PTP identified in 
platelets 
 
- proposed to regulate the 
latter stages of platelet 
activation and aggregation 
 
- positive regulator of αIIbβ3 
proximal signalling 
 
- dephosphorylates LAT and 
Src inhibitory tyrosine 
Frangioni et. al. EMBO 1993 
Ragab et. al. JBC 2003 
Arias-Salgado et. al. Blood 
2005 
Kuchay et. al. MCB 2007 
LMW-
PTP 
-cytosolic in resting 
platelets 
- dephosphorylates the ITAM-
containing FcγRIIA receptor 
in vitro and in vivo  
Mancini et. al. Blood 2007 
Shp1 - cytosolic/inactive in 
resting platelets 
 
- translocates to the 
PM and becomes 
activated via 
interaction with ITIM 
receptors upon 
platelet activation 
- positive regulator of GPVI-
mediated activation 
 
- interacts with actinin and 
Src 
 
- dephosphorylates Src 
inhibitory tyrosine 
Somani et. al. JBC 1997 
Hua et. al. JBC 1998 
Pasquet et. al. JBC 2000 
Lin et. al. JBC 2004 
Senis et. al. MCP 2007 
Shp2 - cytosolic/inactive in 
resting platelets 
 
- translocates to the 
PM and becomes 
activated via 
interaction with ITIM 
receptors upon 
platelet activation 
implicated as positive and 
negative regulator of platelet 
activation 
Hua et. al. JBC 1998 
Cicmil et. al. Blood 2002 
Barrow et. al. JI 2004 
Washington et. al. Blood 
2004 
Wee et. al. Blood 2005 
Dhanjal et. al. Platelets 2007 
Receptor-like PTPs 
CD148 PM - first RPTP identified in 
platelets 
- positive regulator of all 
SFKs in resting and activated 
platelets 
Borgess et. al. Circ Res 1996 
Fuente-Garcia et. al. Blood 
1998 
Senis et. al. MCP 2007 
Senis et. al. Blood 2009 
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Studies on CD148 in non-haematopoietic cells have focused on its role as a negative 
regulator of cell growth and differentiation, as it is postulated to be a tumour suppressor 
(Ruivenkamp et al. 2002; Trapasso et al. 2004).  More recently, studies have focused on the 
involvement of CD148 in regulating cell-cell and cell-ECM interactions.  CD148 has been 
shown to inhibit PDGF-mediated cell migration and enhance cell-ECM adhesion of NIH3T3 
mouse fibroblasts that inducibly express CD148 (Jandt et al. 2003).  Similarly, rat fibroblasts 
stably expressing CD148 exhibit increased adhesion to substratum (Pera et al. 2005).  In 
contrast, CD148 has also been shown to negatively regulate cell-ECM interactions, motility 
and chemoxtaxis of NIH3T3 inducibly expressing CD148 (Kellie et al. 2004).  These 
contradictory findings suggest that CD148 can both positively and negatively regulate cell 
adhesion, depending on the cell type and level of expression.   
There is a growing body of evidence that CD148 plays an important role in regulating 
immune receptor signalling in haematopoietic cells.  Early studies suggested that CD148 was 
a negative regulator of signalling from the ITAM-containing T cell receptor (TCR) and the 
low affinity immune receptor FcγRIIA in lymphocytes and neutrophils, respectively (Hundt et 
al. 1997; de la Fuente-Garcia et al. 1998; Baker et al. 2001; Lin et al. 2003).  These early 
studies were performed using transient and stable CD148 expressing cell lines, primary 
leukocytes and antibody-mediated cross-linking of CD148.  A CD148 mutant mouse line in 
which the entire cytoplasmic region was replaced with green fluorescence protein led to 
embryonic lethality and severe defects in vascular development (Takahashi et al. 2003).  The 
same group also demonstrated that antibody-mediated cross-linking of CD148 inhibited 
endothelial-cell growth and angiogenesis in mouse cornea in vivo (Takahashi et al. 2006).  
More recently two different CD148 knock-out and knock-in mouse models have been 
generated to determine the physiological functions of CD148.  Trapasso and Fusco generated 
a CD148-deficient mouse model by deleting exons 3, 4 and 5 (Trapasso et al. 2006).  In 
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contrast to the CD148:GFP knockin mutant mice described above, these mice were viable and 
healthy demonstrating that CD148 is dispensable for growth and development.  However, this 
knockout mouse model was not studied in any detail for haematopoitic or immune system 
defects.  A third mutant CD148 mouse model generated by Zhu et. al. lacking the 
transmembrane domain of CD148 (CD148 TM-KO) also did not exhibit any obvious defects 
in growth and development; however, detailed analysis of haematopoietic cells revealed a 
function of CD148 in the immune system (Zhu et al. 2008).  It should be pointed out that the 
CD148 TM-KO mouse model expresses a truncated, soluble form of CD148. 
Analysis of the T cell lineage, which express low levels of CD148, in CD148 TM-KO 
mice, did not reveal any defects in T cell development or function (Zhu et al. 2008).  In 
contrast these mice exhibited almost an exact phenocopy of the block in B cell development 
observed in CD45-deficient mice.  CD45:CD148 double deficient mice displayed substantial 
alterations in B and myeloid lineage development and defective immunoreceptor signalling 
(Zhu et al. 2008).  B cell and macrophage functional responses were severally impaired, as 
were BCR- and Fc receptor-mediated signalling in CD45:CD148 double deficient B cells and 
macrophages, respectively.  Biochemical analysis of CD45:CD148 double deficient B cells 
and macrophages revealed hyperphosphorylation of the C-terminal inhibitory tyrosine of 
SFKs, suggesting that the C-terminal inhibitory tyrosine of SFKs is a common substrate of 
both CD45 and CD148 and that decreased SFK activity is likely the cause of at least some of 
the phenotypes observed in mutant mice.  These findings suggest a high level of redundancy 
between the two structurally distinct RPTPs in regulating SFKs (Zhu et al. 2008). 
Several receptors and signalling proteins have been suggested to be substrates of 
CD148 (Table 1.3).  The hepatocyte growth factor receptor MET, the adapter protein Gab1 
and the junctional component p120 catenin were identified as potential substrates of CD148 in 
a study of human breast cancer cell lines (Palka et al. 2003).  CD148 was also shown to 
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interact with p120 catenin in K562 erythroleukemia and A549 lung fibroblast cell lines 
(Holsinger et al. 2002).  CD148 expression was concentrated at sites of cell-cell contact and 
was found to be co-localised with p120 catenin further reinforcing the theory that CD148 
plays an important role in cell-cell contacts and adherens junctions.  CD148 has also been 
shown to dephosphorylate the PDGFβ-receptor in a site-selective manner that acts to modulate 
rather than attenuate signalling; and to preferentially dephosphorylate the C-terminal 
inhibitory tyrosine of Src in transiently transfected rat fibroblasts (Kovalenko et al. 2000; Pera 
et al. 2005). 
 
 
Table 1.3: Summary of substrates identified for CD148 
Substrate 
 
Cell type Reference 
MET 
 
Human breast tumour cell lines (Palka et al. 2003) 
Gab1 Human breast tumour cell lines 
 
(Palka et al. 2003) 
p120cat 
 
 
Human breast tumour cell lines, 
erythroleukemia and lung 
fibroblast cell lines 
 
(Palka et al. 2003) 
PDGFβ Porcine aortic endothelial cells (Kovalenko et al. 2000) 
 
SFKs Rat fibroblasts (Pera et al. 2005) 
 
PLCγ1 Jurkat T cell (Baker et al. 2001) 
LAT Jurkat T cell (Baker et al. 2001) 
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The presence of multiple FNIII domains in the extracellular region of CD148 suggests 
that it may be regulated by soluble ligands or adhesive molecules present on neighbouring 
cells or in the ECM, as FNIII domains are present in adhesion molecules and growth factor 
receptors (Patthy 1990).  In support of this hypothesis, CD148 expressing X23 porcine aortic 
endothelial cells stimulated with Matrigel exhibited a >2-fold increase in CD148 specific 
activity suggesting that the ligand for CD148 may present in Matrigel (Sorby et al. 2001).  It 
has also been suggested that CD148 localisation in the membrane may be regulated through a 
size exclusion model (Lin et al. 2003; Choudhuri et al. 2005).   
The crystal structure of the CD148 PTP domain was recently determined by Barr et al 
(Barr et al. 2009).  X-ray diffraction techniques and phosphatase activity assays were used to 
study the PTP domain structures and activities of a representative panel of classical PTPs.  
Interestingly, the CD148 WPD loop was found to be in a closed conformation and signifies a 
catalytically active state.  In kinetics studies, recombinant CD148 PTP domain had one the 
highest enzymatic actives compared with a panel of 21 other recombinant PTP domains (Barr 
et al. 2009). 
 
1.7.2.6.1.2  Other platelet RPTPs 
Another RPTP that may be expressed in platelets is PTPRO (also referred to as GLEPP1 and 
PTP-U2), which belongs to the same subgroup and is structurally related to CD148 (Figure 
1.11).  PTPRO is primarily expressed in the brain and kidney, but is also present in 
hematopoietic stem cells, lungs, lymph nodes, spleen and placenta (Avraham et al. 1997; 
Aguiar et al. 1999; Beltran et al. 2003).  It was recently shown to be expressed in human 
megakaryocytes and detected in a mouse megakaryocyte SAGE library (Taniguchi et al. 1999; 
Senis et al. 2007).  It has been implicated in megkaryocytopoeisis and that its role is regulated 
by the SCF receptor, Kit.  Importantly, knockdown of PTPRO expression in megakaryocytic 
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cell lines has been shown to significantly inhibit megakaryocyte progenitor proliferation.  
PTPRO knockout mice have defects in kidney function as a result of a change in podocyte 
structure, however, they have not been examined in detail for other physiological defects 
(Wharram et al. 2000). 
The structurally distinct RPTP CD45, which is highly and exclusively expressed in all 
hematopoietic cells, except platelets and erythrocytes, was also recently detected in a large 
immature population of murine megakaryocytes, suggesting that it may be involved in 
megakaryocyte development and switched off during megakaryocyte maturation and platelet 
formation (Matsumura-Takeda et al. 2007).   
 
1.7.2.6.2  Non-transmembrane PTPs 
1.7.2.6.2.1  PTP-1B 
PTP-1B is a small (50 kDa) NTPTP that is expressed in all tissues.  Structurally, PTP-1B is 
comprised of an N-terminal PTP domain, followed by two tandem proline-rich motifs that 
may allow the interaction with SH3-domain containing proteins, and a short C-terminal 
hydrophobic stretch of amino acids that localize it to the cytoplasmic surface of the ER 
(Figure 1.11) (Frangioni et al. 1992).  It is a major regulator of metabolism as demonstrated 
by two PTP-1B-deficient mouse models that are resistant to high fat-induced obesity and 
insulin hypersensitivity (Elchebly et al. 1999; Klaman et al. 2000).  The obesity phenotype is 
due to its role in dephosphorylating Jak-2 downstream of the leptin receptor, and the insulin 
hypersensitivity is due to its role in dephosphorylating the insulin receptor and possibly 
insulin receptor substrate-1 (IRS-1).  PTP-1B has also been linked to other diseases, including 
cancer and autoimmunity, through its role in regulating cytokine and growth factor receptor 
signalling in haematopoietic and lymphoid cells (Tonks 2006).   
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PTP-1B was the first PTP identified in platelets and is likely the most abundant, 
comprising ~0.2% of all soluble platelet proteins, comparable to that of Src kinase (Frangioni 
et al. 1993).  Platelet activation accompanied by integrin αIIbβ3 engagement causes cleavage 
of the C-terminal hydrophobic tail of PTP-1B by calpain, releasing it from the ER and 
increasing its specific activity (Frangioni et al. 1993).  Recent work using a PTP-1B:calpain-1 
double deficient mouse model confirmed that calpain is essential for this cleavage (Kuchay et 
al. 2007).  In support of PTP-1B being involved in outside-in αIIbβ3 integrin signalling, 
Ragab et al demonstrated that PTP-1B regulates FcγRIIA-mediated irreversible aggregation 
(Ragab et al. 2003). 
Platelets from PTP-1B-deficient mice exhibit a number of functional defects attributed 
to defective outside-in integrin αIIbβ3 signalling (Arias-Salgado et al. 2005).  These defects 
include: reduced spreading on fibrinogen, defective clot retraction, reduced aggregate 
formation on collagen under flow, and reduced thrombus formation in vivo.  Interestingly, 
convulxin-, ADP- and PAR-4 peptide-induced responses were normal, suggesting that GPVI, 
P2Y1, P2Y12 and PAR-4 receptor signalling were normal.  The molecular basis of the 
phenotype exhibited by PTP-1B-deficient platelets is a block in outside-in integrin αIIbβ3 
proximal signalling, caused by hyperphosphorylation of the C-terminal inhibitory tyrosine 
(Tyr-529) of Src.  Based on their findings, Arias-Salgado et. al. proposed a model whereby 
fibrinogen binding to αIIbβ3 triggers PTP-1B recruitment to the αIIbβ3-Src-Csk complex, 
dissociation of Csk, dephosphorylation of Src Tyr-529 resulting in Src activation and 
initiation of the signalling cascade (Arias-Salgado et al. 2005).  PTP-1B therefore is an 
essential positive regulator of the initiation of outside-in integrin αIIbβ3 signalling in 
platelets.  How PTP-1B gets activated downstream of the integrin αIIbβ3 remains to be 
answered.  Further, why PTP-1B specifically activate Src downstream of αIIbβ3 and not other 
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SFKs downstream of other platelet surface receptors, such as Fyn and Lyn downstream of 
GPVI also needs to be addressed. 
 
1.7.2.6.2.2  Shp1 and Shp2 
 
Shp1 and Shp2 are a subfamily of NTPTPs characterized by the presence of two tandem SH2 
domains, a classic PTP domain and a C-terminal tail containing two tyrosyl phosphorylation 
sites (Figure 1.11).  Expression of Shp1 is restricted, with the highest levels found in 
haematopoietic cells, whereas Shp2 is widely expressed in a number of cell types (Neel et al. 
2003).   The SH2 domains of Shp1 and Shp2 play a crucial role in regulating PTP activity 
through intra- and inter-molecular binding that obstructs the catalytic cleft and mediate 
protein-protein interactions, primarily with ITIM proteins. 
Shp1 is generally recognized as a negative regulator of tyrosine kinase-linked receptor 
signalling.  For example, it has been proposed that Shp1 maintains the BCR in a non-
signalling state by dephosphorylating the associated ITAMs and thereby controlling the 
threshold for receptor activation (Pani et al. 1995).  Similarly, it has been suggested that Shp1 
attenuates the earliest events in TCR signalling by dephosphorylating the SFK Lck and the 
tyrosine kinase ZAP-70 (Plas et al. 1996; Chiang et al. 2001).  Shp1 has also been shown to 
inhibit integrin signalling in macrophages and neutrophils (Roach et al. 1998; Kruger et al. 
2000; Griffiths et al. 2001; Peterson et al. 2001).  Collectively, these findings are interesting 
from a platelet perspective as several candidate substrates of Shp1 downstream of the BCR 
and TCR are also involved in GPVI and/or integrin αIIbβ3 signalling (Kon-Kozlowski et al. 
1996; Pani et al. 1996; Cuevas et al. 1999; Dustin et al. 1999; Mizuno et al. 2000; Stebbins et 
al. 2003; Mizuno et al. 2005).  Two naturally occurring point mutations exist in the murine 
Shp1 gene, resulting in no expression of Shp1 (motheaten allele) or expression of catalytically 
inactive Shp1 (motheaten viable allele).  The phenotypes of the two mutations differ only in 
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severity, with motheaten mice dying earlier (2 – 3 weeks) than motheaten viable mice (9 – 12 
weeks) due to severe inflammation and tissue damage (Van Vactor et al. 1998; Zhang et al. 
2000; Neel et al. 2003). Mechanistically, most of the abnormalities of motheaten mice can be 
explained by the loss of negative regulatory pathways in the absence of Shp1.  The functional 
role of Shp1 in platelets has been investigated using motheaten viable mice (Pasquet et al. 
2000).  This work demonstrated the surprising observation that Shp1 plays a positive role in 
supporting platelet activation through GPVI. 
Shp2 is predominantly regarded as a positive regulator of the Ras-Erk pathway 
(Noguchi et al. 1994; Shi et al. 2000).  It has also been implicated in regulating the PI-3 kinase 
and Rho pathways (Schoenwaelder et al. 2000; Zhang et al. 2002).  The role of Shp2 in ITAM 
receptor signalling is less well understood than for Shp1.  However, studies of TCR signalling 
and several inhibitory receptors implicate Shp2 as a negative regulator of immunoreceptor 
signalling pathways (Kwon et al. 2005).  Another mechanism by which Shp2 inhibits TCR 
signalling may involve its association with inhibitory ITIM receptors, including CEACAM1 
and PECAM-1 (Ilan et al. 2003; Gray-Owen et al. 2006).  Shp2-deficient mice die between 8 
and 10 weeks with a range of developmental defects (Van Vactor et al. 1998; Saxton et al. 
2000).  Interestingly, mice homozygous for the Shp2 D61G gain-of-function mutation die at 
mid-gestation, exhibiting a gross hemorrhagic phenotype, and heterozygotes develop a 
Noonan syndrome-like disorder with excessive bleeding (Araki et al. 2004).  The dramatically 
different phenotypes exhibited by Shp1- and Shp2-deficient mutant mice demonstrate that 
they have different biological functions (Van Vactor et al. 1998). 
It is presently not clear, whether Shp1 and Shp2 are predominantly negative or positive 
regulators of platelet activation.  Although Shp1 and/or Shp2 have been shown to interact with 
each of the known platelet receptor-like ITIMs, namely PECAM-1, TLT-1, G6b-B and 
CEACAM1, the relative contributions of Shp1 and Shp2 to signalling by each of these 
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receptors is not known (Jackson et al. 1997; de Vet et al. 2001; Barrow et al. 2004; Newland 
et al. 2007; Senis et al. 2007; Wong et al. 2009). 
 
1.7.2.6.2.3  MEG-2 
MEG-2 is a NTPTP and is distinguished from other mammalian PTPs by the presence of an 
N-terminal lipid-binding domain. MEG-2 resides on internal membranes, including secretory 
vesicles and granules in neutrophils and lymphocytes, and has been shown to modulate 
murine development and platelet and lymphocyte activation through secretory vesicle function 
(Wang et al. 2005).  Wang et al demonstrated that platelets from MEG-2-deficient mice did 
not aggregate when stimulated with a high dose of thrombin compared to wild-type platelets 
(Wang et al. 2005).  In contrast, ADP-induced aggregation was only slightly impaired in the 
MEG-2 deficient platelets.  The author suggests a link with defective release of α-granules 
however, the exact mechanism remains unclear.   
 
1.7.2.6.2.4  LMW-PTP 
LMW-PTP is a small (18 kDa) archaic PTP that consists of a single PTP domain containing 
the active-site signature motif HCX5R and no other known domains or motifs (Alonso et al. 
2004).  It is not classified as a classical PTP, but rather is the only class II NTPTP based on its 
unique structural features.  Although its physiological function is not known, it has been 
implicated in regulating cell adhesion and spreading (Chiarugi et al. 2000; Rigacci et al. 
2002).  One study reports the expression of LMW-PTP in platelets and DAMI human 
megakaryocytic cells (Mancini et al. 2007).  Mancini et. al. demonstrate that human platelets 
express high levels of LMW-PTP (~0.05% of total protein) and that it dephosphorylates the 
ITAM-containing FcγRIIA receptor in vitro and in cell lines (Mancini et al. 2007).  The 
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authors conclude that LMW-PTP plays an important role in regulating FcγRIIA receptor 
signalling in platelets.   
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1.8   Aims of this thesis 
The main objective of this thesis was to determine the expression, biochemical properties and 
function of CD148 in platelets.  The reason I focused on CD148 is because it was the only 
RPTP identified by multiple peptide hits in a global platelet membrane proteomics study 
conducted by my supervisor, Dr. Senis, and he hypothesized that platelets express a CD45-
like RPTP that is critical for initiating signalling from the ITAM receptor GPVI.  He also 
hypothesized that platelets express a PTPα-like RPTP that could initiate integrin αIIbβ3 
signalling.  These two hypotheses formed the basis of this thesis. 
 A third hypothesis which underpins the work on PTP-1B and TC-PTP in the final 
chapter of this thesis is that other PTPs compensate in the absence of CD148 in platelets.  
Since I was unable to conclusively demonstrate expression of another RPTP in platelets that 
could fulfil this functional redundancy, I turned my attention to PTP-1B and the structurally 
related TC-PTP.  PTP-1B was the primary candidate as recent work by Arias-Salgado et. al. 
showed that PTP-1B was essential for activating integrin αIIbβ3-associated Src in platelets, 
by a similar mechanism to the one we had discovered for CD148.  When we found that the 
aggregation, secretion and phosphorylation defects observed in PTP-1B-deficient platelets 
were much milder and complicated by strain variation compared with the defects observed in 
CD148-deficient platelets, we hypothesized that TC-PTP may have similar functional roles to 
CD148 in platelets, which is why I analyzed platelets from TC-PTP-deficient platelets for 
functional defects. 
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2.1  Materials 
2.1.1  Antibodies and chemicals 
All antibodies, agonists and inhibitors used in this thesis are detailed in Tables 2.1, 2.2 and 
2.3, respectively.  Alexa488-conjugated phalloidin was purchased from Molecular Probes.  
Bovine serum albumin (BSA) used for blocking western blots was purchased from First Link 
UK Ltd.  Fatty acid free BSA used for blocking slides and coating plates was purchased from 
Sigma.   Phosphopeptides corresponding to the activation loop and C-terminal inhibitory tail 
of SFKs were synthesized by GenScript (Piscataway, NJ, USA) (Table 2.5).  All other 
chemicals were purchased from Sigma, unless otherwise indicated. 
 
2.1.2  Molecular biology reagents 
All expression constructs used in this thesis are detailed in Table 2.4.  All cDNAs were 
sequenced at Alta Biosciences (University of Birmingham, UK), prior to use.  TOP10 DH5α 
competent bacteria were purchased from Invitrogen.  Mini-prep kits and maxi-prep kits were 
purchased from Sigma.  HEK 293T cells and DT40 chicken B cells were kindly provided by 
Dr. Mike Tomlinson.  RPMI, DMEM, foetal bovine serum, chicken serum, GlutaMAX, 
antibiotics and antimycotics were purchased from Gibco (Invitrogen). 
 
2.1.3  Genetically modified mice 
CD148 transmembrane knockout (CD148 TM-KO) mice on a C57BL/6 background were 
kindly provided by Professor Arthur Weiss (UCSF, California, USA) (Zhu et al. 2008).  PTP-
1B-deficient mice on a Balb/c and a C57BL/6 background were kindly provided by Professor 
Michel Tremblay (McGill University, Montreal, Canada) (Elchebly et al. 1999).  All 
procedures were undertaken with United Kingdom Home Office approval in accordance with 
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the Animals (Scientific Procedures) Act of 1986 (Project License No: 40/2212, 40/2803, 
40/2908 and 40/2749). 
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Table 2.1.  Antibodies 
 
Antigen 
(species) 
Species antibody 
raised in 
(clone or catalogue 
number) 
Source Working 
dilution 
αIIbβ3 
(m, resting) 
rat,  
PE-conjugated 
(Leo-H4) 
Emfret Analytics 
 
FC: 1/100 
αIIbβ3 
(m, high affinity) 
rat,  
PE-conjugated 
(JON/A) 
Emfret Analytics FC: 1/100 
actin 
(h, m) 
mouse monoclonal 
(ac-40) 
Sigma WB: 1/1,000 
CD148 
(h, m) 
mouse monoclonal 
(143-41) 
Biosource  
 
IP: 1/500  
WB: 1/1,000 
Csk 
(h) 
rabbit polyclonal 
(sc-286) 
Santa Cruz Biotechnology IP: 1/1,000  
WB: 1//1,000 
FcR γ-chain 
(h,m) 
rabbit polyclonal 
 
Millipore WB: 1/1,000 
Fyn  
(h, m) 
rabbit monoclonal 
(clone: 04-353) 
Millipore WB: 1/1,000 
Fyn  
(h, m) 
rabbit polyclonal 
(clone: BL90) 
Dr. Joseph Bolen 
(DNAX) 
IP: 1/1,000   
WB: 1/1,000 
Fyn p-Tyr 530 
(h, m) 
rabbit polyclonal 
(53690) 
Abcam  WB: 1/1,000 
goat IgG  
FITC-conjugate 
chicken 
(HAF019) 
R&D Systems 
 
WB: 1/5,000 
GPVI 
(m) 
rat, 
FITC-conjugated 
(JAQ1) 
Emfret Analytics IP: 1/1,000  
WB: 1//1,000 
GPVI 
(h) 
rabbit polyclonal 
 
Professor Masaki Moroi 
(Japan) 
FC: 1/100 
WB: 1//1,000 
LAT 
(h, m) 
rabbit polyclonal 
(AB4093) 
Millipore WB: 1/500 
Lyn  
(h, m) 
rabbit polyclonal 
(sc-15) 
Santa Cruz Biotechnology WB: 1/1,000 
Lyn p-Tyr 507 
(h, m) 
rabbit polyclonal 
(2731) 
Cell Signaling WB: 1/1,000 
mouse IgG 
FITC-conjugate 
sheep 
(26851) 
Amersham  
 
WB: 1/10,000 
non-immune 
mouse IgG1 
mouse 
(MOPC1) 
Sigma IP: 1/500 
non-immune 
rabbit IgG 
rabbit 
(12-370) 
Millipore  IP: 1/500 
PLCγ2 
(h, m) 
rabbit polyclonal 
(DN84) 
Dr. Joseph Bolen 
(DNAX) 
IP: 1/1,000   
WB: 1/1,000 
h, human; m, mouse; r, rat; p, phospho; FC, flow cytometry; IP: immunoprecipitation; WB: 
western blotting 
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Table 2.1 (continued) 
 
Antigen 
(species) 
Species antibody 
raised in 
(clone or catalogue 
number) 
Source Working 
dilution 
P-selectin 
(h) 
rat, FITC 
conjugated 
(AC1.2) 
BD Biosciences 
 
FC: 1/100 
P-selectin 
(m) 
rat, FITC 
conjugated 
(WUG.E4) 
Emfret Analytics FC: 1/100 
p-Tyr 
(h, m) 
mouse monoclonal 
(4G10) 
Millipore  WB: 1/1,000 
PTPRO 
(h, m) 
goat polyclonal 
(sc-33415) 
Santa Cruz Biotechnology IP: 1/1,000  
WB: 1/1,000 
rabbit IgG  
FITC-conjugate 
donkey 
(A50-201A) 
Amersham WB: 1/10,000 
RPTPσ 
(h,m) 
mouse monoclonal 
(17G7.2) 
Dr. M.L. Tremblay 
(McGill University) 
WB: 1/100 
 
Src pan 
(h, m) 
rabbit polyclonal 
(44656G) 
Invitrogen IP: 1/500 
WB: 1/1,000 
Src p-Tyr 418 
(h, m) 
rabbit polyclonal 
(44660G) 
Invitrogen WB: 1/1,000 
Src p-Tyr 529 
(h, m) 
rabbit polyclonal 
(44-662G) 
Biosource WB: 1/1,000 
Syk 
(h, m) 
rabbit polyclonal 
(BR15) 
Dr. Joseph Bolen 
(DNAX) 
WB: 1/1,000 
TC-PTP 
(h,m,r) 
mouse monoclonal 
(252294) 
R & D systems 
 
WB: 1/1,000 
 
h, human; m, mouse; r, rat; p, phospho; FC, flow cytometry; IP: immunoprecipitation; WB: 
western blotting 
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Table 2.2.  Agonists 
 
Agonist Target receptor Source 
ADP P2Y1, P2Y12 Sigma 
collagen (HORM; equine; 
primarily types I and III) 
GPVI, α2β1 Nycomed 
convulxin (snake toxin) GPVI, 
GPIb-IX-V 
Latoxan 
collagen-related peptide 
(CRP; GCO-[GPO]10-
GCOG-NH2) chemically 
cross-linked as previously 
described (Morton et al, 
Biochem J, 1995; Asselin et 
al, Biochem J, 1999) 
GPVI Department of Biochemistry, 
Cambridge, UK 
fibrinogen (human) αIIbβ3 Enzyme Research 
Laboratories 
ionomycin Ca2+ ionophore Sigma 
PMA PKC Sigma 
thrombin (bovine) PAR-1, PAR-4 Sigma 
U46619 TP Sigma 
prostacyclin (PGI2) PGI2 receptor Camen Chemicals 
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Table 2.3.  Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitor Target Final 
concentration 
Source 
apyrase ADP/ATP scavenger 2 U/ml Sigma  
indomethacin cyclooxygenase 10 µM Sigma 
integrilin αIIbβ3 9 µM Sigma 
EDTA divalent cation 
chelator 
1 µM Sigma 
EGTA divalent cation 
chelator – primarily 
Ca2+ 
1 µM Sigma 
pervanadate protein tyrosine 
phosphatases 
100 µM Sigma 
PP1 Src family kinases 10 µM Calbiochem  
PP2 Src family kinases 10 µM Calbiochem  
AEBSF serine proteases 200 µg/ml Sigma 
leupeptin serine proteases 10 µg/ml Sigma 
aprotinin serine proteases 10 µg/ml Sigma 
pepstatin serine proteases 10 µg/ml Sigma 
heparin acts as a cofactor for 
anti-thrombin III, 
which inhibits 
coagulation factors,  
including thrombin 
10 U/ml Sigma 
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       Table 2.5: Phosphopepetides used in in vitro phosphatase assay. 
 
 
 
 
 
Peptides custom manufactured by Genscript 
 
 
 
 
 
 
 
 
 
 
 
 
 
SFK peptide peptide sequence
Lyn activation loop VIEDNEpY397TAREGA
Lyn inhibitory site TATEGQpY508QQQP
Src activation loop LIEDNEpY419TARQGA
Src inhibitory site TSTEPQpY530QPGENL
Fyn inhibitory site TATEPQpY531QPGENL
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2.2 Methods 
2.2.1 Platelet preparation 
2.2.1.1 Washed human platelets 
Blood was drawn on the day of experiment from healthy, drug-free volunteers into 1:10 (v:v) 
sterile sodium citrate and 1:9 (v:v) acid citrate dextrose (ACD: 120 mM sodium citrate, 110 
mM glucose, 80 mM citric acid).  Platelet rich plasma (PRP) was obtained by centrifugation 
at 200 ×g for 20 minutes.  Platelets were isolated from PRP by centrifugation at 1000 ×g in 
the presence of 10 μg/ml PGI2.  The platelet pellet was washed in 25 ml modified Tyrodes-
HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM 
HEPES, 5 mM glucose, 1 mM MgCl2 pH 7.3) and 3 ml ACD followed by centrifugation at 
1,000 ×g for 10 minutes in the presence of 10 μg/ml PGI2.  Platelets were counted using a 
Coulter Z2 Particle Count and Size Analyzer (Beckman Coulter Ltd), and resuspended to a 
concentration of 2 × 108/ml for aggregation studies or 5 × 108/ml for protein studies in 
Tyrodes-HEPES buffer.  Washed platelets were rested for at least 30 minutes prior to use to 
allow the effects of PGI2 to wear off. 
 
2.2.1.2 Washed mouse platelets 
Blood samples were drawn from terminally CO2-narcosed mice by cardiac puncture.  
Approximately 900 µl blood was collected from each mouse into 100 µl ACD.  Subsequent to 
collection, anti-coagulated blood was further diluted with 200 μl modified Tyrodes-HEPES 
buffer.  Blood was centrifuged at 180 ×g for 5 minutes and then the supernatant and the top 
third of the erythrocyte layer were removed and centrifuged at 200 ×g for 6 minutes.  The 
PRP layer was transferred into a new tube and 300 μl of modified Tyrodes-HEPES buffer was 
added to the remaining erythrocyte layer.  The diluted erythrocyte layer was centrifuged at 
200 ×g for 6 minutes, the PRP layer was removed and pooled with the previously collected 
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PRP.  Modified Tyrode’s-HEPES buffer was added to the PRP to a final volume of 1 ml.  
Washed platelets were prepared by centrifugation of the diluted PRP at 1000 ×g for 6 minutes 
in the presence of 10 µg/ml PGI2.  The platelet pellet was resuspended in modified Tyrodes-
HEPES buffer, platelets were counted using a Coulter Z2 Particle Count and Size Analyzer, 
and platelets were diluted to 2 × 108/ml for aggregation studies or 5 × 108/ml for protein 
studies.  All washed platelets were rested for at least 30 minutes prior to use to allow the 
effects of PGI2 to wear off. 
 
2.2.1.3 Preparation of ADP-sensitive mouse platelets 
Blood samples were drawn from terminally CO2-narcosed mice by cardiac puncture.  
Approximately 900 µl of blood was collected from each mouse into 100 µl 100 U/ml heparin 
diluted in modified Tyrodes-HEPES buffer.  Anti-coagulated blood was further diluted with 
200 μl of 10 U/ml heparin in modified Tyrodes-HEPES buffer.  Blood was centrifuged at 180 
×g for 5 minutes and the platelet-rich plasma (PRP) was collected.  Platelets were counted 
using a Coulter Z2 Particle Count and Size Analyzer and diluted to a concentration of 2 × 
108/ml with modified Tyrodes-HEPES buffer for aggregation studies. 
 
2.2.1.4 Preparation of platelet poor plasma  
Platelet poor plasma (PPP) was prepared by centrifuging the remaining erythrocyte layer 
following collection of PRP at 1000 ×g for 6 minutes.  PPP was collected and diluted with 
Tyrodes-HEPES buffer to the same extent as PRP. 
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2.2.2  Platelet Functional Assays 
2.2.2.1  Platelet Aggregation and ATP secretion 
Platelet aggregation and ATP secretion were measured simultaneously, in real-time as a 
change in optical density and luciferase/luciferin generated luminescence, respectively, using 
a Born lumi-aggregometer (Chronolog, Labmedics).  Samples (washed platelets or PRP at 2 × 
108/ml) were maintained at 37°C with constant stirring at 1,200 rpm throughout the 
experiment.  The optical density and luminescence of the each platelet suspension were 
recorded in real-time using a pen recorder over a 6 minute period (Chronolog, Labmedics).  
Modified Tyrodes-HEPES buffer and PPP were used as blanks for washed platelets and PRP, 
respectively.  Glass tubes and stir bars in which samples were stimulated were siliconized.  
Samples were pre-warmed at 37°C for 2 minutes without stirring followed by 30 seconds at 
37°C with continuous stirring at 1,200 rpm prior to addition of agonists.  Inhibitors were 
added to platelets 5 – 10 minutes prior to addition of agonists. 
 
2.2.2.2  Platelet spreading 
Coverslips were coated with 200 µl of either 100 μg/ml fatty acid free BSA (control), 100 
μg/ml collagen or 100 μg/ml fibrinogen and incubated overnight at 4°C.  Coated coverslips 
were washed twice with phosphate buffered saline (PBS: 0.01 M phosphate buffer, 0.0027 M 
potassium chloride and 0.137 M sodium chloride, pH 7.4) and blocked with 200 µl of 
denatured (10 minutes at 100°C) 5 mg/ml fatty acid free BSA for 60 minutes at room 
temperature.  Coverslips were washed twice with PBS prior to addition of platelets (200 µl at 
2 × 107/ml) pre-treated with 2 U/ml apyrase and 10 µM indomethacin.  Platelets were 
incubated on protein-coated slides for 45 minutes at 37°C.  Non-adherent platelets were 
washed away with modified Tyrode’s-HEPEs  buffer, platelets were fixed for 10 minutes with 
3.7% paraformaldehyde (Sigma) then permeabilized with 0.2% Trition-X 100 for 5 minutes at 
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room temperature.  Platelets were washed with 3 × 300 µl of PBS then actin filaments were 
stained with 300 µl of 0.5 µg/ml Alexa488-phalloidin in PBS at room temperature for 1 hr in 
the dark.  Cover-slips were washed with 3 × 300 µl of PBS, mounted on microscope slides 
with Immuno Fluore Mounting Media (ICN Biomedicals, CA, USA) and platelets viewed 
using a Zeiss Axiovert 200M microscope with a 63 × oil immersion lens.  Images were 
captured using a Hamamatsu Orca 285 cool digital camera (Cairn, UK).  Images were 
analyzed using ImageJ software (NIH, Maryland, USA).  Individual platelets (25 – 50 
platelets per image; at least three images per slide) platelets were outlined and surface area 
quantified by determining the number of pixels within the outlined area.  Imaging a graticule 
under the same conditions allowed the conversion of pixels to microns.  For platelet adhesion 
analysis, the number of platelets per image were counted (at least three images per slide). 
 
2.2.2.3  Flow cytometry 
Washed human or mouse platelets (1 × 107/ml) in modified Tyrodes-HEPES buffer 
containing 1 mM EGTA were incubated with primary antibody (or isotype control antibody at 
the same concentration) for 20 minutes at room temperature in the presence and absence of 1 
U/ml thrombin.  Platelets were subsequently centrifuged at 1000 ×g for 6 minutes and 
resuspended in modified Tyrodes-HEPES buffer containing FITC-conjugated secondary 
antibody for 20 minutes at room temperature in the dark.  The final volume was increased to 
500 µl and platelets were analyzed using a FACScaliber instrument (Becton Dickinson) and 
Cell-Quest software.  For P-selectin staining, washed platelets (1 × 107/ml) were stimulated 
with 1 U/ml thrombin (without stirring) for 10 minute at room temperature then stained with 
100 μg/ml FITC-conjugated P-selectin antibody (or 100 μg/ml FITC-conjugated isotype 
control antibody) for 10 minutes.  Two-hundred 200 µl of modified Tyrodes-HEPES buffer 
was added to samples prior to flow cytometric analysis.  The same method was used to stain 
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active integrin αIIbβ3 PE-conjugated JON/A antibody, which only recognises the active, high 
affinity conformation of the integrin αIIbβ3.  Total intergrin αIIbβ3 was stained using a PE-
conjugated antibody that recognizes both active and inactive forms of the integrin. 
 
2.2.3  Platelet biochemistry 
2.2.3.1  Sample preparation of platelets in suspension 
Washed platelets (5 × 108/ml) in modified Tyrodes-HEPES were pre-treated with: 100 μM 
EGTA or 9 µM integrillin, to inhibit outside-in integrin αIIbβ3 signalling; 10 μM 
indomethacin, to inhibit TxA2 production; and 2 U/ml apyrase, to degrade released ADP.  
Platelets were stimulated with various agonists for various lengths of time (as indicated in the 
Results Chapters).  Stimulations were performed in siliconized cuvettes at 37°C with constant 
stirring at 1,200 rpm.  Following stimulation, platelets were lysed with an equal volume of 2 × 
lysis buffer containing protease and phosphatase inhibitors (300 mM NaCl, 20 mM Tris, 
2mM EGTA, 2 mM EDTA, 2% NP-40 pH 7.4 with 2.5 mM Na3VO4, 100 μg/ml AEBSF, 5 
μg/ml leupeptin, 5 μg/ml aprotinin and 0.5 μg/ml pepstatin). 
 
2.2.3.2  Sample preparation of spread platelets  
Ten centimetre diameter bacterial grade plastic plates were coated with 100 μg/ml fatty acid 
free BSA (control), 100 μg/ml collagen or 100 μg/ml fibrinogen and incubated overnight at 
4°C.  Plates were washed 2 × 5 ml PBS.  Plates were subsequently blocked with 5 mg/ml 
denatured (10 minutes at 100°C) fatty acid free BSA for 1 hour at room temperature.  Washed 
platelets (1.5 ml of 5 × 108/ml) in the presence of 10 μM indomethacin and 2 U/ml apyrase 
were placed on the various surfaces for 45 minutes at 37°C.  Non-adherent platelets were 
removed from BSA-coated plates and lysed in an equal volume of ice cold 2× lysis buffer 
containing protease and phosphatase inhibitors (same as above).  Adherent platelets were 
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washed from collagen- and fibrinogen-coated platelets with 2× 5 ml modified Tyrodes-
HEPES buffer, and adherent platelets were lysed with 1× lysis buffer containing protease and 
phosphatase inhibitors.  Plates were incubated on ice for 15 minutes following addition of 
lysis buffer to ensure complete lysis of platelets. 
 
 
2.2.3.3  Immunoprecipitation 
 
Platelet lysates generated as described above were pre-cleared by addition of 25 µl of a 50% 
slurry of protein-A or protein-G sepharose (PAS and PGS, respectively) hydrated in TBS-T 
(137 mM NaCl, 20 mM Tris, 0.1 % Tween-20, pH 7.6) for 30 minutes at 4°C with constant 
mixing.  PAS, PGS and insoluble platelet debris were pelleted at 13,000 ×g for 10 minutes at 
4°C.  Supernatants were collected and protein concentrations determined using the BioRad-
Detergent Compatible Protein Assay Kit according to the manufacturer’s instructions.  Whole 
cell lysates (WCLs) were prepared by adding 50 µl of 2× reducing Laemmli sample buffer (4 
% SDS, 10 % 2-mercaptoethanol, 20 % glycerol, 50 mM Tris, trace Brilliant Blue R) to 50 µl 
aliquots of the pre-cleared platelet lysate and heating to 100°C for 5 minutes.  Specific 
proteins were immunoprecipited (IP’d) from the remaining WCLs by adding 1 – 5 µg of 
antibody, incubating for 30 minutes at 4°C with constant mixing then adding 20 µl of a 50% 
slurry of either PAS (to IP rabbit antibodies) or PGS (to IP mouse and goat antibodies) and 
incubating overnight at 4°C with constant mixing.  The following day, beads were pelleted at 
9,000 ×g for 30 seconds and washed 4 × 1 ml ice cold TBS-T.  Proteins were eluted from 
beads by adding 2× Laemmli sample buffer under reducing conditions and heating to 100°C 
for 5 minutes. 
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2.2.3.4  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting 
Proteins were resolved on either 10% or pre-cast 4 – 12 % gradient SDS-PAGE gels 
(Invitrogen).  Pre-stained molecular weight markers (Bio-Rad) were run on all 10% gels. 
Non-stained molecular weight markers (Bio-Rad) were run on all 4 – 12 % gradient gels. 
Proteins were transferred from SDS-PAGE gels to polyvinylidene diflouride membranes 
(PVDF) using a Semi-Dry Transfer apparatus (Bio-Rad).  Gels and PVDF membranes were 
soaked in transfer buffer (48 mM Tris, 39 mM glycine, 1.3 mM SDS pH 9 containing 20% 
methanol) for 15 minutes prior to transferring at 110 mAmp per gel for 35 minutes.  
Membranes were blocked overnight at 4ºC in blocking buffer (TBS-T containing 5% [w/v] 
bovine serum albumin [BSA] and 0.1 % [w/v] sodium azide).  Blocked membranes were 
immunoblotted with primary antibodies diluted in blocking buffer for 1 hour at room 
temperature or overnight at 4°C.  Membranes were washed 3 times with 50 ml TBS-T for 15 
minutes per wash and subsequently incubated for 1 hour with HRP-conjugated secondary 
antibodies in TBS-T.  Membranes were washed 3 more times as described above.  Bands were 
visualized by enhanced chemiluminescence according to the manufacturer’s protocol 
(Amersham Bioscience, Bucks, UK).  Blots were stripped by incubating in stripping buffer 
(TBS-T, 2% SDS) containing 1% 2-mercaptoethanol for 20 minutes at 80ºC followed by 20 
minutes in stripping buffer alone without 2-mercaptoethanol; re-blocked (TBS-T, 5% BSA, 
0.1% azide) overnight; and re-blotted using the same protocol described above.  For 
densitometry analysis, band intensities were calculated using Photoshop cs version 8.0. 
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2.2.4  Functional studies in DT40 cells 
2.2.4.1  Cell culture 
DT40 chicken B cells were cultured in RPMI supplemented with 10% foetal bovine serum, 
1% chicken serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 50 μM mercaptoethanol 
and 20 mM GlutaMAX. 
 
2.2.4.2  DT40-NFAT luciferase assay 
DT40 cells were transfected in a volume of 400 µl non-supplemented RPMI by 
electroporation using a GenePulser II (Bio-Rad) set at 350 V, 500 µF.  DT40 cells were 
transfected with either 10 μg of CD148 wild-type or 10 μg CD148 catalytically inactive 
expression constructs and 2 μg GPVI and 2 μg FcR γ-chain constructs, in addition to 15 μg of 
the luciferase reporter construct and 2 μg of pEF6-lacZ to control for transfection efficiency. 
Twenty hours after transfection, live cells were counted by trypan blue exclusion, and samples 
were divided into three parts for luciferase assay, β-galactosidase assay and flow cytometry.  
Luciferase assays were performed in triplicate with 105 live cells in a total volume of 100 μl.  
Cells were stimulated for 6 hours with 10 μg/ml collagen, then lysates were prepared by 
adding 11 μl of harvest buffer (1 M potassium phosphate buffer pH 7.8 containing 12.5% 
Triton X-100 and 1 M DTT).  90 μl of lysate was added to 90 μl of assay buffer (1M 
potassium phosphate buffer pH 7.8 containing 0.1 M MgCl2 and 0.1 M ATP).  Following the 
addition of 50 μl of 1 mM luciferin (MP Biomedicals, UK), luciferase activity was measured 
with a Centro LB 960 microplate luminometer (Berthold Technologies, Germany).  Data is 
expressed as either luminescence units normalised to β-galactosidase activity or as the fold 
increase in luminescence units over basal as indicated.  All luciferase data is averaged from 3 
readings and shown ± standard deviation.  All experiments were performed 3 – 5 times. 
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2.2.4.3  β-galactosidase assay 
β-galactosidase activity was measured in 5 × 105 cells using the Galacto-Light 
Chemiluminescent Reporter Assay according to the manufacturer’s instructions (Applied 
Biosystems).  Samples were measured in triplicate using a Centro LB960 Microplate 
luminometer Centro (Berthold Technologies, Wildbad, Germany).  All luciferase 
measurements were normalised to β-galactosidase activity/5 × 105 cells. 
 
2.2.4.4  Quantification of surface expression of receptors 
Surface expression of GPVI and CD148 on transiently transfected DT40 cells was measured 
by flow cytometry.  Half a million cells in 50 μl PBS were stained with 10 μg/ml of either 
anti-CD148 antibody or anti-GPVI antibody that recognize the extracellular regions of CD148 
and GPVI, respectively, for 20 minutes.  As negative controls, cells were stained with equal 
amounts of isotype control antibodies under the same conditions.  Cells were washed and 
incubated for 20 minutes with 15 μg/ml FITC-conjugated secondary antibodies.  Stained cells 
were analysed using the FACScalibur flow cytometer and CellQuest software. 
 
 
2.2.5  In vitro substrate trapping   
2.2.5.1  Bacterial transformation 
Precast agar plates containing 100 µg/ml ampicillin and SOC medium (Invitrogen) were 
warmed at 37 °C.  Competent DH5α bacteria (Invitrogen) were thawed on ice.  Two 
microlitres of CD148 expression constructs (Table 2.4) were mixed with 50 µl of DH5α 
bacteria and incubated on ice for 30 minutes.  Bacteria were heat shocked for 30 seconds at 
42°C to induce take up of plasmids, then placed on ice for a further 5 minutes.  Two-hundred 
and fifty microlitres of warm SOC medium was added to bacteria, which were incubated at 
37°C for 30 minutes to allow expression of the ampicillin resistance gene.  Bacteria were then 
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spread on the pre-warmed agar/ampicillin plates using sterile technique and grown overnight 
at 37°C.  Colonies were picked the next day and expanded in 250 ml liquid broth (1% 
tryptone, 0.5% yeast extract, 1% sodium chloride, pH 7.0 containing 100 µg/ml ampicillin) 
overnight at 37°C.  The following day 50% glycerol stocks of each construct culture were 
prepared and the remaining culture maxipreped using standard protocols. 
 
2.2.5.2  Expression and purification of recombinant proteins 
Pilot experiments were initially performed to determine optimal conditions for expression of 
MBP.CD148 fusion proteins, according to the vector manufacturer’s protocol (pMAL Protein 
Fusion and Purification System, New England BioLabs).  Five samples were collected at 
various stages of the expression/purification protocol to monitor expression levels of fusion 
proteins: (1) non-induced bacteria; (2) IPTG-induced bacteria; (3) total bacterial crude extract; 
(4) insoluble material from the crude extract; and (5) protein bound to amylose resin 
(Appendix - Figure 1). 
Based on results from pilot experiments, the following protocol was devised for the 
expression and purification of the MBP.CD148 fusion proteins.  Five millilitres of Liquid 
Broth (LB) containing 0.2 % glucose and 100 µg/ml ampicillin was inoculated with either 
MBP, MBP:CD148 wild-type, MBP:CD148 catalytically inactive or MBP:CD148 substrate 
trapping glycerol stocks and grown up overnight at 37°C with constant mixing.  The 
following day, 1 ml of each culture was used to inoculate 250 ml LB containing glucose and 
ampicillin.  Bacteria were cultured at 37°C until they reached an optical density of ~0.5 at an 
absorbance of 600 nm, corresponding to ~2 × 108 bacteria at the exponential growth phase.  
Expression of the fusion proteins was induced by the addition of 1 mM IPTG and incubation 
for 3 hours.  Cultured bacteria were then pelleted at 4,500 ×g at 4 °C for 30 minutes, 
supernatant was discarded and pellets frozen at -20°C.  Bacterial pellets were suspended in 20 
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ml ice cold column buffer containing protease inhibitors (20 mM Tris-HCl pH 7.4, 200 mM 
NaCl ,1 mM EDTA, 200 μg/ml AEBSF, 10 μg/ml leupeptin, 10 mM β-ME).  Bacteria were 
lysed using a Vibra-Cell ultrasonic processor model VC130PB (Sonics & Materials, Inc., 
Newtown, CT, USA) for 15 second bursts for 2 minutes on ice.  Samples were centrifuged at 
9,000 ×g at 4°C for 30 minutes to remove insoluble bacterial debris.  Crude supernatant was 
diluted 1:5 with column buffer. 
Four 2.5 × 10 cm amylose resin columns were prepared.  Columns were washed with 
8 column volumes of column buffer prior to the addition of samples.  Diluted crude extract 
was loaded on the columns and the flow rate adjusted to 10× (diameter of column in cm)2 
ml/hr (approximately 1 ml/minute for a 2.5 cm diameter column).  Columns were then 
washed with 12 column volumes of column buffer.  Fusion proteins were eluted from the 
columns with column buffer containing 10 mM maltose.  Ten to twenty 3 ml fractions (1/5th 
column volume) were collected for each fusion protein.  Fusion protein expression in 
fractions was monitored by measuring the absorbance at 280 nm of each fraction.  Fractions 
with high fusion protein expression were pooled and concentrated to approximately 1 mg/ml 
using a Centriprep concentrator according to the manufacturer’s protocol (Millipore). 
 
2.2.5.3  Protein pull-down and elution 
Substrate-trapping/pull-downs were performed using a similar protocol to that desribed by 
Palka et al (Palka et al, 2003).  Washed human platelets (5 × 108/ml) in modified Tyrodes-
HEPES buffer containing 1 mM EGTA, 10 µM indomethacin and 2 U/ml apyrase were 
stimulated with 100 µM pervanadate for 3 minutes at 37ºC with constant stirring.  Platelets 
were washed with modified Tyrodes-HEPES buffer containing 1 mM EGTA then lysed with 
an equal volume of 2× lysis buffer containing protease and phosphatase inhibitors as 
described above (section 2.2.3.1), with the exception that 2.5 mM Na3VO4 was replaced with 
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2.5 mM iodoacetic acid.  Following incubation on ice for 15 minutes dithiothreitol was added 
to a final concentration of 10 mM to inactivate any unreacted iodoacetic acid.  Samples were 
pre-cleared with 1 µg recombinant MBP bound to amylose resin per 1 ml of platelet lysate, by 
incubating at 4°C for 30 minutes with constant stirring, then pelleting cell debris and beads at 
13,000  ×g for 15 minutes.  Either MBP or MBP:CD148 fusion proteins bound to amylose 
resin (20 µl of a 50% slurry) was added to platelet lysates at a ratio of 1 µg of fusion protein 
to 500 µg of platelet lysate and incubated at 4°C for 2 hours.  Resins were then washed 4 
times with column buffer.  Proteins were eluted from resins by boiling for 5 minutes in 2× 
Laemmli sample buffer under reducing conditions. 
 
2.2.5.4  Sample preparation for mass spectrometry 
Samples generated using the substrate-trapping/pull-down assay were resolved on 4 – 20% 
SDS-PAGE gradient gels (Invitrogen) and proteins stained with ProtoBlue Safe Colloidal 
Coomassie blue (Geneflow, Fradley, UK).  Bands of interest were excised from gels using a 
clean scalpel blade in a laminar flow hood and prepared for mass spectrometry analysis 
according to the in-gel trypsinization protocol of Shevchenko et. al. (Shevchenko et al. 1996).  
Gel slices were put into 1.5 ml snap-cap tubes rinsed with 0.1% formic acid/50% acetonitrile; 
washed twice with 500 µl of 50% acetonitrile in 50 mM ammonium bicarbonate for 45 
minutes/wash at 37°C with constant mixing; and dried using a SpeedVac Plus AR model 
SC110AR (Savant Instruments, Inc., Holbrook, NY, USA) connected to a Universal Vacuum 
System Plus model UVS400A (Long Island City, NY, USA).  Gel slices were rehydrated in 
50 µl of 50 mM DTT in 10% acetonitrile in 50 mM ammonium bicarbonate at 56°C for 1 hr.  
Any remaining supernatant was removed and 50 µl of 100 mM iodoacetamide in 10% 
acetonitrile in 50 mM ammonium bicarbonate was added and incubated at room temperature 
in the dark for 30 minutes.  Any remaining supernatant was removed; gel slices were washed 
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three times with 10% acetonitrile in 40 mM ammonium bicarbonate for 15 minutes/wash at 
room temperature with constant mixing; and gel slices were dried using the SpeedVac (details 
above).  Gel slices were rehydrated with 20 µl or 1.5× the gel volume if greater than 20 µl of 
12.5 µg/ml sequence grade trypsin (Promega) in 10% acetonitrile in 40 mM ammonium 
bicarbonate for 1 hr at room temperature.  A further 20 µl of 10% acetonitrile in 40 mM 
ammonium bicarbonate was added and incubated overnight at 37°C.  The supernatant was 
collected, replaced with 30 µl of 3% formic acid and incubated for a further 1 hr at 37°C. This 
final step was repeated once more.  Mass spectrometric analysis (peptide mass fingerprinting) 
and database searches were performed by Dr. Ángel García (University of Santiago de 
Compostela, Spain).  Mass spectra of tryptic fragments were measured using a Bruker 
Autoflex Matrix-Assisted Laser Desorption/Ionization – Time-of-Flight (MALDI-TOF) mass 
spectrometer.  Database searches were performed using the Mascot v2.1 search tool (Matrix 
Science, London, UK) screening SwissProt and MSDB databases. 
 
2.2.6  In vitro dephosphorylation assays 
2.2.6.1  Dephosphorylation of SFKs 
WCLs were prepared of pervanadate (100 µM) stimulated human platelets as described 
above.  Equal amounts (1 µg) of recombinant MBP, wild-type recombinant CD148 PTP 
domain and catalytically inactive MBP-CD148 cytoplasmic domain fusion protein were 
added to equal amounts (75 µg) of platelet lysates and incubated at 37°C for 30 minutes.  
Reactions were terminated by addition of an equal volume of 2× lysis buffer and boiling for 5 
minutes at 100°C.  Samples were resolved by SDS-PAGE and western blotted with phospho-
specific antibodies. 
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2.2.6.2  Dephosphorylation of SFK-derived phosphopeptides 
Rates of dephosphorylation of SFK-derived phosphopeptides (Table 2.5) by recombinant 
CD148 and PTP-1B PTP domains were measured using the EnzChek Phosphatase Assay Kit 
(Molecular Probes).  The kit is based on the purine nucleoside phosphorylase (PNPase)-
coupled assay developed by Webb (Webb 1992).  Phosphopeptides were reconstituted to 3 
mM in 10 mM HEPES buffer pH 7.5.  Recombinant CD148 and PTP-1B PTP domains 
(kindly provided by Dr. Alistair Barr, Structural Genomics Consortium, Oxford) were diluted 
in gel filtration buffer (250 mM NaCl, 10 mM DTT in 10 mM HEPES pH 7.5).  Reactions 
were performed in 384-well clear bottom plates at room temperature.  Reactions consisted of: 
125 µM substrate phosphopeptide and 20 ng of CD148 or PTP-1B PTP domain, in reaction 
buffer (100 mM NaCl, 1 mM DTT, 200 μM 2-amino-6-mercapto-7-methylpurine 
ribonucleoside [MESG] and 1 U/ml purine nucleoside phosphorylase [PNPase]).  MESG and 
PNPase concentrations were optimized to ensure that the phosphatase activity was rate-
limiting.  The plate was read in a SpectraMax microplate reader (Molecular Devices, 
Sunnyvale, CA, USA) at an absorbance of 360 nm at 20 second intervals for 3 minutes. 
 
2.2.8  Statistical analysis 
Data shown throughout this thesis is representative of 2 – 5 separate experiments.  Where 
experiments were performed in triplicate (e.g. DT40/NFAT luciferase assay) results were 
averaged for each experiment.  Mean ± standard deviation or standard error of the mean are 
indicated.  Statistical analysis was carried out using unpaired Student’s t-test, with P values < 
0.05 taken as significant.  All graphs were generated using GraphPad Prism version 4 
software (GraphPad Software, Inc., San Diego, CA). 
 
 
 
 
Table 2.4  Expression constructs and uses  
 
Expression 
construct 
Backbone Source Protein expressed Mutation Use Reference 
CD148 catalytically 
inactive 
pEF.BOS AW full length CD148 C1239S 
 
DT40/NFAT 
luciferase assay 
(Baker et al. 2001) 
CD148 substrate 
trapping 
pEF.BOS AW full length CD148 D1205A DT40/NFAT 
luciferase assay 
(Baker et al. 2001) 
CD148 wild type pEF.BOS AW full length CD148 none DT40/NFAT 
luciferase assay 
(Baker et al. 2001) 
FcR γ-chain pEF6 MT FcR γ-chain none DT40/NFAT 
luciferase assay 
(Tomlinson et al. 2007) 
GPVI pRC MT GPVI none DT40/NFAT 
luciferase assay 
(Tomlinson et al. 2007) 
LacZ pEF6 Invitrogen 
 
LacZ none DT40/NFAT 
luciferase assay 
(Tomlinson et al. 2007) 
MBP.CD148 
catalytically inactive 
pMAL.c2E NT cytoplasmic tail of 
CD148 as MBP fusion 
C1239S in vitro substrate 
trapping 
(Palka et al. 2003) 
MBP.CD148 
substrate trapping 
pMAL.c2E NT cytoplasmic tail of 
CD148 as MBP fusion 
D1205A in vitro substrate 
trapping 
(Palka et al. 2003) 
MBP.CD148 wild 
type 
pMAL.c2E NT cytoplasmic tail of 
CD148 as MBP fusion 
none in vitro substrate 
trapping 
(Palka et al. 2003) 
NFAT reporter pEF6 MT NFAT reporter none DT40/NFAT 
luciferase assay 
(Tomlinson et al. 2007) 
NT, Professor Nicholas Tonks (Cold Spring Harbour Laboratory, NY, USA); AW, Professor Art Weiss (UCSF, CA, USA);  
MT, Dr. Michael Tomlinson (University of Birmingham, UK) 
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Palka, H. L., et al. (2003). "Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase 
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Tomlinson, M. G., et al. (2007). "Collagen promotes sustained glycoprotein VI signaling in platelets and cell lines." J Thromb Haemost 
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3.1  Aim 
In this chapter, I checked for expression of CD148 in human and mouse platelets by western 
blotting and flow cytometry.  CD148 was quantified in resting human platelets and changes in 
surface expression following platelet activation were investigated.  Expression of PTPRO, 
RPTPσ and CD45 was also investigated in human and mouse platelets by either western 
blotting or flow cytometry. 
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3.2  Introduction 
Pioneering work to elucidate the functional roles of PTPs in platelets relied heavily on the use 
of non-selective PTP inhibitors, such as pervanadate (Pumiglia et al. 1992).  These studies 
demonstrated that PTPs were important for maintaining basal levels of phosphorylation in 
platelets (Pumiglia et al. 1992).  PTPs were shown to regulate several important platelet 
functions including aggregation, clot retraction and microvesicle formation (Chiang 1992; 
Pumiglia et al. 1992; Pasquet et al. 1998; Osdoit et al. 2001; Ragab et al. 2003). 
To date five non-transmembrane PTPs and a single RPTP have been identified in 
platelets.  The non-transmembrane PTPs include: Shp1, Shp2, PTP-1B, PTP-MEG and the 
non-classical PTP, LMW-PTP (Frangioni et al. 1993; Somani et al. 1997; Hua et al. 1998; 
Wang et al. 2005; Xing et al. 2007).  The lone RPTP is CD148 (Borges et al. 1996; de la 
Fuente-Garcia et al. 1998; Senis et al. 2007).  Other RPTPs that may be expressed in platelets 
include PTPRO, RPTPσ and CD45.  PTPRO was first identified in human megakaryocytes 
(Taniguchi et al. 1999).  Forty-one SAGE tags of PTPRO were also identified in a mouse 
megakaryocyte SAGE library, suggesting that it is highly expressed (Senis et al. 2007).  
However, it has yet to be identified in human or mouse platelets.  A single peptide from 
RPTPσ was recently identified in human platelets using a mass spectrometry approach, 
suggesting that it may be expressed at low levels (Senis et al. 2007).  It is widely accepted that 
CD45 is not expressed in platelets, however it has been detected in megakaryocytes at a low 
level of expression (Stelzer et al. 1993; Qiao et al. 1996; Dahlke et al. 2004; Li et al. 2007).  
We therefore speculated that it may be expressed in platelets at a low level. 
CD148 and PTPRO are structurally related classical PTPs that belong to the R3 
subfamily of transmembrane PTPs (Tonks 2006).  They consist of a large extracellular region 
composed of 8 fibronectin type III (FNIII) repeats, a single transmembrane segment and a 
single intracellular PTP domain.  CD148 is expressed in all hematopoietic lineages, 
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endothelial cells, fibroblasts, epithelial cells and smooth muscle cells (Borges et al. 1996; 
Autschbach et al. 1999).  The majority of research on CD148 has focused on its role in 
negatively regulating cell growth and differentiation.  Recently, it has been demonstrated that 
CD148 negatively regulates cell-extracellular matrix contacts in fibroblasts by modulating Src 
and FAK activation (Jandt et al. 2003; Kellie et al. 2004; Pera et al. 2005).  Knockin mice 
expressing a mutant CD148 that lacks the cytoplasmic phosphatase domain die at embryonic 
day 11.5 and have severe defects in vascular development (Takahashi et al. 2003).  More 
recently, CD148 and the structurally distinct RPTP CD45 have been shown to have positively 
regulate B cell receptor signalling and Fcγ receptor signalling, in B cells and macrophages 
respectively, using single and double knockout mouse models (Zhu et al. 2008). 
PTPRO is primarily expressed in the brain and kidney, but is also found in 
hematopoietic stem cells, lungs, lymph nodes, spleen and placenta (Avraham et al. 1997; 
Beltran et al. 2003).  Alternatively spliced PTPRO transcripts are expressed in a tissue-
specific manner (Aguiar et al. 1999).  PTPRO has been studied primarily as a receptor 
involved in glomerulus function and axon guidance.  The only paper describing its expression 
in megakaryocytes suggested that it is involved in megakaryocytopoeisis and that its role is 
regulated by the SCF receptor, c-Kit, which is a tyrosine kinase receptor (Taniguchi et al. 
1999).  PTPRO knockout mice have defects in kidney function as a result of a change in 
podocyte structure, however, they have not been examined in detail for other physiological 
defects (Wharram et al. 2000).  
RPTPσ is structurally distinct from CD148 and PTPRO, belonging to the R2A 
subfamily of RPTPs.  It consists of a large extracellular domain containing several 
immunoglobulin-like and FNIII repeats, a single transmembrane domain and a cytoplasmic 
tail containing a PTP catalytic domain and a pseudo-catalytic domain.  It is predominantly 
expressed in the nervous system, with some expression also detected in the kidney and in 
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selected epithelial cells (Pulido et al. 1995).  RPTPσ-deficient mice display severe 
neuroendocrine and neuronal defects, pituitary dysfunction, as well as central and peripheral 
nervous system abnormalities (Elchebly et al. 1999; Wallace et al. 1999; Batt et al. 2002). 
CD45 is the prototypical RPTP belonging to the R1/R2 subfamily of RPTPs.  The 
extracellular domain exists as multiple isoforms due to alternative splicing.  It has a single 
transmembrane domain and a cytoplasmic region containing a PTP domain and a pseudo-PTP 
domain.  CD45 is highly and specifically expressed in all nucleated haematopoietic cells.  
Different splice variants of CD45 are expressed in the different haematopoietic lineages.  The 
lowest molecular weight form is termed CD45RO and the highest molecular weight form is 
CD45ABC.  Naive T cells express primarily the RB isoform then switch to the RO isoform 
upon activation.  B-cells primarily express the highest molecular weight isoform RABC, 
while the myeloid lineage cells generally express the RO isoform then switch to RA isoforms 
upon activation.  There is a large body of research on the role of CD45 in immune cells, as it 
plays a central role in immune receptor signalling (Hermiston et al. 2003).  It has redundant 
functions with CD148 in immune cells (Zhu et al. 2008).  CD45 deficiency results in severe 
combined immunodeficiency phenotype in mouse and humans (Byth et al. 1996; Mee et al. 
1999).  More recently it has been implicated as a potential genetic modifier in autoimmune, 
infectious and malignant diseases (Tchilian et al. 2006).  
It has been known for many years that CD45 is essential for initiating B and T cell 
receptor signalling.  It has also been known that structurally distinct RPTP PTPα plays an 
important role in initiating integrin signalling in fibroblasts.  Based on these findings, we 
hypothesized that platelets express a CD45-like RPTP that is required to initiate signalling 
from the collagen receptor GPVI.  The GPVI signalling pathway is essentially a hybrid of the 
B and T cell receptor signalling pathways.  We also hypothesized that this platelet RPTP also 
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initiates integrin receptor signalling, similar to PTPα in fibroblasts.  The primary candidate 
was CD148, followed by PTPRO, RPTPσ and CD45. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  CD148 Expression in Platelets 
91 
3.3  Results 
3.3.1  Expression of CD148 in human platelets 
I initially detected CD148 in human platelets by western blotting.  Whole cell lysates prepared 
of washed human platelets were resolved by SDS-PAGE and western blotted with an anti-
CD148 antibody.  A single band was detected at approximately 220 kDa, which is the correct 
size for CD148 (Figure 3.1A).  Flow cytometry was subsequently used to determine if CD148 
was expressed on the surface of human platelets.  Washed human platelets were stained with a 
monoclonal antibody to the extracellular region of CD148 followed by a FITC-conjugated 
anti-mouse secondary antibody prior to flow cytometric analysis (Figure 3.1B).  Platelets 
were stained with an isotype control antibody instead of the primary antibody in parallel as a 
control for non-specific binding of the primary antibody.  Platelets stained with the anti-
CD148 monoclonal antibody showed a clear shift to the right in FITC fluorescence relative to 
platelets stained with the isotoype control antibody, demonstrating that CD148 was expressed 
on the platelet surface.  
 
3.3.2  Quantification of surface expression of CD148 on resting human platelets 
A commercially available flow cytometry-based assay was used to quantify surface 
expression of CD148 on resting human platelets.  Washed human platelets from 6 healthy 
volunteers were stained with a monoclonal antibody to the extracellular region of CD148 
followed by a FITC-conjugated anti-mouse secondary antibody prior to flow cytometric 
analysis.  The expression level of CD148 on the platelet surface was quantified by plotting the 
geometric mean fluorescence intensities (GMFI) of immunostained platelets on a standard 
curve generated using calibration beads coated with a known number of binding sites for the 
secondary antibody (Figure 3.2A and B).  The GMFI of platelets stained with the isotype 
control antibody was subtracted from the GMFI of platelets stained with the anti-CD148 
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antibody before the number of surface molecules per platelet was calculated.  Human platelets 
were found to express 2,834 ± 90 (mean ± standard error of the mean) copies of CD148 on 
their surface using this method (Figure 3.2C).  GPVI surface levels were quantified in parallel 
to CD148 levels on the same platelets as a positive control of the assay.  GPVI surface 
expression was calculated to be 6,081 ± 252 copies per platelet, which is slightly higher than 
published levels of GPVI (3,500 – 5,000 copies/platelet) (Best et al. 2003).  We suspect this 
discrepancy is related to a variety of reasons, which will be discussed later in this chapter.  
Based on these results, CD148 is expressed at approximately half the level of GPVI.  This is 
an intermediate/low level of expression relative to other platelet surface glycoproteins.  
Interestingly, there was very little variability in surface levels of CD148 in the six individuals 
tested, suggesting that it may has an important functional role in platelets. 
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Figure 3.1:  Expression of CD148 in human platelets.  (A) Whole cell lysate (WCL) 
prepared from human platelets was western blotted for CD148 using a mouse anti-CD148 
monoclonal antibody.  A band at approximately 220 kDa was detected. (B) Resting human 
platelets were incubated with either anti-CD148 (green line) or an isotype control antibody 
(IgG, purple histogram) for 15 minutes, then stained for 15 minutes with a FITC-conjugated 
anti-mouse antibody before being analyzed by flow cytometry. n=6. 
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Figure 3.2: Expression level of CD148 on the surface of resting human platelets 
measured by quantitiative flow cytometry. (A) Calibration beads coated with a known 
number of antibody binding sites (490, 13,000, 38,000 and 96,000) were stained with FITC-
conjugated anti-mouse antibody for 15 minutes and analysed by flow cytometry. (B) A 
calibration curve was obtained by plotting the geometric mean fluorescence intensity (GMFI) 
of the peaks in panel (A) against the known number of antibody binding sites for each peak.  
(C) The mean number of copies of CD148 on the surface of resting human platelets was 
calculated to be 2,834 ± 90 (± standard error of the mean).  Each dot represents an individual 
and the horizontal line represents the mean. The number of copies of GPVI was also 
quantified. 
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3.3.3  Surface levels of CD148 in activated human platelets 
Having established that CD148 is expressed on the surface of human platelets, I next wanted 
to investigate whether surface levels of CD148 are altered following platelet activation.  
There are several examples of platelet surface proteins that are up-regulated upon platelet 
activation including the integrin αIIbβ3, GPIb-IX-V, P-selectin and TLT-1 (Wagner et al. 
1996; Berndt et al. 2001; Washington et al. 2004).  Intracellular pools of these and other 
surface proteins are found in the open canalicular system and the platelet α-granules.  
Conversely, there are several examples of platelet surface glycoproteins that are shed from the 
surface of activated platelets, including GPVI and GPIb-IX-V (Bergmeier et al. 2004; 
Gardiner et al. 2007). 
Surface levels of CD148 were compared between resting and thrombin activated 
platelets by flow cytometry.  Platelets were stimulated with a high concentration (1U/ml) of 
the physiological agonist thrombin, which signals through PAR-1 and PAR-4 receptors in 
human platelets.  A high dose of thrombin was used in order to induce maximal platelet 
activation and α-granule secretion.  Under these conditions, surface expression of CD148 was 
not altered following thrombin stimulation (Figures 3.3A and B), suggesting the absence of 
any intracellular pool and that it does not get shed from the surface of platelets.  P-selectin 
expression was used as a marker of α-granule secretion (Figures 3.3C and D). 
 
3.3.4  Expression of CD148 in mouse platelets 
I next checked for expression of CD148 in mouse platelets in order to establish the mouse as a 
model for studying the functional role of CD148 in platelets.  CD148 had never before been 
shown to be expressed in mouse platelets.  CD148 was detected on the surface of resting 
wild-type (WT) mouse platelets by flow cytometry.  Washed mouse platelets were 
immunostained with a hamster anti-mouse CD148 monoclonal antibody to the extracellular 
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region of CD148 followed by a FITC-labelled anti-hamster secondary antibody prior to being 
analyzed by flow cytometry.  The primary antibody was replaced with an isotype control 
antibody as a negative control.  There was a clear shift to the right in FITC fluorescence of 
CD148 stained platelets relative to the isotype control antibody stained platelets, 
demonstrating that CD148 is expressed in mouse platelets (Figure 3.4A). 
Western blotting was then used to confirm the expression of CD148 in wild-type 
mouse platelets.  Platelets from CD148 transmembrane knockout (TM-KO) mice were used as 
a negative control.  Platelet lysates were resolved by SDS-PAGE and immunoblotted with an 
anti-CD148 antibody.  A band migrating at approximately 220 kDa was detected in the WT 
platelets, but not in platelets from CD148 TM-KO platelets, demonstrating that WT mouse 
platelets express CD148 and validating the CD148 TM-KO model (Figure 3.4B). 
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Figure 3.3: Subcellular localisation of CD148 in human platelets.  Flow cytometry was 
used to investigate whether CD148 expression is restricted to the platelet surface. Resting (A) 
or thrombin stimulated human platelets (B) were incubated with 10 µg/ml of either anti-
human CD148 monoclonal antibody (CD148, green peak), that recognises the extracellular 
region of CD148 or the same amount of isotype control antibody (IgG, purple histogram) for 
15 minutes, then stained for 15 minutes with a FITC-conjugated anti-mouse antibody.  As a 
positive marker for platelet activation and secretion, resting (C) and thrombin (D) stimulated 
human platelets were stained with 10 µg/ml anti-CD62P antibody (P-selectin, red peak)  or 
the same amount of control antibody (IgG, purple histogram). n=3. 
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Figure 3.4: Expression of CD148 in mouse platelets.  (A) Resting wild-type mouse platelets 
were incubated with either hamster anti-mouse CD148 (green line), that recognizes the 
extracellular region of mouse CD148, or an isotype control antibody (IgG, black line) for 15 
minutes, then stained for 15 minutes with a FITC-conjugated anti-hamster antibody before 
being analyzed by flow cytometry.  (B) Whole cell lysates (WCLs) prepared of wild-type 
(WT) and CD148 transmembrane-knockout (CD148 TM-KO) mouse platelets were western 
blotted for CD148 using the same monoclonal antibody used for flow cytometry in panel (A).  
A 220 kDa band was detected in the WT sample which was absent from the CD148 TM-KO 
sample.  (Note: FACS data was initially generated by Mike Tomlinson and repeated by 
myself). n=3. 
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3.3.5  Expression of PTPRO in mouse platelets 
Since PTPRO has been previously identified on the platelet progenitor cell, the 
megakaryocyte, I wanted to check for its expression on platelets (Taniguchi et al. 1999; Senis 
et al. 2007).  Whole cell lysates of mouse platelets, mouse foetal liver-derived 
megakaryocytes, mouse splenocytes (positive control) and mouse brain (positive control) 
were resolved by SDS-PAGE and western blotted with a goat anti-PTPRO polyclonal 
antibody (Figure 3.5).  PTPRO has been reported to migrate at 200 and 158 kDa, and a 
truncated splice variant, PTPROt, expressed in B cells migrates at 44 kDa (Aguiar et al. 
1999).  A prominent band at 158 kDa was detected in mouse brain, as expected (Figure 3.5).  
Similar size bands were also detected in the spleen and platelet WCLs, which could 
potentially be PTPRO.  However, due to the large number of background bands present in all 
of the samples it is difficult to conclude which of these bands are PTPRO or its splice 
variants.  A prominent band of the expected size for PTPRO was not detected in 
megakaryocytes.  This is somewhat surprising as several tags for PTPRO were detected in a 
mouse megakaryocyte SAGE library, suggesting that they express high levels of the protein 
(Senis et al. 2007).   
 
3.3.6  Expression of RPTPσ in human and mouse platelets 
Whole cell lysates prepared from human platelets, mouse platelets, mouse foetal liver-derived 
megakaryocytes, mouse splenocytes and mouse brain were resolved by SDS-PAGE and 
western blotted with an anti-RPTPσ monoclonal antibody (Figure 3.6).  RPTPσ is reported to 
migrate at 220 kDa and a splice variant at 75 kDa (Pulido et al. 1995).  The prominent 75 kDa 
band detected in brain WCL is presumably RPTPσ.  Although similar size band was also 
detected in the human platelet lysate, it resembled a background band rather than a 
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specifically labelled band.  A prominent 220 kDa was also detected in the human platelet 
WCL that may represent RPTPσ. 
 
 
 
Figure 3.5: PTPRO may be expressed in mouse platelets.  Whole cell lysates prepared of 
mouse platelets, mouse foetal liver-derived megakaryocytes, mouse splenocytes and mouse 
brain were western blotted with a goat anti-PTPRO polyclonal antibody. 10-20 µg of protein 
was loaded per lane. PTPRO has been reported to migrate at 200 and 158 kDa.  A truncated 
splice variant, PTPROt, expressed in B cells migrates at 44 kDa. n=2. 
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Figure 3.6: PTPRσ may be expressed in human platelets.  Whole cell lysates prepared of 
human platelets, mouse platelets, mouse foetal liver-derived megakaryocytes, mouse 
splenocytes and mouse brain were western blotted with an anti-PTPRσ monoclonal antibody 
(courtesy of Professor Michel Tremblay, McGill University). 10-20 µg of protein was loaded 
per lane. PTPRσ has been reported to migrate at 220 and 75 kDa.  A prominent band 
migrating at 75 kDa in brain lysate is PTPRσ.  The high molecular band in the human platelet 
lysate may represent PTPRσ. n=2. 
 
 
 
 
 
 
Chapter 3  CD148 Expression in Platelets 
102 
3.3.7  CD45 expression in human and mouse platelets 
Although it is widely accepted that platelets do not express CD45, a recent study 
demonstrated that mouse megakaryocytes express low levels of CD45 (Dahlke et al, 2004).  I 
therefore wanted to confirm whether CD45 is express in human and mouse platelets.  
Peripheral blood leukocytes which express high levels of CD45 were stained with a FITC-
conjugated anti-CD45RA antibody as a positive control (Figure 3.7A).  CD45RA is primarily 
found on cells of the myeloid lineage.  Unstimulated or thrombin (1 U/ml) stimulated washed 
human platelets were stained with FITC-conjugated anti-CD45RA antibody prior to being 
analysed by flow cytometry (Figure 3.7B and C).  Leukocytes, and resting and activated 
platelets were stained with an FITC-conjugated isotype antibody in parallel as a negative 
control.  Leukocytes were strongly labelled for CD45 compared with the isotype control 
stained leukocytes, demonstrating that the antibody was working in this assay (Figure 3.7A).  
In contrast, both resting and thrombin stimulated platelets did not stain for CD45RA, 
demonstrating that platelets do not express this isoform of CD45 (Figures 3.7B and C 
respectively).  The experiment was repeated with an antibody for CD45RO isoform, which is 
primarily expressed on T cells and myeloid cells, with the same result (data not shown). 
The same experiment described above was also performed on mouse platelets.  Mouse 
thymocytes were used as a positive control.  Thymocytes showed a large shift to the right in 
CD45RA staining compared to control cells stained with the isotype control antibody, 
indicating very high levels of CD45 expression in thymocytes (Figure 3.8A).  In contrast, 
unstimulated and thrombin stimulated mouse platelets exhibited comparable, relatively small 
shifts to the right relative to control stained platelets, suggesting mouse platelets may express 
very low levels of CD45RA (Figure 3.8B and C).  Similar results were observed for CD45RO 
isoform (data not shown). 
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Figure 3.7: CD45 is not expressed on human platelets.  Flow cytometry was used to 
investigate CD45 expression on human platelets. (A) As a positive control human leukocytes 
were stained with a FITC-conjugated anti-CD45 RA antibody (CD45, orange line) or an 
isotype matched IgG control antibody which was then detected with a secondary FITC 
antibody (IgG, purple peak). (B and C) Resting and thrombin stimulated human platelets were 
then analysed for CD45 expression using the same antibodies as in (A).  n=2. 
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Figure 3.8: CD45 maybe expressed on mice platelets at low levels. Flow cytometry was 
used to investigate CD45 expression on mouse platelets. (A) As a positive control mouse 
thymocytes were stained with a FITC-conjugated anti-CD45 RA antibody (CD45, orange 
line) or an isotype matched IgG control antibody which was then detected with a secondary 
FITC antibody (IgG, purple peak). (B and C) Resting and thrombin stimulated mouse 
platelets were then analysed for CD45 expression using the same antibodies as in (A). n=2. 
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3.4  Discussion 
To date, CD148 is the only RPTP identified in platelets by immunological-based techniques.  
It is a large glycoprotein that migrates at approximately 220 kDa by SDS-PAGE.   Resting 
human platelets express approximately 2,800 copies on their surface.  Surface levels are not 
altered upon platelet activation, demonstrating that platelets do not contain an intracellular 
pool of CD148 and that it does not get shed under the conditions tested.  The very tight intra-
individual surface levels on human platelets, suggests that it may play an important role in 
regulating platelet function.  We suspect the discrepancy in the levels of GPVI I quantified on 
resting platelets (~6,000 copies) compared with published levels (3,500 – 5,000 copies) is due 
to a number of factors, including: different methods used to quantify GPVI levels; different 
batches of anti-GPVI antibody used to quantify; different numbers of secondary antibody 
binding sites on the calibration beads; different fluorescence intensities of the secondary 
antibodies; and sample size and variation. 
The number of copies of CD148 on human platelets is intermediate/low relative to 
other surface glycoproteins and its expression is tightly regulated.  The most abundant surface 
glycoprotein is the integrin αIIbβ3, which is present at approximately 80,000 copies on the 
surface of resting platelets (Wagner et al. 1996).  Surface levels of other platelet glycoproteins 
are: 25,000 copies for GPIb-IX-V and 45,000 copies for CD9 (Hato et al. 1988); 10,000 
copies for PECAM-1 (Newman et al. 1990); and 1,000 – 2,000 for the integrin α2β1 (Bennett 
1990).  In contrast, the copy number of CD148 is approximately 20 fold greater than the ADP 
receptor, P2Y1, which is amongst the least abundant platelet receptors expressed on the 
surface of resting human platelets at approximately 150 copies (Baurand et al. 2001).   
To date no other RPTPs have been identified in human or mouse platelets by western 
blotting or flow cytometry.  However, PTPRO and CD45 have been reported to be expressed 
in megakaryocytes, and a single peptide for RPTPσ was identified in human platelets by mass 
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spectrometry (Avraham et al. 1997; Tomer 2004; Senis et al. 2007).  Presumably, PTPRO and 
CD45 are involved in regulating megakarycoyte function and/or development and their 
expression is turned off during differentiation and platelet formation.  Based on findings 
presented in this chapter, I cannot conclude with any certainty whether PTPRO, RPTPσ or 
CD45 are expressed in human or mouse platelets.  It may be that platelets express low levels 
or alternatively spliced isoforms of all three of these RPTPs.  Further characterisation with 
better antibodies and positive control lysates are required in the case of PTPRO and RPTPσ.  
Although my findings suggest that mouse platelets may express low levels of CD45RA and 
RO, I believe that they probably do not.  This is based on previously published findings and 
on a follow-up study performed by our collaborators in which they could not detect CD45 on 
mouse platelets (personal communication, Dr. Jing Zhu and Professor Arthur Weiss, UCSF, 
USA).  Therefore, I suspect the minor shift in CD45RA and RO stained mouse platelets is 
likely due to lower fluorescence labelling of the isotyped control antibody relative to the anti-
CD45 antibodies. 
Collectively, these findings suggest that CD148 is the most abundant and possibly the 
only RPTP expressed on platelets.  This is the opposite to other blood cells, with the 
exception of erythrocytes, which express high levels of CD45 and lower levels of CD148.  
The following chapters in this thesis focus on elucidating the biological and biochemical 
functions of CD148 in platelets. 
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4.1 Aim 
In this chapter, CD148 transmembrane knockout (CD148 TM-KO) mice, which lack cell 
surface expression of CD148, were utilized to investigate the functional role of CD148 in 
platelets.  We hypothesized that CD148 plays a fundamental role in ITAM receptor signalling 
and integrin-mediated functional responses, as it has previously been shown to be involved in 
regulating ITAM and integrin receptor signalling in other cell types (Hundt et al. 1997; 
Tangye et al. 1998; Zhu et al. 2008).  
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4.2  Introduction 
It has been known for many years that CD45 is essential for initiating ITAM receptor 
signalling in haematopoietic cells (Hermiston et al. 2003).  In the case of the B and T cell 
receptors (BCR and TCR, respectively), it does so by modulating Lck downstream of the 
TCR and Lyn downstream of the BCR, leading to the recruitment and activation of Syk and 
PLCγ (McNeill et al. 2007; Zhu et al. 2008).  Similarly, CD148 has been shown to play a 
fundamental role in regulating lymphocyte signal transduction, in particular CD148 is able to 
regulate BCR and TCR signalling pathways (Tangye et al. 1998; Baker et al. 2001).  
Recently, CD45 and CD148 have been shown to play redundant functions in activating SFKs 
downstream of BCRs and Fc receptors in B cells and macrophages, respectively (Zhu et al. 
2008).  Since the collagen activation receptor complex GPVI/FcR γ-chain signals in a similar 
way to the BCR and TCR, we hypothesized that CD148 plays a similar role in initiating GPVI 
signalling in platelets. 
Work done in other cell types has shown that CD148 regulates cell adhesion and 
spreading (Jandt et al. 2003; Kellie et al. 2004; Pera et al. 2005; Dave et al. 2009).  It has been 
hypothesized to do so by regulating key components of integrin signalling complexes, 
including SFKs, FAK and paxillin (Kellie et al. 2004; Pera et al. 2005).  Similarly, the 
structurally distinct RPTP PTPα has been shown to positively regulate outside-in signalling 
from the fibronectin integrin α5β1 in fibroblasts (Chen et al. 2006).  We therefore 
hypothesized that CD148 plays a similar function in regulating integrin signalling in platelets.  
Interestingly, GPVI and the fibrinogen integrin αIIbβ3 share the same backbone signalling 
pathway, consisting of the sequential activation of SFKs, Syk and PLCγ2 (Watson et al. 
2005).  SFKs have also been shown to play a minor role in signalling from various G protein-
couple receptors (GPCRs), including the thrombin receptors PAR-1 and PAR-4, the 
thromboxane A2 receptor TP and the ADP receptor P2Y1 (Jarvis et al. 2000; Harper et al. 
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2006; Minuz et al. 2006).  We therefore speculated that CD148 may also play a minor role in 
regulating signalling from various GPCRs in platelets. 
The generation of a CD148 TM-KO mouse model that lacks any cell surface 
expression of CD148 has been an invaluable tool to study the functional role of CD148 in 
platelets (Zhu et al. 2008).  In this chapter I utilised platelets from these mice to study the 
biological function of CD148 in platelets.  I measured the ability of platelets from C148 TM-
KO mice to aggregate together, secrete their contents and spread on collagen- and fibrinogen-
coated surfaces.  From these findings, I demonstrate that CD148 is an essential positive 
regulator of ITAM-, integrin- and to a lesser extent GPCR-mediated functional responses. 
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4.3  Results 
4.3.1  CD148-deficient platelets exhibit impaired aggregation and secretion 
The ability of platelets to aggregate and secrete was measured simultaneously, in real-time, 
using a lumi-aggregometer.  Platelet aggregation was measured as a change in light 
transmission, through a platelet suspension (2 × 108/ml), following addition of an agonist.  
ATP secretion from platelet dense granules was measured as an increase in luminescence.  
This is mediated through luciferin, which is added to the platelet suspension, prior to 
stimulation. 
Washed platelets from litter-matched WT and CD148 TM-KO mice were stimulated 
with low, intermediate and high doses of the GPVI-specific agonist, CRP (1, 3 or 10 μg/ml). 
CD148-deficient platelets exhibited marked impairment in aggregation and secretion 
responses to CRP compared with wild-type platelets (Figure 4.1A).  Inhibition of platelet 
aggregation and secretion was observed even at the highest concentration of CRP tested (10 
μg/ml), demonstrating that CD148 is an essential, positive regulator of GPVI-mediated 
aggregation and dense granule secretion.  Aggregation and ATP secretion of CD148-deficient 
platelets were also inhibited in response to low and intermediate concentrations (1 and 3 
μg/ml) of the physiological agonist collagen, which acts through both GPVI and the integrin 
α2β1 (Figure 4.1B).  This effect was largely overcome at a higher concentration of collagen 
(10 μg/ml), which induced almost full aggregation and ATP secretion (Figure 4.1B). The 
selective recovery of response to high concentrations of collagen, but not CRP reflects the 
role of the integrin α2β1 in mediating activation to collagen (Chen et al. 2003). 
Collagen-mediated aggregation and ATP secretion are heavily dependent on the 
release of the secondary mediators ADP and TxA2 from platelets.  The release of ADP from 
dense granules and synthesized TxA2 amplifies the process of platelet activation by a positive 
feedback mechanism (FitzGerald 1991; Gachet 2006).  To eliminate the contribution of these 
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secondary mediators to the collagen-induced aggregation and secretion responses, platelets 
were treated with the ADP scavenger, apyrase, and the cyclooxygenase inhibitory 
indomethacin prior to stimulation (Figure 4.1C).  Under these conditions, CD148-deficient 
platelets exhibited impaired aggregation at all three concentrations of collagen tested (1, 3 and 
10 μg/ml).  The magnitude of the defects was enhanced in the presence of apyrase and 
indomethacin, demonstrating that ADP and indomethacin were masking defects in the 
collagen response.  The greatest difference between WT and CD148-deficient platelet 
aggregation was observed at the highest dose of collagen (10 μg/ml).  ATP secretion was 
effectively abolished in the presence of the inhibitors of secondary mediators. This data 
provides further evidence that CD148 is a positive regulator of GPVI- and α2β1-mediated 
signalling.   
Aggregation and ATP secretion of CD148-deficient platelets were also tested in 
response to various GPCRs, which act through distinct receptors and signalling pathways.  
We initially investigated the ability of CD148-deficient platelets to aggregate and secrete ATP 
in response to the powerful GPCR agonist thrombin, which acts through the PAR-4 receptor 
in mouse platelets.  Aggregation and ATP secretion were marginally reduced in response to 
low, intermediate and high doses of thrombin (0.03, 0.09 and 0.3 U/ml respectively) (Figure 
4.1D), suggesting CD148 may play a minor role downstream of PAR-4.  Platelets were then 
pre-treated with the Src kinase inhibitor PP1 before stimulation with thrombin to determine if 
SFKs were getting activated in mutant platelets.  PP1 blocked the aggregation and secretion 
responses of CD148-deficient platelets to the same extent as WT platelets, demonstrating that 
SFKs are not completely inactive in mutant platelets.  The only exception was at the 
intermediate does of thrombin (0.03 U/ml), where PP1 had more of an effect on the mutant 
platelets, suggesting that CD148 may regulate other components of the thrombin signalling 
pathway besides SFKs (Figure 4.1E). 
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We next investigated aggregation and ATP secretion in response to the TxA2 analogue 
U46619, which signals through the TP receptor.  CD148-deficient platelets exhibited a minor 
aggregation defect to all doses of U46619 (1, 3 and 10 μM) tested (Figure 4.1F).  A minor 
delay in the secondary wave of aggregation and ATP secretion was also observed at 10 µM 
U46619 (Figure 4.1F).  In contrast, CD148-deficient platelets exhibited normal aggregation 
and ATP secretion responses to ADP, which signals through the P2Y1 and P2Y12 receptors 
(Figure 4.1G).  Together, these results demonstrate that CD148 is essential for tyrosine 
kinase-linked receptor-mediated aggregation and secretion responses, and also plays a minor 
role in selective GPCR-mediated responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. CD148-deficient platelets exhibit impaired GPVI-mediated platelet 
aggregation and ATP secretion. Washed platelets (2 × 108/ml) prepared from littermatched 
wild-type (WT) and CD148 transmembrane-knockout (CD148-/-) mice were stimulated with 
low, intermediate and high doses of: A) collagen- related peptide (CRP) (3, 10 and 30 μg/ml); 
B) collagen (1, 3 and 10 μg/ml); C) collagen (1,3 and 10 μg/ml) in the presence of secondary 
mediator inhibitors apyrase and indomethacin, D) thrombin (0.009, 0.03 and 0.09 U/ml) and 
E) thrombin in the presence of PP1. Platelet rich plasma prepared from litter-matched WT and 
CD148 TM-KO mice were stimulated with low, intermediate and high doses of: F) 
thromboxane A2 analogue U46619 (1, 3 and 10 μM) and G) ADP (1, 3 and 10 μM). Platelet 
aggregation was measured as a change in light transmission and ATP secretion was measured 
as luciferin/luciferase-mediated luminescence, using a lumi-aggregometer. Representative 
images are shown (n = 3 – 6 mice per condition). 
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4.3.2  Impaired spreading of CD148-deficient platelets 
We next investigated the ability of CD148-deficient platelets to adhere to and spread on a 
collagen-coated surface under static conditions.  As with collagen-mediated aggregation, the 
spreading response is mediated through GPVI and the integrin α2β1.  Released ADP and 
TxA2 enhance the response.  WT and CD148-deficient platelets were placed on collagen-
coated coverslips for 45 minutes.  Adherent platelets were subsequently fixed, permeabilized 
and actin filaments stained with Alex 488-conjugated phalloidin.  Although the same number 
of WT and CD148-deficient platelets adhered to the collagen-coated surface (data not shown), 
CD148-deficient platelets did not spread to the same extent as WT platelets (Figure 4.2A).  
There was approximately a 20% reduction in the surface area of collagen-adherent CD148-
deficient platelets compared with WT control platelets (Figure 4.2B).  Morphologically, 
mutant platelets looked the same as WT platelets, exhibiting filopodia and lamellipodia, 
except that they did not spread to the same extent as WT platelets.  This demonstrated that 
CD148 positively regulates platelet spreading on collagen. 
The same spreading experiment described above was also performed on fibrinogen-
coated coverslips to investigate whether CD148 contributes to outside-in signalling by the 
integrin αIIbβ3.  The same number of CD148-deficient platelets adhered to the fibrinogen-
coated surface however, mutant platelets exhibited a marked reduction in spreading on the 
fibrinogen-coated surface (Figure 4.3A). The fibrinogen spreading defect was more 
pronounced compared with the collagen spreading defect.  CD148-deficent platelets exhibited 
a 30% reduction in spreading on fibrinogen compared with WT platelets under the same 
conditions (Figure 4.3B).  Morphologically, mutant platelets had fewer filopodia and no 
lamellipodia, whereas all WT platelets had extended filopodia and several had formed 
lamellipodia. This data suggested that CD148 positively regulates αIIbβ3 signalling in 
platelets. 
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Figure 4.2: CD148-deficient mouse platelets have a spreading defect on collagen.  
Washed platelets (2 × 107/ml) were placed on collagen-coated cover slips for 45 mins at 37°C.  
Adherent platelets were permeabilized with 0.2% Triton-X 100 and actin filaments stained 
with Alex 488-conjugated phalloidin.  (A) Representative images of wild-type and CD148-
deficient platelets spread on collagen.  (B) The surface area of 50 - 100 platelets from 3 wild-
type and 2 CD148-/- mice was quantified using ImageJ software (mean ± SEM). 
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Figure 4.3: CD148 deficient mouse platelets do not spread properly on fibrinogen.  
Washed platelets (2 × 107/ml) were placed on fibrinogen-coated cover slips for 45 mins at 
37°C.  Adherent platelets were permeabilized with 0.2% Triton-X 100 and actin filaments 
stained with Alex 488-conjugated phalloidin.  (A) Representative images of wild-type and 
CD148 deficient platelets spread on fibrinogen.  (B) The surface area of 50 - 100 platelets 
from 3 wild-type and 2 CD148-/- mice was quantified using ImageJ software (mean ± SEM). 
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4.4  Discussion 
 
Results from this Chapter demonstrate for the first time that CD148 is an essential positive 
regulator of platelet function.  GPVI- and αIIbβ3-mediated functional responses were 
severely inhibited in CD148-deficient platelets.  In contrast, thrombin- and TxA2-mediated 
responses were minor, and ADP-mediated responses were normal.  Impaired responsiveness 
of CD148-deficient platelets to collagen was less apparent at high concentrations of collagen.  
Conversely, it was enhanced in the presence of inhibitors of the secondary mediators ADP 
and TxA2, demonstrating that these agonists were getting released and masking any defects in 
GPVI and α2β1 signalling.  The more severe spreading defect exhibited by CD148-deficient 
platelets on a fibrinogen- rather than a collagen-coated surface is also probably due to 
masking by released ADP and TxA2.  The spreading defects suggest defects in outside-in 
integrin αIIbβ3 and α2β1 signalling.  This is the first time that a RPTP has been shown to 
inhibit such a broad range of functional response to a variety of ITAM, integrin and GPCR 
agonists. 
A potential explanation for the CRP- and collagen-mediated functional defects of 
CD148-deficient platelets is a reduction in GPVI and/or α2β1 integrin levels.  GPVI levels 
were in fact reduced by 42 ± 1.5% (mean ± standard error; n = 9) of controls, whereas integrin 
α2β1 and αIIbβ3 levels were normal on platelets from CD148-deficient mice (appendix: 
Senis et al. 2009).  However, despite this almost 60% reduction in GPVI levels on the surface 
of CD148-deficient platelets, CD148-deficient platelets exhibited more severe aggregation 
and secretion defects compared with FcR γ-chain heterozygous-deficient (γ-chain+/-) platelets, 
which express comparable surface levels of GPVI (Snell et al. 2002; Senis et al. 2009). 
The reduction in ATP release from CD148-deficient platelets may be due to reduced 
dense granule secretion as thrombin-mediated ATP secretion was not as severely reduced.  A 
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similar reduction in P-selectin expression on the surface of CRP- and thrombin-stimulated 
CD148-deficient platelets, suggesting a concomitant reduction in α-granule secretion from 
mutant platelets (appendix: Senis et al. 2009).  Integrin αIIbβ3 activation on the surface of 
CRP-stimulated CD148-deficient platelets was also reduced in mutant platelets.  Collectively, 
these findings provide further evidence suggesting that CD148 positively regulates GPVI 
signalling. 
Platelet adhesion and spreading are complex processes that require bi-directional 
integrin signalling.  Platelets undergo a series of characteristic morphological changes during 
adhesion and spreading on collagen- and fibrinogen-coated surfaces.  These include initially 
extending filopodia that then firmly adhere to the surface and subsequently fill in with 
lamellipodia.  Failure of CD148-deficient platelets to spread properly on these surfaces 
suggested defective ITAM and integrin receptor signalling.  Spreading on collagen is 
mediated by GPVI, which triggers inside-out signalling to the integrin α2β1 causing it to 
undergo a conformational change to a high affinity state.  GPVI and α2β1 recognize different 
amino acid sequences in collagen fibrils (GPO repeats and GFOGER repeats, respectively).  
GPVI also triggers release of the secondary mediators ADP and TxA2, which act in a 
paracrine and autocrine manner to enhance platelet activation.  Spreading on fibrinogen is 
mediated primarily by the integrin αIIbβ3, without the need of an activation receptor and less 
of a contribution from secondary mediators.  The less severe spreading defect exhibited by 
CD148-deficient platelets on a collagen-coated surface is likely due to synergy between GPVI 
and α2β1 signalling and amplification by released ADP and TxA2.  The pronounced 
spreading defect exhibited by mutant platelets on a fibrinogen-coated surface suggests CD148 
also plays an important role in regulating outside-in integrin αIIbβ3 signalling.  Interestingly, 
real-time imaging demonstrated that CD148-deficient platelets take longer and extend fewer 
filopodia than WT control platelets on fibrinogen (appendix: Senis et al. 2009).  Filopodia 
Chapter 4  Functional Characterization of CD148 
121 
extended by mutant platelets did not remain firmly attached to the fibrinogen surface, but 
retract with time (appendix: Senis et al. 2009).  Taken together, these findings demonstrate an 
essential, positive regulatory role of CD148 in ITAM and integrin receptor signalling. 
Minor aggregation and secretion responses of CD148-deficient platelets were also 
detected in response to thrombin and TxA2, which signal through the GPCRs PAR-4 and TP 
receptors in mouse platelets, respectively.  This is the first time that a RPTP has been shown 
to regulate GPCR-mediated functional responses in any cell type, to our knowledge.  In 
contrast, ADP receptor responses were normal in CD148-deficient platelets, demonstrating 
that platelet responses were differentially affected by deletion of CD148.  We hypothesize this 
is due to a minor SFK component that is required for optimal thrombin- and TxA2-mediated 
responses, but not for ADP responsiveness.  This will be discussed in further detail in the 
General Discussion.  
The physiological relevance of the above functional defects have been characterized 
by several members of the Watson and Senis groups and were recently published in Blood 
(appendix: Senis et al. 2009).  CD148-deficient mice had a minor but significant prolongation 
of tail bleeding time and exhibited reduced thrombus formation and stability using two 
separate models of arterial thrombosis, namely the ferric chloride- and laser-induced injury 
models (appendix: Senis et al. 2009).  
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5.1  Aim 
In the previous chapter, I demonstrated that CD148 positively regulates ITAM and integrin 
receptor mediated platelet responses.  The aim of this chapter was to investigate the molecular 
mechanism underlying these defects.  Experiments were designed to investigate differences in 
collagen- and fibrinogen-mediated signalling between wild-type and CD148-deficient 
platelets.  Previous reports have demonstrated that CD148 regulates ITAM receptor signalling 
and SFK phosphorylation (Pera et al. 2005; Zhu et al. 2008).  Our hypothesis was that CD148 
would regulate proximal ITAM and integrin receptor signalling events, similar to CD45 and 
PTPα in lymphocytes and fibroblasts, respectively (Zeng et al. 2003; McNeill et al. 2007).  I 
therefore focussed my attention on investigating the phosphorylation status of three of the 
main platelet SFKs, Fyn, Lyn and Src, as well as other key signalling proteins downstream of 
GPVI and αIIbβ3. 
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5.2  Introduction 
SFKs are critical for initiating and propagating signalling from most platelet tyrosine kinase-
linked receptors.  They have also been shown to play a minor role in propagating signalling 
from some platelet GPCRs, including the thrombin receptors PAR-1 and PAR-4, and the 
TxA2 receptor TP.  To date, platelets have been demonstrated to express five of the eight 
SFKs, namely Fyn, Lyn, Src, Fgr and Yes with Src being the most abundant (Huang et al. 
1991; Pestina et al. 1997).  
The earliest identified GPVI signalling event is the activation of SFKs.  Previous 
studies using mutant mouse models and transfected cell lines have shown that the SFKs Fyn 
and Lyn are constitutively associated with the proline-rich region of GPVI via their SH3 
domains (Ezumi et al. 1998; Suzuki-Inoue et al. 2002).  Similarly, Src is constitutively 
associated with the carboxy-terminal tail of the β3 integrin cytoplasmic tail (Obergfell et al. 
2002; Arias-Salgado et al. 2003; Watson et al. 2005).  It is thought that by having 
constitutively associated SFKs, GPVI and αIIbβ3 can signal more rapidly in response to 
ligand mediated cross-linking. 
The activity of SFKs is tightly regulated by tyrosine phosphorylation and intra-
molecular interactions, as described in the General Introduction.  Activation of SFKs requires 
disruption of the intra-molecular SH2 and SH3 interactions, allowing substrates to access the 
catalytic site.  Phosphorylation of the C-terminal tail inhibitory tyrosine residue by Csk and 
the related kinase Ctk/Chk maintains the molecule in an inactive conformation, whereas 
dephosphorylation of this site allows the SFK to adopt an open, active conformation (Okada 
et al. 1991; Murphy et al. 1993).  SFKs can also be activated by out-competing the SH2 and 
SH3 interactions through inter-molecular interactions (Xu et al. 1999).  Maximal SFK 
activation also requires trans-autophosphorylation of the activation loop tyrosine residue, 
which locks it in an open conformation (Xu et al. 1999).  
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Several PTPs have been shown to dephosphorylate the C-terminal inhibitory tyrosine 
residue of SFKs, including the RPTPs CD45, PTPα, PTPε and PTPλ and the non-
transmembrane PTPs PTP-1B, Shp1 and Shp2.  In the case of the B and T cell receptors this 
action is primarily carried out by the RPTP CD45, with the structurally distinct CD148 also 
playing a minor role in B cells (Lin et al. 2003; McNeill et al. 2007; Zhu et al. 2008).  To 
date, only CD45 and the non-transmembrane PTP PTP-BAS have been shown to 
dephosphorylate the activation loop of SFKs (Roskoski 2005).  Recently, CD148 was also 
shown to interact directly with Src and to dephosphorylate both of its regulatory 
phosphorylation sites in vitro (Pera et al. 2005). The interaction was also observed in 
transfected cells, however, CD148 only dephosphosphorylated the inhibitory site and not the 
activation site in transfected cells (Pera et al. 2005). 
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5.3  Results 
This section is divided in the following three sub-sections: (1) Regulation of collagen-
mediated signalling by CD148; (2) Regulation of fibrinogen-mediated signalling by CD148; 
and (3) Tyrosine phosphorylation of CD148 in human platelets. 
 
5.3.1  Regulation of collagen-mediated signalling by CD148 
5.3.1.1  CD148 positively regulates GPVI proximal signalling in mouse platelets 
In the previous chapter, CD148-deficient mouse platelets were shown to have severely 
reduced responses to CRP.  Western blotting was used as a way of identifying signalling 
defects in resting and CRP-stimulated CD148-deficient platelets.  Washed platelets in 
suspension from wild-type and CD148-deficient mice were stimulated with a high 
concentration (10 µg/ml) of CRP, in the presence of inhibitors of the secondary mediators 
TxA2 and ADP, and the integrin αIIbβ3, in order to focus specifically on GPVI signalling.  
There was a striking inhibition of the increase in tyrosine phosphorylation of most proteins to 
CRP in the CD148-deficient platelets throughout a 300 second time course (Figure 5.1).  This 
included a loss of tyrosine phosphorylation of the 12 kDa doublet that has been previously 
identified as FcR γ-chain, thereby establishing a proximal signalling defect in the GPVI 
pathway (Gibbins et al. 1996; Poole et al. 1997).  Consistent with this observation, there was a 
marked reduction in inducible tyrosine phosphorylation of important downstream signalling 
molecules, such as Syk and PLCγ2 (Figure 5.2A and B). 
Since FcR γ-chain phosphorylation was decreased, we turned our attention to the 
GPVI-associated SFKs, Lyn and Fyn, which directly phosphorylate the FcR γ-chain (Ezumi et 
al. 1998; Quek et al. 2000).  Lyn exhibited increased phosphorylation at its C-terminal 
inhibitory tyrosine residue (Tyr-507) in resting and CRP-stimulated CD148-deficient 
platelets, suggesting that higher proportions of Lyn were in an inactive conformation in 
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resting and activated CD148-deficient platelets (Figure 5.3A).  Fyn and Src also showed a 
slight increase in phosphorylation at their C-terminal inhibitory tyrosine residues (Tyr-530 
and Tyr-529 respectively) which was fully reproducible, suggesting they too are in an inactive 
conformation in resting and activated CD148-deficient platelets (Figure 5.3B and C).  In line 
with this, SFKs were hypo-phosphorylated at their respective activation loop tyrosine residues 
in CD148-deficient platelets (Figure 5.3C). Since this is a trans-autophosphorylation event, it 
indicates a general reduction in SFK activity in the absence of CD148.  Together, these results 
demonstrate that SFKs are in a state of reduced activation in both resting and CRP-stimulated 
CD148-deficient platelets. 
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Figure 5.1. Reduced whole cell phosphorylation in CD148-deficient platelets.
Whole cell lysates (WCL) of resting and collagen-related peptide (CRP) activated
platelets from wild-type (WT) and CD148 transmembrane-knockout (KO) mice were
prepared and western blotted with an anti-phosphotyrosine antibody (p-Tyr). Platelets
were stimulated with 10 µg/ml CRP for 90 and 300 seconds (sec). Bands corresponding
to Src family kinases (SFKs) and FcR γ-chain are indicated. Blots are representative of
4 – 6 experiments.  
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Figure 5.2. Reduced Syk and PLCγ2 tyrosine phosphorylation in CRP-stimulated
CD148-deficient platelets. (A) Syk and (B) PLCγ2 were immunoprecipitated (IP)
from equal amounts of whole cell lysates prepared from both wild-type (WT) and
CD148 transmembrane-knockout (KO) mouse platelets. Platelets were stimulated with
10 µg/ml collagen-related peptide (CRP) for 90 and 300 seconds (sec). Membranes
were blotted with an anti-phosphotyrosine (p-Tyr) antibody, and subsequently stripped
and re-blotted with anti-Syk (Syk) and anti-PLCγ2 (PLCγ2) antibodies. Blots are
representative of 4 – 6 experiments.
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Figure 5.3. Reduced Src family kinase (SFK) activation in resting and CRP-
stimulated CD148-deficient platelets. Whole cell lysates (WCLs) prepared from
resting and collagen-related peptide (CRP)-stimulated wild-type (WT) and CD148
transmembrane-knockout (KO) platelets were western blotted with phosphospecific
anti-SFK antibodies. Platelets were stimulated with 10 μg/ml CRP for 90 and 300
seconds. Membranes were blotted with: (A) anti-Lyn p-Tyr-507 and anti-Lyn-pan
antibodies; (B) anti-Fyn p-Tyr-530 and anti-Fyn-pan antibodies; and (C) anti-SFK
activation loop p-Tyr, anti-Src p-Tyr-529 and anti-Src-pan antibodies. Blots are
representative of 4 – 6 experiments.
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5.3.1.2  CD148 positively regulates collagen-mediated signalling in mouse platelets 
In the previous chapter I demonstrated that defects in collagen-mediate responses of CD148-
deficient platelets could be partially overcome at high concentrations of collagen (Chapter 4).  
Here I checked for signalling defects in collagen-stimulated CD148-deficient platelets.  
Unlike CRP, which is GPVI-specific, collagen binds to and signals through both GPVI and 
the integrin α2β1 simultaneously (Jarvis et al. 2002; Snell et al. 2002).  Further, collagen-
mediated responses are heavily dependent on positive feedback from released secondary 
mediators, ADP and TxA2 (Atkinson et al. 2003).  Initially, I checked whole cell 
phosphorylation in collagen-stimulated CD148-mutant platelets in the presence of an integrin 
αIIbβ3 antagonist to prevent platelet aggregation and outside-in integrin αIIbβ3 signalling.  A 
dramatic reduction in the number and intensity of most bands was observed in CD148-
deficient platelets compared with wild-type platelets, suggesting a block in GPVI and integrin 
α2β1 proximal signalling (Figure 5.4).  Phosphorylation of the FcR γ-chain was marginally 
reduced in mutant platelets under these conditions (Figure 5.4). 
SFKs were hypo-phosphorylated at their activation loop tyrosine in resting and 
collagen-stimulated CD148-deficient platelets relative to control platelets (Figure 5.5).  
Collagen-stimulated mutant platelets did however show a slight increase in phosphorylation 
of the activation loop of SFKs with time, suggesting a marginal increase in activity (Figure 
5.5, top panel).  Lyn, Fyn and Src were concomitantly hyper-phosphorylated at their C-
terminal inhibitory tyrosines Tyr-507, Tyr-530 and Tyr-529, respectively, suggesting that 
these may be substrates of CD148 (Figure 5.5).  Interestingly, Lyn was more highly 
phosphorylated at its inhibitory site than Fyn or Src, suggesting that CD148 may 
preferentially dephosphorylate the Lyn inhibitory tyrosine. 
Experiments similar to those described above were performed in the presence of ADP 
and TxA2 antagonists.  Platelets were initially stimulated with 10 µg/ml collagen, but this was 
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subsequently increased to 100 µg/ml in order to better visualize weak staining bands, such as 
the FcR γ-chain (Figure 5.6).  A dramatic reduction in tyrosine phosphorylation of most 
proteins was observed in CD148-deficient platelets stimulated with 10 µg/ml collagen 
compared with wild-type platelets throughout a 300 second time course (Figure 5.6A).  
Reduced whole cell phosphorylation in both mutant and control platelets the presence of ADP 
and TxA2 antagonists (Figures 5.4 and 5.6A), demonstrated that released ADP and TxA2 
enhance collagen-mediated signalling.  Interestingly, stimulation of mutant platelets with a 
10-fold higher dose of collagen (100 µg/ml) induced more phosphorylation in mutant platelets 
compared with the lower dose (10 µg/ml collagen) (Figures 5.6A and B), indicating a partial 
block in collagen signalling in mutant platelets.  This was supported by a marginal 
enhancement of tyrosine phosphorylation of the SFK activation loop (middle bands) over time 
in the CD148-deficient platelets, suggesting a very slight increase in SFK activity (Figure 
5.7B).  Although slight, this marginal increase in phosphorylation was fully reproducible, 
however to support this conclusion gel scanning should be performed. This observation 
correlated with increased phosphorylation of the FcR γ-chain with time (Figure 5.6A and B). 
A critical early event in GPVI signalling is the recruitment and activation of Syk 
tyrosine kinase to the phosphorylated FcR γ-chain (Watson et al. 2005).  This interaction is 
mediated by the tandem SH2 domains of Syk and the ITAM of the FcR γ-chain.  Syk 
activation is also important for α2β1 signalling (Keely et al. 1996).  Using a phospho-specific 
antibody, Syk was found to be hypo-phosphorylated at Tyr-352 in collagen-stimulated 
CD148-deficient platelets.  This was clearly observed at 100 µg/ml collagen (Figure 5.7B).  
Phosphorylation of Syk Tyr-352 is a SFK-mediated event that enhances activation of 
PLCγ (Law et al. 1994). 
 
 
Chapter 5  Biochemical Analysis of CD148 
132 
 
Figure 5.4. Reduced whole cell phosphorylation in CD148-deficient platelets.
Whole cell lysates (WCL) prepared from resting and collagen-stimulated platelets from
wild-type (WT) and CD148 transmembrane-knockout (KO) mice were western blotted
with an anti-phosphotyrosine antibody (p-Tyr). Platelets were stimulated with 10
µg/ml collagen in the presence of 9 µM integrillin for 30, 90 and 300 seconds (sec).
Blots are representative of 3 experiments.
158
116
97
66
56
43
36
27
20
14
6
blot: p-Tyr
KO
0 90 300
WT
10 µg/ml collagen
300 90 30030 (sec)
FcR γ-chain
 
 
 
 
 
 
 
 
 
 
Chapter 5  Biochemical Analysis of CD148 
133 
 
KO
0 90 300
WT
10 µg/ml collagen
300 90 30030
blot: SFK p-Tyr
activation loop
blot: Lyn p-Tyr-507
blot: Fyn p-Tyr-530
(sec)
blot: Lyn-pan
blot: Src p-Tyr-529
Figure 5.5. Impaired collagen-mediated Src family kinase activation in CD148-
deficient platelets. (A) Platelet whole cell lysates (WCLs) prepared from wild-type
(WT) and CD148 transmembrane knockout (KO) mice stimulated with 10 µg/ml
collagen for 30, 90 and 300 seconds in the presence of 9 µM integrillin. WCLs were
western blotted with phosphotyrosine-specific anti-Src family kinase (SFK), -Lyn, -
Fyn, -Src antibodies, and anti-Lyn-pan antibody. Blots are representative of 3
experiments.  
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Figure 5.6. Reduced whole cell phosphorylation in CD148-deficient platelets.
Whole cell lysates (WCL) prepared from resting and collagen-stimulated platelets
from wild-type (WT) and CD148 transmembrane-knockout (KO) mice were western
blotted with an anti-phosphotyrosine antibody (p-Tyr). Platelets were stimulated with
either (A) 10 µg/ml or (B) 100 µg/ml collagen in the presence of 9 µM integrillin for
30, 90 and 300 seconds (sec). The bands corresponding to the FcR γ-chain are shown
in the lower panels. Blots are representative of 3 experiments.  
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Figure 5.7. Impaired collagen-mediated Src family kinase and Syk kinase
activation in CD148-deficient platelets. Platelet whole cell lysates (WCLs)
prepared from wild-type (WT) and CD148 transmembrane knockout (KO) mice
stimulated with 10 µg/ml collagen for 30, 90 and 300 seconds. Platelets were treated
with 10 µM indomethacin (cyclooxygenase inhibitor) and 2 U/ml apyrase (ADP
scavenger) prior to being stimulated with either (A) 10 µg/ml or (B) 100 µg/ml
collagen. WCLs were western blotted with phosphotyrosine specific anti-Src family
kinase (SFK), -Lyn, -Fyn, -Src antibodies, anti-Lyn-pan antibody. and
phosphotyrosine specific anti-Syk antibody. Blots are representative of 3 experiments.  
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5.3.2  Regulation of fibrinogen-mediated signalling by CD148 
 
5.3.2.1  CD148 positively regulates αIIbβ3 proximal signalling in mouse platelets 
 
We next investigated the molecular mechanism underlying the fibrinogen spreading defect 
exhibited by CD148-deficient platelets described in Chapter 4.  We hypothesized that this was 
due to a signalling defect as platelets from mutant mice expressed normal levels of integrin 
αIIbβ3 (Senis et al. 2009).  Consistent with this theory, western blotting of whole cell lysates 
prepared of fibrinogen-spread WT and mutant platelets revealed a significant reduction in 
phosphorylation of most proteins in CD148-deficient platelets, including Syk and PLCγ2, 
both of which are essential components of the αIIbβ3 signalling cascade (Figure 5.8A – C).  
Both Src and Lyn were hyper-phosphorylated at their C-terminal inhibitory sites (Tyr-529 and 
Tyr-507, respectively) in fibrinogen-spread CD148-deficient platelets relative to control 
platelets (Figure 5.8D).  In line with the result GPVI signalling results, SFKs were 
concomitantly hypo-phosphorylated at their activiaton loops relative to controls in BSA non-
adherent and fibrinogen-spread CD148-deficient platelets (Figure 5.8D).  Together, these 
results demonstrate that CD148 positively regulates SFKs downstream of αIIbβ3, providing a 
molecular explanation for the fibrinogen spreading defect exhibited by CD148-deficient 
platelets. 
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Figure 5.8. Defective αIIbβ3 signalling in CD148-deficient platelets. Wild-type
(WT) and CD148-deficient (KO) platelets were plated on BSA- and fibrinogen-coated
surfaces for 45 minutes at 37°C. Whole cell lysates (WCLs) were prepared from BSA
(BSA) non-adherent and fibrinogen (fib) adherent platelets. (A) Equal amounts of
total protein were resolved by SDS-PAGE and western blotted with an anti-
phosphotyrosine antibody. (B and C) Syk and PLCγ2 were immunoprecipitated from
equal amounts of WCLs and blotted with an anti-phosphotyrosine antibody.
Membranes were subsequently stripped and re-blotted with anti-Syk and anti-PLCγ2
antibodies. (D) WCLs were western blotted with an anti-Src family kinase (SFK)
activation loop p-Tyr antibody, an anti-Src p-Tyr-529 antibody and an anti-Lyn p-Tyr-
507 antibody. Results are representative of three experiments.
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5.3.3  Tyrosine phosphorylation of CD148 
 
Tyrsoine phosphorylation has been shown to regulate the activity of some RPTPs, including 
PTPα and PTPε (Chen et al. 2006; Berman-Golan et al. 2007).  In this sub-section, I 
investigated tyrosine phosphorylation of CD148 in resting and activated platelets, the 
rationale being that this information may provide some insight into the regulation of CD148 
in platelets. 
 
5.3.3.1  Tyrosine phosphorylation of CD148 in suspended platelets  
Immunoprecipitation and western blotting was used to check the phosphorylation status of 
CD148 in resting and activated human platelets in suspension.  CD148 was found to be 
constitutively phosphorylated in resting platelets and this did not change in response to 
stimulation with 10 μg/ml CRP and 5 U/ml thrombin for 3 minutes (Figure 5.9Ai and ii).  A 
significant increase in tyrosine phosphorylation of CD148 was however observed in platelets 
treated with 100 µM of the general PTP inhibitor pervanadate, demonstrating that it was 
submaximally phosphorylated in resting, CRP and thrombin activated platelets (Figure 5.9Ai 
and ii). 
Pre-treatment of platelets with the general Src kinase inhibitor PP2, prior to 
stimulation with CRP and thrombin, abolished tyrosine phosphorylation of CD148 in resting, 
CRP and thrombin activated platelets, demonstrating that this is SFK-dependent event (Figure 
5.9Ai).  PP2 significantly blocked, but did not completely inhibit pervandate-induced tyrosine 
phophorylation of CD148, demonstrating that CD148 can also be phosphorylated by other 
kinases besides SFKs (Figure 5.9Ai).  
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5.3.3.2  Tyrosine phosphorylation of CD148 in spread platelets 
Tyrosine phosphorylation of CD148 was also investigated in fibrinogen-spread platelets, in 
order to determine whether outside-in integrin αIIbβ3 signalling alters its phosphorylation.  
Washed human platelets were placed on either a BSA- or fibrinogen-coated surface for 45 
minutes.  BSA non-adherent (control) or fibrinogen adherent platelets were subsequently 
lysed, CD148 was immunoprecipitated and western blotted.  CD148 was constitutively 
phosphorylated to a similar extent in BSA non-adherent and fibrinogen adherent platelets 
(Figure 5.9B).  
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Figure 5.9. CD148 is constitutively tyrosine phosphorylated by Src kinases. (Ai)
CD148 was immunoprecipitated (IP) from lysates prepared of washed human platelets
under the following conditions: unstimulated (basal), stimulated with 10 µg/ml CRP,
5 U/ml thrombin and 100 µM pervanadate for 3 minutes. IP’s were western blotted
with an anti-phosphotyrosine antibody (p-Tyr). Membranes were subsequently
stripped and re-blotted with an anti-CD148 antibody (CD148). Pre-treatment of
platelets with 20 µM PP2 (Src kinase inhibitor) inhibited tyrosine phosphorylation of
CD148 under all conditions tested. (Aii) Band intensities were quantified. (B) CD148
was IP’d from lysates prepared of BSA non-adherent (BSA) and fibrinogen adherent
(fib) washed human plateles. IP’s were western blotted with an anti-phosphotyrosine
antibody (p-Tyr). Membranes were subsequently stripped and re-blotted with an anti-
CD148 antibody (CD148). n=2.
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5.4  Discussion 
In this chapter I demonstrate proximal signalling defects downstream of both the collagen 
receptor GPVI and the integrin αIIbβ3 in CD148-deficient platelets.  In both cases this 
appears to be due to a global reduction in SFK activity in resting and activated platelets.  The 
C-terminal inhibitory sites of Lyn, Fyn and Src appear to be substrates of CD148, as all three 
proteins were hyper-phosphorylated at their respective inhibitory sites in CD148-deficient 
platelets.  Without this pool of active SFKs in resting CD148-deficient platelets, ligand-
mediated cross-linking of GPVI and αIIbβ3 does not elicit optimal signalling. 
 Until now, the earliest characterized signalling event downstream of GPVI was the 
activation of constitutively associated SFKs Lyn and Fyn (Ezumi et al. 1998; Quek et al. 
2000; Suzuki-Inoue et al. 2002).  However, the molecular mechanism of how SFKs are 
activated in platelets had yet to be addressed.  Biochemical data presented in this chapter 
demonstrated a GPVI proximal signalling defect in the absence of CD148 as tyrosine 
phosphorylation of the FcR γ-chain, Syk and PLCγ2 were all substantially reduced in 
response to CRP.  Additionally, SFKs exhibited markedly reduced phosphorylation of their 
activation loop tyrosines in parallel with increased phosphorylation of their C-terminal 
inhibitory tyrosines in the absence of CD148.  Similar findings were observed in collagen-
stimulated platelets, however these defects were less severe than those observed with CRP 
and could be partially overcome with high dose collagen.  These differences can be explained 
by the contributions of α2β1, ADP and TxA2 to collagen signalling (Inoue et al. 2003; 
Nieswandt et al. 2003).  SFK activation-loop phosphorylation did not appear to change 
significantly following stimulation of wild type platelets with collagen.  A potential reason for 
this is the contribution of α2β1 to collagen signalling.  A higher dose of collagen maybe 
required to replicate the increase in SFK activation-loop phosphorylation observed with the 
GPVI specific agonist CRP.  Collectively, these findings demonstrate that CD148 plays a 
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critical role in activating SFKs in resting platelets and downstream of GPVI.  CD148 would 
therefore appear to play a similar role to that of the structurally distinct RPTP CD45 in B and 
T cell receptor signalling (Hermiston et al. 2003; Zhu et al. 2008).  
Defective spreading of CD148-deficient platelets on a fibrinogen-coated surface can 
also be explained by altered tyrosine phosphorylation of SFKs, resulting in reduced SFK 
activity and signalling downstream of the integrin αIIbβ3.  The Shattil group recently 
demonstrated a critical role for the non-transmembrane tyrosine phosphatase, PTP-1B, in 
activating Src specifically downstream of the integrin αIIbβ3.  Interestingly, their work 
suggests that PTP-1B acts specifically downstream of the integrin and is not involved in 
regulating collagen-, thrombin- or ADP-mediated responses (Arias-Salgado et al. 2005).  
Therefore, CD148 appears to be a global regulator of SFKs in platelets, whereas PTP-1B acts 
specifically on αIIbβ3-associated Src. 
The biochemical explanation why CD148 is constitutively tyrosine phosphorylated in 
platelets is presently not known.  This is a SFK-dependent event and does not change in 
response to various platelet agonists, including CRP, thrombin and fibrinogen.  Tyrosine 
phosphorylation may alter activity, protein-protein interactions or the half-life of CD148.  
Tyrosine phosphorylation has previously been shown to regulate the activity of other RPTPs, 
such as PTPα and PTPε, however, this does not seem to be a general mechanism that applies 
to all RPTPs (Chen et al. 2006; Berman-Golan et al. 2007).  
The major finding of this chapter is that global SFK activity is significantly reduced in 
resting and activated CD148-deficient platelets compared with wild-type platelets.  This 
appears to be due to hyperphosphorylation of SFKs at their C-terminal inhibitory tyrosine 
residues, so they are in an inactive conformation.  A pool of active SFKs is therefore essential 
for initiating a rapid and optimal response when platelets come in contact with the ECM at 
sites of vascular injury. 
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6.1  Aim 
 
The three objectives of this chapter were: (1) to confirm that CD148 is a positive regulator of 
GPVI using a cell line model; (2) to confirm that Lyn, Fyn and Src are substrates of CD148; 
and (3) to identify physiological substrates of CD148 in platelets using an in vitro substrate-
trapping approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6  Identification of CD148 Substrates 
144 
6.2  Introduction 
Results from the previous two chapters demonstrate that CD148 is a critical positive regulator 
of platelet function, and that it does so by maintaining a pool of active SFKs in platelets by 
dephosphorylation their C-terminal inhibitory tyrosines.  However, several important 
questions arise from these findings and conclusions I have made thus far, including: (1) Are 
the functional defects observed in CD148-deficient mouse platelets due to developmental or 
signalling defects?; (2) Does CD148 have other substrates in platelets besides SFKs?; and (3) 
Are SFKs direct substrates of CD148? 
 Although genetically modified mice are the model of choice for studying protein 
function in platelets, one of their limitations is developmental defects masking the functional 
role of a protein.  It is therefore important to validate functions observed in platelets from 
mouse models in a cell-based system.  To address this point, I used the DT40 chicken B 
cell/NFAT luciferase assay to measure the effects of CD148 on GPVI signalling.  This assay 
has been used extensively by immunologists to dissect the B cell receptor signalling pathway 
(Yasuda et al. 2004).  More recently this assay has been adapted by the Watson group for 
studying GPVI, CLEC-2 and G6b-B signalling (Fuller et al. 2007; Tomlinson et al. 2007; 
Mori et al. 2008).  One of the main strengths of this assay is that it is particularly good for 
measuring weak, sustained signals.    
I also wanted to confirm and build on the finding that SFKs are substrates of CD148 in 
platelets; and identify other substrates of CD148 in platelets.  Several phosphatases have been 
demonstrated to have a broad range of substrate specificity in vitro and in vivo (Blanchetot et 
al. 2005).  Comparing the GPVI and the integrin αIIbβ3 signalling pathways provides 
potential CD148 targets.  Some of the signalling molecules common to both receptors are: (1) 
the tyrosine kinases Btk, Tec, and Syk; (2) the lipid kinase PI 3-kinase; (3) the phospholipase 
PLCγ2; and (4) the small GTPases Vav1, Vav3, and Rac1 (Watson et al. 2005).  There are 
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also some important differences between the GPVI and αIIbβ3 signalling pathways, including 
the adaptor protein LAT, which nucleates formation of an essential signalling complex 
downstream of GPVI, but is not required for αIIbβ3 signalling (Watson et al. 2001; Wonerow 
et al. 2002). 
Potential physiological substrates of CD148 identified in other cell systems including: 
(1) the tyrosine kinase-linked receptors Met and PDGFβ; (2) the adapter proteins LAT and 
Gab1; (3) the adherens junction protein p120catenin; (4) PLCγ1; and (5) more recently the 
p85 subunit of PI 3-kinase (Kovalenko et al. 2000; Baker et al. 2001; Holsinger et al. 2002; 
Palka et al. 2003; Tsuboi et al. 2008).  Interestingly, LAT, PLCγ1 and PI 3-kinase all lie 
downstream GPVI signalling cascade, raising the possibility that CD148 regulates multiple 
points in the same signalling cascade (Pasquet et al. 1999; Suzuki-Inoue et al. 2003; 
Watanabe et al. 2003). 
In this chapter I confirmed that CD148 plays a positive regulatory role in GPVI 
signalling using the DT40/NFAT luciferase reporter assay and showed that its catalytic 
activity is essential for this function.  In addition, using in vitro biochemical assays, I 
demonstrate that the SFKs, Src, Lyn and Fyn interact with and are dephosphorylated on their 
activation and inhibitory sites by CD148.  Finally, using a mass spectrometry-based approach, 
I identified myosin heavy chain 9 (MYH9 protein) as a potential novel substrate of CD148. 
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6.3  Results 
6.3.1 CD148 positively regulates GPVI signalling in a cell line model 
In order to determine whether CD148 catalytic activity is required to enhance GPVI signalling 
I used a nuclear factor of activated T-cells (NFAT)–luciferase transcriptional reporter assay, 
which provides a highly sensitive readout and is widely used to study signalling through the 
ITAM-containing B-cell and T-cell receptors.  The NFAT reporter contains three copies of a 
combined NFAT– activator protein-1 (AP-1) element from the human interleukin-2 (IL-2) 
gene promoter, and is maximally activated by mutual Ca2+ elevation and RAS/mitogen-
activated protein kinase (MAPK) signalling, which activate NFAT and AP-1, respectively.  
NFAT-driven luciferase generation over a period of six hours provides a direct readout for 
sustained ITAM signalling (Tomlinson et al. 2007). 
DT40 chicken B cells were transiently transfected with the GPVI/FcR γ-chain 
complex on its own or in combination with either wild-type or catalytically inactive CD148, 
and the NFAT-luciferase reporter.  Cells were grown overnight and stimulated the following 
day with 1 µg/ml collagen for 6 hrs.  Luciferase activity was measured in lysates and used as 
a direct readout of GPVI signalling.  Co-expression of wild-type CD148 with the GPVI/FcR 
γ-chain complex enhanced collagen-induced NFAT reporter activity by approximately 2.5-
fold compared with the GPVI/FcR γ-chain complex alone (Figure 6.1).  Interestingly, basal 
GPVI signalling was also marginally enhanced in the presence of catalytically active CD148.  
In contrast, catalytically inactive CD148 had no effect on GPVI signalling in the same assay 
(Figure 6.2).  These findings correlated with the platelet results from Chapters 4 and 5, 
demonstrating that catalytically active CD148 enhances GPVI signalling. 
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Figure 6.1: CD148 positively regulates GPVI in transiently transfected DT40
cells. An NFAT luciferase reporter assay was used to investigate whether CD148
regulates GPVI signalling. DT40 B cells were transiently transfected with wild-type
CD148 (CD148) on its own, the GPVI-FcR γ-chain complex (GPVI/FcRγ) on its
own, or CD148 and GPVI/FcRγ together. The NFAT luciferase reporter gene was co-
transfected in all cases. Transfected cells were stimulated with either 0.2, 1 or 5
µg/ml collagen for 6 hrs at 37°C and subsequently lysed. Luciferase activity was
measured in a luminometer by addition of luciferin. Luminenscence is directly
proportional to the amount of GPVI signalling. The assay demonstrated that CD148
positively regulates GPVI signalling. Data shown is representative of 3 separate
experiments.
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Figure 6.2. CD148 catalytic activity is essential for regulating GPVI signalling
in transiently transfected DT40 cells. DT40 B cells were transiently transfected
with various combinations of the following expression plasmids: wild-type CD148
(CD148[WT]), catalytically inactive CD148 (CD148[C/S]), GPVI and FcR γ-chain
(GPVI/FcRγ), and the NFAT luciferase reporter. Transfected cells were stimulated
with 1 µg/ml collagen for 6 hrs at 37°C and subsequently lysed. Luciferin was added
to lysates and luciferase activity was measured in a luminometer. Luminenscence is
directly proportional to the amount of GPVI signalling (mean ± standard error of the
mean, n = 4).
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6.3.2 Identification of CD148 substrates in platelets 
 
Since CD148 enzyme activity is essential to positively regulate GPVI signalling, I next 
wanted to identify substrates of CD148 in platelets.  To do this, I used an in vitro substrate-
trapping pulldown assay.  Variations of this assay have been used to identify substrates of 
various PTPs including CD148 (Palka et al. 2003).  Wild-type and mutant forms of the 
cytoplasmic tail of CD148 were N-terminally tagged with maltose-binding protein (MBP) and 
used to pull down potential substrates and interacting proteins from pervanadate stimulated 
platelet lysates.  A mutant form of CD148 (D1205A) was used to trap substrates (MBP-
CD148[D/A]) (Figure 6.3).  This mutation within the catalytic pocket of CD148 blocks 
catalysis and results in a more stable enzyme and substrate complex (Flint et al. 1997; Palka et 
al. 2003; Blanchetot et al. 2005).  Wild-type (MBP-CD148[WT]) and catalytically inactive 
(C1239S; MBP-CD148[C/S]) were also used as controls to distinguish between substrates and 
interacting proteins (Figure 6.3).  Bacterially expressed recombinant proteins were purified 
and coupled to amylose-coated beads, which were then used to pulldown CD148 interacting 
proteins (Figure 6.4).  Expression and purification of mutant proteins can be found in the 
appendix. 
Platelets were treated with the general PTP inhibitor pervanadate, so that intracellular 
proteins would be maximally phosphorylated.  Optimal conditions for pervanadate 
stimulation were determined by performing a dose response and time course of pervanadate 
stimulation of platelets.  Washed human platelets were stimulated with either, 1, 3, 10, 30 or 
100 µM pervanadate for 3 minutes (Figure 6.5A), or with 100 µM pervanadate for 0, 30, 60, 
90 or 180 seconds (Figure 6.5B).  Platelets were subsequently lysed, proteins were resolved 
by SDS-PAGE and western blotted with an anti-phosphotyrosine antibody.  The optimal 
concentration and time for pervanadate stimulation was determined to be 100 µM pervanadate 
for 3 minutes, and was used for all subsequent substrate-trapping experiments.  
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Figure 6.3: Recombinant MBP-tagged versions of CD148 cytoplasmic tail used in
in vitro substrate-trapping pull down assay. (A) Full length wild-type CD148
protein consists of a 975 amino acid (aa) extracellular region, a 21 aa transmembrane
domain and a 341 aa cytoplasmic region. The cytoplasmic tail consists of a 20 aa
juxtamembrane region, followed by a 284 aa catalytic PTP domain (red box labelled
‘PTP’) and a 16 aa cytoplasmic tail. (B) Three recombinant maltose-binding protein
(MBP)-tagged versions of the entire CD148 cytoplasmic region were used in the
substrate-trapping pulldown assay: (1) wild-type (MBP-CD148[WT]); (2) catalytically
inactive (MBP-CD148[C/S]), in which cysteine 1239 is replaced with a serine; and (3)
substrate trapping mutant (MBP-CD148[D/A]), in which aspartic acid 1205 is
replaced with an alanine. Expression plasmids for all recombinant proteins were
kindly provided by Professor Nicholas Tonks (Palka et al. 2003) .
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Figure 6.4: Flow diagram of substrate-trapping pulldown assay used to identify
substrates and interacting proteins of CD148 in platelets.
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Figure 6.5. Pervanadate dose response and time course. (A) Washed human
platelets (5 × 108/ml) were stimulated with either 1, 3, 10, 30 or 100 µM pervanadate
for 3 minutes, or (B) 100 µM pervanadate for 0, 30, 60, 90 or 180 seconds. Platelets
were subsequently lysed with 1% NP-40. Whole cell lysates (WCL) were resolved
by SDS-PAGE and western blotted with an anti-phosphotyrosine antibody (p-Tyr).
Blots are representative of 3 experiments.
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6.3.3  SFKs interact with CD148 in platelets 
An initial screen to identify interacting proteins of CD148 in platelets using the above assay 
was implemented.  Recombinant bacterially expressed MBP-tagged CD148 fusion proteins 
were not purified from bacterial lysates prior to coupling to amylose-resin.  Rather, an equal 
amount of amylose-resin was incubated with equal amounts of crude bacterial lysate 
expressing the different wild-type and mutant version of CD148 cytoplasmic region.  Using 
this approach, Lyn and Src were found to preferentially interact with the substrate-trapping 
form of CD148 by western blotting, suggested that they may be substrates of CD148 (Figure 
6.6).  Interestingly, Csk interacted equally well with all three versions of the cytoplasmic 
region of CD148, suggesting that it may be constitutively associated with CD148 (Figure 6.6). 
We next wanted to confirm these interactions using a cleaner, more well-defined 
assay.  This was accomplished by purifying recombinant MBP-tagged fusion proteins from 
bacterial lysates by affinity chromatography, quantifying and coupling equal amounts of 
recombinant proteins to equal amounts of amylose-resin.  Using this refined approach, we 
could now only detect interactions with phosphoproteins using the substrate-trapping 
recombinant protein (Figure 6.7).  Prominent bands migrating at 90, 56, 43 and 40 kDa were 
specifically pulled down with MBP-CD148[D/A] (Figure 6.7).  Several minor bands were 
also identified at 160, 130 and 100 kDa (Figure 6.7).  Bands at 90 and 56 kDa co-migrated 
with MBP-CD148[D/A] and SFKs, respectively.  Lyn, Fyn and Src were now only detected 
with the CD148 substrate-trapping mutant by western blotting (Figure 6.7).  Re-blotting the 
membranes for MBP demonstrated equal amounts of each MBP-tagged recombinant protein 
in each lane (Figure 6.7).  These results supported the hypothesis that Lyn, Fyn and Src are 
substrates of CD148. 
Pulldown samples shown in Figure 6.7 were also immunoblotted for other signalling 
proteins that we hypothesized may be substrates of CD148.  LAT, PLCγ2, as well as other 
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components of the GPVI signalling pathway, including Syk, SLP-76 and the FcR γ-chain 
were not detected, suggesting they are not substrates of CD148. 
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Figure 6.6. Crude screening approach reveals SFKs and Csk interactions with
CD148 cytoplasmic region. Pulldowns were performed from pervandate stimulated
platelets lysates (100 µM pervanadate for 3 minutes) using amylose-resin coated with
equal amounts of crude lysates prepared of bacteria expressing MBP-tagged wild-
type, catalytically inactive or substrate-trapping versions of the cytoplasmic region of
CD148 (MBP-CD148[WT], MBP-CD148[C/S] or MBP-CD148[D/A], respectively).
Non-specifically bound proteins were removed by washing with column buffer.
Specifically bound proteins were eluted from resin and western blotted with: anti-
phosphotyrosine (p-Tyr), anti-Lyn (Lyn), anti-Src (Src) and anti-Csk (Csk)
antibodies. Blots are representative of 3 experiments.
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Figure 6.7. SFKs interact specifically with CD148 substrate-trapping mutant in
vitro. Equal amounts of purified recombinant MBP-tagged fusion proteins of the
cytoplasmic tail of wild-type, catalytically inactive and substrate-trapping forms of
CD148 (MBP-CD148[WT], MBP-CD148[C/S] and MBP-CD148[D/A]) were coupled
to amylose-resin and used to pulldown interacting proteins from pervanadate
stimulated human platelet lystates. Specifically bound proteins were western blotted
with: anti-phosphotyrosine (p-Tyr), anti-Lyn (Lyn), anti-Fyn (Fyn), anti-Src (Src) and
anti-MBP (MBP) antibodies. Major phosphotyrosine bands were only observed with
the MBP-CD148[D/A] substrate-trapping mutant. Prominent bands at 90 and 56 kDa
likely correspond to MBP-CD148[D/A] and SFKs, respectively. The identity of the
prominent doublet below 43 kDa is not known (?). Lyn, Fyn and Src were only pulled
down with MBP-CD148[D/A]. Blots are representative of 5 experiments.
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6.3.4  Src, Lyn and Fyn bind to the active site of CD148 
A vanadate competition assay was used to confirm that Lyn, Fyn and Src interact with the 
catalytic site of CD148.  Recombinant MBP-CD148[D/A] was treated with 2 mM vanadate 
before being incubated with pervanadate treated platelet lysate.  Vanadate binds to the 
catalytic site of all PTPs and blocks any interactions with substrates.  In the absence of 
vanadate the SFKs Lyn, Fyn and Src were pulled down from pervanadate-treated platelet 
lysates.  However, in the presence of 2 mM vanadate, Src, Lyn and Fyn were not pulled 
down, demonstrating that these SFKs interact directly with the active site of CD148 and are 
likely substrates (Figure 6.8). 
 
6.3.5  Recombinant CD148 dephosphorylates platelet-derived SFKs in vitro 
I next investigated whether recombinant CD148 PTP domain could dephosphorylate Src, Lyn 
and Fyn in vitro.  Lysates were prepared in the same way as for the substrate-trapping assay 
before being incubated with either purified recombinant MBP, MBP-CD148[WT] or 
catalytically inactive MBP-CD148[C/S].  Lysates were subsequently western blotted with 
phospho-specific antibodies that recognize either the activation loop tyrosine residues of all 
SFKs or the C-terminal inhibitory tyrosine residues of Src, Lyn and Fyn (Tyr-529, Lyn-507 
and Fyn-530, respectively) (Figure 6.9).  These findings demonstrate that CD148 can 
dephosphorylate both the activation loop tyrosines of SFKs and the inhibitory tyrosines of 
Lyn, Fyn and Src in vitro.  Catalytically inactive CD148 did not dephosphorylate any of these 
sites.  These findings suggest that CD148 preferentially dephosphorylates the activation loop 
tyrosine of SFKs and differentially dephosphorylates the C-terminal inhibitory tyrosines of 
SFKs, preferring the Lyn inhibitory tyrosine over those of Src and Fyn. 
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Figure 6.8: Vanadate out-competes interaction of CD148 substrate-trapping
mutant with Lyn, Fyn and Src. Washed human platelets (5 × 108/ml) were treated
with 100 µM pervanadate and lysed with 1% NP-40 lysis buffer. MBP-tagged CD148
substrate trapping fusion protein (MBP-CD148[D/A]) was pre-incubated with (+) or
without (−) 2 mM vanadate prior to being incubated with the platelet lysates.
Proteins were pulled down using amylose-resin and eluted off of the beads by boiling
in 2× Laemmeli buffer. Samples were western blotted with either anti-
phosphotyrosine antibody (p-Tyr), anti-Lyn (Lyn), anti-Fyn (Fyn) or anti-Src (Src)
antibodies. Blots are representative of 3 experiments.
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Figure 6.9. CD148 dephosphorylates both the activation loop and inhibitory site
tyrosines of SFKs in vitro. Washed human platelets were treated with 100 μM
pervanadate with stirring for 3 minutes prior to lysis. Lysates were incubated with
MBP, wild-type CD148 PTP catalytic domain (CD148[WT]) or catalytically inactive
MBP-CD148 (MBP-CD148[CS]) fusion proteins for 30 minutes at room temperature.
Lysates were subsequently western blotted with phosphospecific antibodies that
recognized either the Lyn inhibitory site tyrosine (Lyn p-Tyr 507), Src inhibitory site
tyrosine (Src p-Tyr 529), Fyn inhibitory site tyrosine (Fyn p-Tyr 530) or the
activation loop tyrosines of all SFKs (SFKs activation loop p-Tyr). Band intensities
(arbitrary units) indicated below each panel were quantified using Adobe Photoshop
cs version 8.0. Representative data from 2 experiments.
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6.3.6  Kinetics of dehosphorylation of SFK-derived phopho-peptides 
The kinetics of dephosphorylation of a panel of synthetic SFK-derived phospho-peptides by 
recombinant CD148 PTP domain was measured in real-time using the EnzCheck 
spetrophotometric assay.  This work was done in collaboration with Dr. Alastair Barr 
(Structural Genomics Consortium Oxford).  Phosphopeptides are shown in Table 2.5.  The 
assay is based on a method originally described by Webb for measuring inorganic phosphate 
(Pi) released from enzymatic reactions (Webb 1992).  In the presence of Pi, the substrate 2-
amino-6-mercapto-7-methylpurine-riboside (MESG) is converted enzymatically by purine 
nucleoside phosphorylase (PNP) to ribose 1-phosphate and 2-amino-6-mercapto-7-
methylpurine.  Enzymatic conversion of MESG results in a spectrophotometric shift in 
maximum absorbance from 330 nm for the substrate to 360 nm for the product.   Absorbances 
were measured continuously at 360 nm using a Spectramax plate reader and initial reaction 
rates were calculated over a 5 min period.  Using this assay, recombinant CD148 PTP domain 
was found to dephosphorylate phosphopeptides corresponding the activation loop and 
inhibitory site of SFKs in the following order: Lyn activation loop = Src activation loop > Lyn 
inhibitory site > Src inhibitory site = Fyn inhibitory site (Figure 6.10A).  These findings 
correlated with what was observed in the in vitro dephosphorylation assay (Figure 6.9). 
PTP-1B catalytic domain was also tested in this assay as PTP-1B is highly expressed 
in platelets and has been shown to be an essential positive regulator of αIIbβ3-associated Src 
in platelets (Figure 6.10B).  Interestingly, the PTP-1B catalytic domain had the opposite 
specificity to that of CD148, preferentially dephosphorylated SFK C-terminal inhibitory 
peptides rather than activation loop peptides (Figure 6Aii).  These findings suggest that 
CD148 and PTP-1B differentially regulate SFK activity. 
The calculated Vmax (absorbance [Abs] 360 nm/sec) of dephosphorylation of Lyn 
phospho-peptides by CD148 PTP domain was comparable for the activation loop and 
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inhibitory sites (5.6 ± 0.5 Abs 360 nm/sec versus 5.3 ± 0.7 Abs 360 nm/sec, respectively) 
(Figure 6.11).  However, the Km for the Lyn activation loop phospho-peptide was half of that 
for the Lyn inhibitory site phospho-peptide (301 ± 56 µM versus 621 ± 144 µM, 
respectively), demonstrating a two-fold higher affinity for the activation loop phospho-peptide 
compared with the inhibitory site phospho-peptide (Figure 6.11). 
Together these results suggest that CD148 has a marginal preference for 
dephosphorylating the activation loop of SFKs rather than the inhibitory site and that Lyn is a 
preferred substrate over Src and Fyn. 
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A) CD148
Blank
Lyn activation loop
Src activation loop
Lyn inhibitory site
Src inhibitory site
Fyn inhibitory site
B) PTP-1B
Figure 6.10. CD148 differentially dephosphorylates SFK phosphorylation sites in
vitro. The kinetics of dephosphorylation of phosphopeptides, corresponding to the
activation loop and inhibitory site of Src family kinases by recombinant CD148 and
PTP-1B PTP domains, were measured using the EnzCheck spectrophotometric
continuous assay. The reaction contained: 2-amino-6-mercapto-7-methylpurine-
riboside (MESG), purine nucleoside phosphorylase (PNP), phosphopeptides and
either: (A) recombinant CD148 PTP domain or (B) PTP-1B PTP domain. Inorganic
phosphate released from the phosphopeptide was measured as an increase in
absorbance at 360 nm using a Spectramax plate reader over 5 minutes. Data generated
in collaboration with Dr.Alistair Barr, SGC, Oxford.  
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5.3±0.7621±144Lyn inhibitory siteCD148
5.6±0.5301±56Lyn activation loopCD148
VmaxKmPhosphopeptideEnzyme
Lyn activation loop
Lyn inhibitory site
Figure 6.11. CD148 PTP domain has a higher affinity for the Lyn activation loop
phosphopeptide compared with the inhibitory site phosphopeptide in vitro. The
initial rates of dephosphorylation of phosphopeptides corresponding to the activation
loop and inhibitory site of Lyn were measured using the EnzCheck
spectrophotometric continuous assay. The reaction contained: 2-amino-6-mercapto-
7-methylpurine-riboside (MESG), purine nucleoside phosphorylase (PNP), SFK
phosphopeptide and recombinant CD148 PTP domain. Inorganic phosphate released
from the phosphopeptide was measured as an increase in absorbance at 360 nm using
a Spectramax plate reader over 5 minutes. Calculated Vmax (Abs 360 nm/sec) and
Km (µM) for each peptide are shown. Data generated in collaboration with
Dr.Alistair Barr, SGC, Oxford.
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6.3.7  Identification of CD148 substrates in platelets 
I next wanted to identify other substrates of CD148 in platelets besides SFKs.  The same 
substrate-trapping/pulldown assay described above was used for this purpose.  Samples were 
resolved by SDS-PAGE and stained with colloidal Coomassie blue to visualize the proteins 
(Figure 6.12).  Several proteins were pulled down specifically with the MBP-CD148(D/A) 
mutant, suggesting these may be substrates.  The most prominent bands migrated at 
approximately 160, 90, 60 and 43 kDa (Figure 6.12).  The diffuse band at 60 kDa may be 
SFKs.  The 160, 90 and 43 kDa bands were excised and protein identification was attempted 
by MALDI-TOF.  CD148 was identified in the 90 kDa band.  This probably represents the 
fusion protein.  Presumably other highly phosphorylated co-migrating substrates are also 
present in this region.  Unfortunately, the 43 kDa protein could not be identified due to 
sample degradation.   
The protein corresponding to the 160 kDa band was found to be non-muscle myosin 
heavy chain IIa (Swiss-Prot: P35579), also referred to a myosin heavy chain 9 or MYH9 
protein (Figure 6.13).  Twenty-nine unique peptides were identified, giving 22% coverage of 
the protein.  There are two isoforms of non-muscle myosin heavy chain IIa.  Isoform 1 is 
1,960 amino acids and has a predicted molecular mass of 226,532 Da, and isoform 2 is 1,382 
amino acids and has a predicted molecular weight of 159,864 Da.  Non-muscle myosin heavy 
chain IIa was recently shown to be phosphorylated at Tyr-754 and Tyr-1408 (Rikova et al. 
2007). 
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Figure 6.12: Nonmuscle myosin heavy chain IIa interacts with a substrate-
trapping form of CD148 in vitro. Potential substrates of CD148 were pulled down
from pervandate-stimulated platelet samples as in Figure 6.9. Samples were resolved
by SDS-PAGE and proteins stained with Colloidal Coommassie blue. Bands were
subsequently excised and proteins sent for analysis by electronstray ionization-liquid
chromatography-tandem mass spectromety. Non-muscle myosin heavy chain IIa
(Swiss-Prot no: P35579) was identified in the high molecular weight band, indicated
by the arrow. CD148 was identified in the doublet where the MBP-CD148 fusion
protein migrates. Proteins have yet to be identified in the other bands. n=2.
non-muscle 
myosin heavy 
chain IIa
MBP-CD148
fusion proteins
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1 AQQAADKYLY VDKNFINNPL AQADWAAKKL VWVPSDKSGF EPASLKEEVG
51 EEAIVELVEN GKKVKVNKDD IQKMNPPKFS KVEDMAELTC LNEASVLHNL
101 KERYYSGLIY TYSGLFCVVI NPYKNLPIYS EEIVEMYKGK KRHEMPPHIY
151 AITDTAYRSM MQDREDQSIL CTGESGAGKT ENTKKVIQYL AYVASSHKSK
201 KDQGELERQL LQANPILEAF GNAKTVKNDN SSRFGKFIRI NFDVNGYIVG
251 ANIETYLLEK SRAIRQAKEE RTFHIFYYLL SGAGEHLKTD LLLEPYNKYR
301 FLSNGHVTIP GQQDKDMFQE TMEAMRIMGI PEEEQMGLLR VISGVLQLGN
351 IVFKKERNTD QASMPDNTAA QKVSHLLGIN VTDFTRGILT PRIKVGRDYV
401 QKAQTKEQAD FAIEALAKAT YERMFRWLVL RINKALDKTK RQGASFIGIL
451 DIAGFEIFDL NSFEQLCINY TNEKLQQLFN HTMFILEQEE YQREGIEWNF
501 IDFGLDLQPC IDLIEKPAGP PGILALLDEE CWFPKATDKS FVEKVMQEQG
551 THPKFQKPKQ LKDKADFCII HYAGKVDYKA DEWLMKNMDP LNDNIATLLH
601 QSSDKFVSEL WKDVDRIIGL DQVAGMSETA LPGAFKTRKG MFRTVGQLYK
651 EQLAKLMATL RNTNPNFVRC IIPNHEKKAG KLDPHLVLDQ LRCNGVLEGI
701 RICRQGFPNR VVFQEFRQRY EILTPNSIPK GFMDGKQACV LMIKALELDS
751 NLYRIGQSKV FFRAGVLAHL EEERDLKITD VIIGFQACCR GYLARKAFAK
801 RQQQLTAMKV LQRNCAAYLK LRNWQWWRLF TKVKPLLQVS RQEEEMMAKE
851 EELVKVREKQ LAAENRLTEM ETLQSQLMAE KLQLQEQLQA ETELCAEAEE
901 LRARLTAKKQ ELEEICHDLE ARVEEEEERC QHLQAEKKKM QQNIQELEEQ
951 LEEEESARQK LQLEKVTTEA KLKKLEEEQI ILEDQNCKLA KEKKLLEDRI
1001 AEFTTNLTEE EEKSKSLAKL KNKHEAMITD LEERLRREEK QRQELEKTRR
1051 KLEGDSTDLS DQIAELQAQI AELKMQLAKK EEELQAALAR VEEEAAQKNM
1101 ALKKIRELES QISELQEDLE SERASRNKAE KQKRDLGEEL EALKTELEDT
1151 LDSTAAQQEL RSKREQEVNI LKKTLEEEAK THEAQIQEMR QKHSQAVEEL
1201 AEQLEQTKRV KANLEKAKQT LENERGELAN EVKVLLQGKG DSEHKRKKVE
1251 AQLQELQVKF NEGERVRTEL ADKVTKLQVE LDNVTGLLSQ SDSKSSKLTK
1301 DFSALESQLQ DTQELLQEEN RQKLSLSTKL KQVEDEKNSF REQLEEEEEA
1351 KHNLEKQIAT LHAQVADMKK KMEDSVGCLE TAEEVKRKLQ KDLEGLSQRH
1401 EEKVAAYDKL EKTKTRLQQE LDDLLVDLDH QRQSACNLEK KQKKFDQLLA
1451 EEKTISAKYA EERDRAEAEA REKETKALSL ARALEEAMEQ KAELERLNKQ
1501 FRTEMEDLMS SKDDVGKSVH ELEKSKRALE QQVEEMKTQL EELEDELQAT
1551 EDAKLRLEVN LQAMKAQFER DLQGRDEQSE EKKKQLVRQV REMEAELEDE
1601 RKQRSMAVAA RKKLEMDLKD LEAHIDSANK NRDEAIKQLR KLQAQMKDCM
1651 RELDDTRASR EEILAQAKEN EKKLKSMEAE MIQLQEELAA AERAKRQAQQ
1701 ERDELADEIA NSSGKGALAL EEKRRLEARI AQLEEELEEE QGNTELINDR
1751 LKKANLQIDQ INTDLNLERS HAQKNENARQ QLERQNKELK VKLQEMEGTV
1801 KSKYKASITA LEAKIAQLEE QLDNETKERQ AACKQVRRTE KKLKDVLLQV
1851 DDERRNAEQY KDQADKASTR LKQLKRQLEE AEEEAQRANA SRRKLQRELE
1901 DATETADAMN REVSSLKNKL RRGDLPFVVP RRMARKGAGD GSDEEVDGKA
1951 DGAEAKPAE
Figure 6.13. Tryptic fragments of non-muscle myosin heavy chain IIa identified
by mass spectrometry. The entire amino acid sequence of non-muscle myosin
heavy chain IIa (Swiss-Prot no: P35579) is shown. Tryptic fragments identified by
mass spectrometry are highlighted in bold and red. Tyrosine phosphorylation sites at
positions Tyr-754 and Tyr-1,408 are highlighted in bold, blue and underlined.
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6.4 Discussion  
The main findings of this chapter were: (1) CD148 positively regulates GPVI signalling in 
DT40 cells; (2) SFKs are direct substrates of CD148; (3) CD148 differentially 
dephosphorylates the activation loop and inhibitory tyrosine residues of SFKs; and (4) Non-
muscle myosin heavy chain IIa may be a novel substrate of CD148 in platelets.  These 
findings provide additional information of the molecular mechanism of how CD148 regulates 
GPVI-mediated platelet activation.  
Here I build on data presented in the previous chapter that CD148 is a positive 
regulator of GPVI signalling, by demonstrating that CD148 positively regulates GPVI 
signalling in transiently transfected DT40 cells.  I show that CD148 up-regulates basal and 
collagen-induced GPVI signalling by approximately 2 – 3 fold.  I also demonstrate that 
CD148 catalytic activity is essential for mediating this effect.  These findings also establish 
this DT40 NFAT-luciferase report assay as a good tool for studying the role of CD148 in 
GPVI signalling.  The DT40 chicken B cell line has been used extensively for studying B cell 
receptor signalling (Yasuda et al. 2004).  There a large panel of mutant DT40 cells that have 
been generated which lack expression of specific signalling molecules, including Shp1, Shp2, 
SHIP-1 and Dok-3, making it possible to investigate the importance of particular molecules 
downstream of specific receptors (Ono et al. 1997; Maeda et al. 1998; Stork et al. 2007).  It 
can also be used for structure function analysis of CD148. 
In this chapter I demonstrate that Lyn, Fyn and Src interact directly with the active site 
of CD148 and undergo dephosphorylation by recombinant CD148 in vitro, providing further 
evidence that these SFKs are physiological substrates of CD148 in platelets.  I also show that 
recombinant CD148 is able to dephosphorylate both the inhibitory and activation loop 
tyrosines of Lyn, Fyn and Src. Furthermore, our data indicates that CD148: (1) has a 
preference for dephosphorylation of the activation loop tyrosine over the inhibitory site in 
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vitro, and (2) favours dephosphorylation of Lyn over Fyn and Src.  In a recent study of T cell 
receptor signalling, the RPTP, CD45, was proposed to act as a rheostat, modulating the 
sensitivity of cells to TCR signals by differentially regulating the two critical Lck inhibitory 
and activation loop tyrosine phosphorylation sites (McNeill et al. 2007).  We propose a 
similar mechanism may exist for the regulation of SFKs by CD148 in platelets, whereby 
CD148 firstly triggers SFK activation by dephosphorylation of the inhibitory tyrosine, 
following GPVI or αIIbβ3 stimulation, and then prevents prolonged signalling by 
dephosphorylation of the activation loop tyrosine. 
Several phosphoproteins besides SFKs were specifically pulled down with the 
substrate trapping mutant form of CD148.  Their sizes ranged from 160 – 43 kDa.  Attempts 
to identify these proteins by western blotting were not successful.  Based on the literature and 
sizes of the bands we immunblotted for PLCγ2, Syk, Csk, LAT, SLP-76 and the FcR γ-chain.  
Csk appeared to be constitutively associated with CD148 cytoplasmic tail in a crude version 
of the pull down assay.  However, subsequent attempts to pull down Csk from pervanadate 
treated platelets using purified recombinant CD148 substrate trapping mutant were 
unsuccessful.  Attempts to co-immunprecipitated Csk with anti-CD148 antibody from resting 
and CRP-activated platelets were inconclusive.  These negative results may be due to the lack 
of an interaction or sub-optimal conditions for the interaction to occur.  Interestingly, Csk has 
been previously shown to interact with the non-transmembrane PTP Lyp using a yeast 2-
hybrid system (Cloutier et al. 1996).  The same group also demonstrated that the association 
was highly specific and speculated that Lyp may be an effector and/or regulator of Csk in T 
cells and other hematopoietic cells. 
Non-muscle myosin heavy chain IIa isoform 2 was identified as a potential novel 
substrate of CD148 in platelets using an in vitro substrate-trapping/pulldown assay and mass 
spectrometry.  Human platelets exclusively express myosin IIa, which is an important 
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component of the intracellular cytoskeleton (Maupin et al. 1994; Sellers 2000).  In resting 
platelets, the cytoskeleton is mainly comprised of polymerized actin and actin cross-linking 
proteins.  Upon stimulation with a variety of agonists, actin undergoes further polymerization, 
and interacts with myosin and other contractile proteins to promote platelet shape change and 
granule secretion (Blockmans et al. 1995).  Outside-in integrin αIIbβ3 signalling promotes the 
association of the actin-myosin filaments with membrane glycoproteins, including αIIbβ3 
itself, and other signal transduction components such as tyrosine kinases, lipid metabolizing 
enzymes, and small GTP-binding proteins (Grondin et al. 1991; Jackson et al. 1994; Torti et 
al. 1999).  Tyrosine phosphorylation of myosin heavy chain IIa has been implicated as an 
early event in human platelet activation following thrombin stimulation (Harney et al. 2003).  
Interestingly, Tyr-1408 is within a consensus immunoreceptor tyrosine-based inhibitory motif 
(ITIM), which has been shown to bind Shp1 (Baba et al. 2003).  Mutations in the gene 
encoding non-muscle heavy chaing IIa, MYH9, cause May-Hegglin anomaly, characterized by 
thrombocytopenia, giant platelets and leukocyte inclusions (Kelley et al. 2000; Seri et al. 
2000; Heath et al. 2001).  The interaction between CD148 and mysosin IIa may provide 
further insight into how CD148 regulates platelet function.  However, further work is required 
to validate the interaction. 
 Unfortunately, the identities of the phosphoproteins comprising the most prominent 
bands (90 and 40 kDa doublet) eluded identification.  The broad band at 90 kDa appears to be 
composed of multiple overlapping bands representing several highly phosphorylated proteins 
that maybe substrates of CD148.  Two attempts at identifying the constituents of this broad 
band by mass spectrometry only revealed CD148, likely representing the MBP-CD148 
substrate trapping fusion protein, which co-migrates at this size.  This finding does however 
raise the possibility that CD148 dephosphorylates itself.  Another explanation is that it is 
hyperphosphorylated CD148 trapping mutant.  In previous chapters I demonstrated that SFKs 
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phosphorylate CD148.  Perhaps the CD148 trapping mutant is getting hyperphosphorylated 
by trapped SFKs? 
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7.1 Aims 
 
The non-transmembrane PTP, PTP-1B, has previously been shown to be an essential positive 
regulator of outside-in integrin αIIbβ3 signalling in platelets (Arias-Salgado et al. 2005).  It 
does so by dephosphorylating the C-terminal inhibitory tyrosine of αIIbβ3-associated Src, at 
position Tyr-529, activating the kinase, initiating integrin signalling (Arias-Salgado et al. 
2003).   However, its role in GPVI signalling has not been thoroughly investigated.  In 
Chapters 5 and 6 I demonstrated that the RPTP, CD148 is a global regulator of SFK activity 
in platelets and that it positively regulates both GPVI and αIIbβ3 signalling in mouse platelets 
through a mechanism that involves activating SFKs by dephosphorylating the C-terminal 
inhibitory tyrosine of SFKs.  Therefore, CD148 and PTP-1B positively regulate SFK activity 
by an apparently similar mechanism.  The main aim of this chapter was to investigate the role 
of PTP-1B in GPVI and integrin αIIbβ3 signalling and to start to address the question of 
possible functional redundancy between CD148 and PTP-1B in platelets.  Since I found that 
PTP-1B-deficient platelets had minor functional and phosphorylation defects that were 
influenced by strain variation, we asked the question whether the structurally related NTPTP, 
TC-PTP, was playing a similar function in platelets and could possibly compensate in its 
absence (Figure 1.11).  I checked for expression of TC-PTP in human and mouse platelets and 
tested platelets from TC-PTP-deficient mice for functional defects. 
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7.2  Introduction 
PTP-1B is a ubiquitously expressed non-transmembrane PTP that is localized to the outer 
surface of the endoplasmic reticulum (Frangioni et al. 1992).  Being the prototypic PTP, PTP-
1B has been extensively studied and is best known for its role in insulin signalling (Elchebly 
et al. 1999).  PTP-1B has been implicated as a negative regulator of insulin action and as an 
important mediator in the pathogenesis of insulin-resistance and non-insulin dependent 
diabetes mellitus (Byon et al. 1998; Shi et al. 2004; Bodula et al. 2005).  Other roles for PTP-
1B include down regulation of cytokine receptor signalling and as a negative regulator of 
macrophage development through CSF-1 signalling (Cheng et al. 2002; Gu et al. 2003; 
Heinonen et al. 2006). 
In platelets, PTP-1B has been shown to get cleaved from the ER surface by the 
calcium-dependent protease calpain, following agonist-induced platelet activation (Frangioni 
et al. 1993; Ragab et al. 2003; Kuchay et al. 2007).  This results in translocation of PTP-1B 
from the ER membrane to the cytosol.  Recent work by Arias-Salgado et. al. demonstrated 
that fibrinogen-binding to αIIbβ3 triggers PTP-1B recruitment to the αIIbβ3-Src-Csk 
complex.  Platelets lacking PTP-1B expression exhibited reduced integrin αIIbβ3-mediated 
signalling (Arias-Salgado et al. 2003; Arias-Salgado et al. 2005).  The molecular basis of this 
defect was shown to be a lack of dissociation of Csk from the αIIbβ3-Src-Csk complex, and 
concomitant hyper-phosphorylation and inactivation of Src at its inhibitory tyrosine (Arias-
Salgado et al. 2005).  The functional consequences included reduced spreading on fibrinogen, 
clot retraction and calcium signalling.  PTP-1B-deficient mice also exhibited reduced 
thrombus formation in vivo.  Interestingly, GPVI signalling was reported to be normal in PTP-
1B-deficient platelets.  This was somewhat surprising, as the SFKs Fyn and Lyn, are essential 
for initiating GPVI signalling.  This suggests that PTP-1B specifically regulates Src in 
platelets, perhaps through enzyme specificity or compartmentalization.  However, one 
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limitation of the GPVI signalling data in the Arias-Salgado et. al. study was that GPVI 
signalling was being initiated by a high concentration of the snake toxin convulxin, which is 
not GPVI-specific, but also signals through the receptor for VWF, GPIb-IX-V (Andrews et al. 
2000; Andrews et al. 2003). 
Two PTP-1B knockout (KO) mouse models have been generated by two separate 
groups in order to determine the physiological function of PTP-1B.  One was generated in the 
Tremblay laboratory and the other in the Neel laboratory by homologous recombination using 
slightly different strategies (Elchebly et al. 1999; Klaman et al. 2000).  The PTP-1B KO 
mouse model generated in the Tremblay laboratory was made by deleting a portion of the 
gene that includes exon 5 and the tyrosine phosphatase active site in exon 6 (Elchebly et al. 
1999).  This mouse model (PTP-1B Ex5/6 KO) was bred onto a Balb/c background.  The 
PTP-1B KO mouse model generated in the Neel laboratory was made by deleting exon 1 of 
the gene.  This mouse model (PTP-1B Ex1 KO) was bred onto a mixed C57BL/6 × 129SvJ 
background.  Both knockout strategies generated mice that lacked any expression of PTP-1B 
protein.  Despite the strain variations, both knockout mouse models exhibited similar 
phenotypes, including: resistance to weight gain, insulin sensitivity and glucose tolerance 
(Elchebly et al. 1999; Klaman et al. 2000).  Both models exhibited increased phosphorylation 
of the insulin receptor and the adaptor protein IRS-1, demonstrating that PTP-1B negatively 
regulates insulin receptor signalling.  They also exhibited enhanced basal metabolic rate and 
total energy expenditure (Klaman et al. 2000).   
The PTP-1B mouse model used by Arias-Salgado et. al. to show that PTP-1B is an 
essential positive regulator of platelet integrin αIIbβ3 signalling was the PTP-1B Ex1 KO.  
Whereas the PTP-1B Ex5/6 KO backcrossed onto a C57BL/6 background were used to 
generate compound PTP-1B/calpain-1 double-deficient mice and demonstrate that PTP-1B is 
a physiological substrate of calpain in platelets (Kuchay et al. 2007).  PTP-1B activity was 
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significantly increased in calpain-1-deficient mouse platelets and correlated with reduced 
tyrosine phosphorylation of platelet proteins, platelet aggregation, and impaired clot retraction 
(Kuchay et al. 2007).  Interestingly, these defects were rescued in the PTP-1B/calpain-1 
double knockout mice (Kuchay et al. 2007).  
TC-PTP belongs to the same subfamily as PTP-1B.  It is ubiquitously expressed, with 
high levels in hematopoietic cells, however, it has not previously been shown to be expressed 
in platelets.  Although structurally similar, PTP-1B and TC-PTP are not functionally 
redundant, regulating both common and distinct signalling pathways.  A common pathway 
both proteins are involved in regulating is the insulin signalling pathway.  TC-PTP has been 
mainly implicated in negatively regulating the Jak/STAT signalling pathway downstream of 
cytokine and growth factor receptors (Simoncic et al. 2002; Shields et al. 2008).  TC-PTP-
deficient mice are of normal size and health following birth, however, after approximately 2 
weeks begin to display signs of runting, and by 3 to 5 weeks of age exhibit closed eyes, 
hunching, decreased mobility and diarrhoea followed by death (You-ten et al. 1997).  Low 
hematocrit levels in these mice indicate they also suffer from severe anaemia contributing to 
their early death (You-Ten et al. 1997). 
In this chapter, I test two hypotheses through the use of mouse models: (1) PTP-1B 
regulates GPVI and integrin αIIbβ3 signalling in platelets; and (2) TC-PTP regulates GPVI 
signalling in platelets.  Findings presented in this chapter demonstrate that PTP-1B plays a 
minor role in GPVI and integrin αIIbβ3 signalling, that is influenced by strain variation or 
modifier loci.  This demonstrates that CD148 and PTP-1B have fundamentally different 
functions in platelets.  Finally, I show that TC-PTP is expressed in human and mouse platelets 
and that it plays a role in platelet development. 
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7.3  Results 
 
7.3.1  PTP-1B 
 
7.3.1.1  PTP-1B-deficient platelets on a Balb/c background exhibit minor aggregation 
and secretion defects to low concentration CRP 
It has previously been reported that PTP-1B is a selective positive regulator of αIIbβ3-
associated Src kinase, with no role downstream of the collagen activation receptor GPVI 
(Arias-Salgado et al. 2005).  However, we question this conclusion as it was based on work 
done using a high concentration of the snake toxin convulxin, which is a non-specific GPVI 
agonist (Andrews et al. 2000).  To test our hypothesis that PTP-1B positively regulates GPVI 
signalling, we measured the ability of platelets from PTP-1B Ex5/6 KO mice on a Balb/c 
background to aggregate to the GPVI-specific agonist, CRP.  PTP-1B-deficient platelets were 
stimulated with either low (0.3 µg/ml) or intermediate (1 µg/ml) concentrations of CRP and 
aggregation was measured as a change in light transmission using an optical aggregometer.  
Platelets from PTP-1B-deficient mice did not aggregate in response to low concentration CRP 
(Figure 7.1Ai).  This block in aggregation was partly overcome at a higher concentration of 
CRP (1 μg/ml) (Figure 7.1Aii).  PTP-1B-deficient platelets responded normally to an 
intermediate concentration of thrombin (0.06 U/ml), demonstrating that this was a GPVI-
specific aggregation defect (Figure 7.1B).  This was the first evidence that that PTP-1B has a 
positive regulatory role downstream of GPVI signalling.  
 
 
7.3.1.2  PTP-1B-deficient platelets on a Balb/c background have impaired P-selectin 
expression and αIIbβ3 activation in response to CRP 
Flow cytometry studies were carried out to investigate the role of PTP-1B in α-granule 
secretion and integrin αIIbβ3 activation.  P-selectin expression on the surface of platelets was 
used as a measure of α-granule secretion and inside-out activation of αIIbβ3 was detected 
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using JON/A antibody binding, which only recognizes the active, high-affinity conformation 
of the integrin.  Platelets were stimulated with either 10 μg/ml CRP or 1 U/ml thrombin for 10 
minutes then stained with either FITC-conjugated anti-P-selectin or JON/A antibodies.  
Samples were subsequently analyzed by flow cytometry. CRP-mediated P-selectin expression 
and integrin αIIbβ3 activation were reduced in PTP-1B-deficient platelets compared with 
wild-type (WT) control platelets (Figure 7.2A and B), whereas thrombin-mediated responses 
were normal (Figure 7.2C and D).  These findings provided further evidence of a positive 
regulatory role of PTP-1B downstream of GPVI. 
Surface expression of GPVI and αIIbβ3 in resting PTP-1B deficient and WT platelets 
were also analysed by flow cytometry.  GPVI levels were reduced by approximately 33% 
(Figure 7.3A and B), whereas integrin αIIbβ3 levels were normal (Figure 7.3C and D).  This 
reduction in GPVI expression may partially explain the functional defects, as platelets 
expressing 50% of GPVI levels were previously reported to exhibit a two-fold shift in the 
dose response curve in aggregation to collagen, convulxin and the anti-GPVI antibody JAQ1 
(Snell et al. 2002). 
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Figure 7.1: Platelets from PTP-1B-deficient mice (Balb/c background) exhibit
impaired GPVI-mediated platelet aggregation. Washed platelets (2 × 108/ml)
prepared from litter-matched wild-type (WT) and PTP-1B-deficient (PTP-1B KO)
mice on a Balb/c background were stimulated with either (Ai) 0.3 µg/ml CRP, (Aii) 1
µg/ml CRP or (B) 0.06 U/ml thrombin. Platelet aggregation was measured as a change
in light transmission using a lumi-aggregometer. Representative images are shown (n
= 2-3 mice per condition).
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Figure 7.2: GPVI-mediated P-selectin expression and integrin αΙΙbβ3 activation
are impaired in PTP-1B-deficient platelets (Balb/c background). Platelets from
wild-type (WT) and PTP-1B-deficient (PTP-1B KO) mice on a Balb/c background
were unstimulated (purple histograms), or stimulated with 10 µg/ml collagen-related
peptide (CRP) or 0.06 U/ml thrombin (green and red lines respectively), stained with a
FITC-conjugated P-selectin antibody (A and B) or JON/A antibody (C and D) and
analysed by flow cytometry. Results are representative of three mice per genotype.
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Figure 7.3: Reduced GPVI and normal integrin αIIbβ3 expression on PTP-1B-
deficient platelets (Balb/c background). Wild-type (WT) and PTP-1B-deficient
platelets (PTP-1B KO) on a Balb/c background were immunostained with either a
FITC-conjugated GPVI (green lines-panels A and B) and αIIbβ3 antibodies (orange
lines-panels C and D). Purple histograms represent platelets stained with FITC-
conjugated IgG isotype control antibody.
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7.3.1.3  GPVI signalling is normal in PTP-1B-deficient platelets on a Balb/c 
background 
Although less severe than the GPVI-mediated functional defects reported in CD148-deficient 
platelets (Senis et al. 2009), the above observations demonstrated that PTP-1B positively 
regulates GPVI-mediated functional responses.  We therefore wanted to investigate the 
molecular basis of this functional defect.  Since PTP-1B has been shown to be a positive 
regulator of Src tyrosine kinase in platelets (Arias-Salgado et al. 2005), we hypothesized that 
it also regulates Fyn and Lyn SFKs, which are essential for initiating and propagating GPVI 
signalling (Watson et al. 2005).  We started by analysing protein tyrosine phosphorylation in 
resting and CRP-stimulated platelets.  The pattern of whole cell phosphorylation was near 
identical between WT and PTP-1B-deficient platelets stimulated with 10 μg/ml CRP for 0, 90 
and 300 seconds (Figure 7.4).  This was in stark contrast to the overall decrease in protein 
tyrosine phosphorylation observed in CRP-simulated CD148-deficient platelets (Chapter 5, 
Figure 5.1).  Tyrosine phosphorylation of the FcR γ-chain was normal in CRP-stimulated 
PTP-1B-deficient platelets, suggesting that Fyn and Lyn were getting properly activated 
following GPVI engagement and cross-linking.  This was confirmed by immunoblotting with 
phospho-specific antibodies for the SFK activatory and inhibitory tyrosine phosporylation 
sites.  Fyn, Lyn and Src were all found to be phosphorylated to the same extent at both their 
activatory and inhibitory sites in resting and CRP-stimulated mutant platelets compared with 
WT control platelets (Figure 7.5).  These findings demonstrated that PTP-1B is not involved 
in regulating these SFKs in resting or CRP-stimulated platelets.  This was in complete 
contrast to the observation in CD148-deficient platelets, demonstrating that CD148 and PTP-
1B have fundamentally different functions in platelets (Senis et al. 2009). 
We next wanted to determine if there was a signalling defect further downstream in 
the GPVI signalling pathway.  We investigated tyrosine phosphorylation of Syk and PLCγ2 as 
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they are essential components of the GPVI signalling pathway and lie downstream of the FcR 
γ-chain (Watson et al. 2005).  Syk and PLCγ2 were immunoprecipitated from CRP-stimulated 
wild-type and PTP-1B-deficient platelets, resolved by SDS-PAGE and western blotted with 
an anti-phosphotyrosine antibody.  Consistent with the whole cell lysate data, there was no 
reduction in CRP-induced tyrosine phosphorylation of Syk and PLCγ2 in PTP-1B-deficient 
platelets (Figure 7.6).  This result suggested the defect may lie further downstream of PLCγ2 
or in a different biochemical process. 
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Figure 7.4: Normal GPVI signalling in PTP-1B-deficient platelets (Balb/c
background). Washed platelets (5 × 108/ml) from wild-type (WT) and PTP-1B-
deficient (PTP-1B KO) mice on a Balb/c background were stimulated with 10 μg/ml
CRP for 0, 90 and 300 seconds. Whole cell lysates (WCLs) were resolved on a 10%
SDS-PAGE gel then western blotted with an anti-phosphotyrosine antibody (p-Tyr).
The doublet corresponding to the FcR γ-chain is indicated at the bottom of the gel.
Blot representative of 3 experiments.
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Figure 7.5: Normal Src family kinase phosphorylation in resting and CRP-
activated PTP-1B-deficient platelets (Balb/c background). Washed platelets (5 ×
108/ml) from wild-type (WT) and PTP-1B-deficient (PTP-1B KO) mice on a Balb/c
background were stimulated with 10 μg/ml CRP for 0, 90 and 300 seconds. Whole
cell lysates (WCLs) were resolved on a 10% SDS-PAGE gel then western blotted with:
(i) an anti-Src family kinase (SFK) activation loop p-Tyr antibody; (ii) an anti-Src p-
Tyr 529 antibody; (iii) an anti-Fyn p-Tyr 530 antibody; (iv) an anti-Lyn p-Tyr 507
antibody and (v) an anti-Lyn antibody as a control for protein loading. Blot
representative of 3 experiments.
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Figure 7.6: Normal Syk and PLCγ2 phosphorylation in resting and CRP-activated
PTP-1B-deficient platelets (Balb/c background). Washed platelets (5 × 108/ml)
from wild-type (WT) and PTP-1B-deficient (PTP-1B KO) mice on a Balb/c
background were stimulated with 10 μg/ml CRP for 0, 90 and 300 seconds. (i) Syk
and (ii) PLCγ2 were immunoprecipitated from whole cell lysates and western blotted
with an anti-phosphotyrosine antibody, then stripped and re-blotted with anti-Syk and
anti-PLCγ2 antibodies, respectively. Blot representative of 2 experiments.
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7.3.1.4  PTP-1B-deficient platelets on a C57BL/6 background aggregate normally in 
response to  low concentration CRP 
One possible explanation for the discrepancy in our findings with those of Arias-Salgado et. 
al. regarding GPVI-mediated functional defects in PTP-1B-deficient platelets is that the 
mouse models that were analyzed are different.  These differences may be due to strain 
variation or modifier loci.  In our study, we used PTP-1B Ex5/6 KO mice on a Balb/c 
background, whereas Arias-Salgado et. al. used PTP-1B Ex1 KO mice on a mixed C57BL/6-
129SvJ background.  Neither mouse model generated a truncated version of PTP-1B.  To test 
the possibility that strain variation can alter the phenotype, PTP-1B Ex5/6 KO mice 
backcrossed on a C57BL/6 background (>12 generations) were analyzed for functional and 
biochemical defects. 
 Unlike PTP-1B-deficent platelets on a Balb/c background which exhibit aggregation 
and secretion defects to low concentration (0.3 and 1 µg/ml) CRP, PTP-1B-deficient platelets 
on a C57BL/6 background exhibited normal aggregation and a reduction in ATP secretion to 
the same concentrations of CRP (Figures 7.1 and 7.7).  This finding suggests that modifier 
loci in different strains of mice can alter the GPVI-mediated aggregation/secretion phenotype.  
It should be noted that PTP-1B-deficient platelets on a C57BL/6 background 
aggregated/secreted normally to low dose thrombin stimulation (data not shown). 
  
7.3.1.5  GPVI signalling is normal in PTP-1B-deficient platelets on a C57BL/6 
background 
PTP-1B-deficient platelets on a C57BL/6 background were next examined for GPVI 
signalling defects.  Platelets were stimulated with an intermediate concentration of CRP (5 
µg/ml) for 0, 30, 60, 120 and 240 seconds in the presence of apyrase (ADP scavenger), 
indomethacin (cyclooxygenase inhibitor) and lotrafiban (αIIbβ3 antagonist).  Whole cell 
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phosphorylation was almost identical between WT and mutant platelets pre- and post-CRP 
stimulation (Figure 7.8i).  Some bands, including a prominent band at approximately 25 kDa, 
were marginally hyperphosphorylated in mutant platelets, suggesting they may be substrates 
of PTP-1B (Figure 7.8i).  Phosphorylation of the FcR γ-chain was normal in resting and 
activated mutant platelets, as was phosphorylation of Syk at its activation loop (Tyr525/526) 
(Figure 7.8ii and iv), demonstrating normal GPVI proximal signalling in PTP-1B-deficient 
platelets on a C57BL/6 background. 
 The same experiments described above were repeated in the absence of lotrafiban to 
allow platelets to aggregate following CRP stimulation.  The purpose of these experiments 
was to test whether PTP-1B was involved in aggregation-dependent signalling via the integrin 
αIIbβ3.  Whole cell phosphorylation was normal in mutant platelets under these conditions 
(Figure 7.9i).  Further, phosphorylation of the FcR γ-chain and the activation loop of Syk 
were also normal, demonstrating that PTP-1B is not involved in aggregation-dependent 
signalling. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7  PTP-1B and TC-PTP 
188 
 
%
 a
gg
re
ga
tio
n
0
70
0.3 µg/ml CRP
PTP-1B KO
(C57BL/6)
WT
(C57BL/6)
%
 a
gg
re
ga
tio
n
0
70
1 µg/ml CRP
time (mins)0 6 time (mins)0 6
0
2
AT
P
 (n
m
ol
)
Figure 7.7: Platelets from PTP-1B-deficient mice (C57BL/6 background)
aggregate normally and have an ATP secretion defect to CRP. Washed platelets (2
× 108/ml) prepared from litter-matched wild-type (WT) and PTP-1B-deficient (PTP-
1B KO) mice on a C57BL/6 were stimulated with 0.3 and 1 µg/ml CRP. Platelet
aggregation was measured as a change in light transmission using a lumi-aggregometer.
Representative images are shown (n = 2 mice per condition).
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Figure 7.8: Normal GPVI signalling in PTP-1B-deficient platelets (C57BL/6
background) in suspension. Washed platelets (2 × 108/ml) pooled from three wild-
type (WT) and three PTP-1B-deficient (PTP-1B KO) mice on a C57BL/6 background
were stimulated with 5 µg/ml collagen-related peptide (CRP) in the presence of 2
U/ml apyrase, 10 µM indomethacin and 10 µM lotrafiban for 30, 60, 120 and 240
seconds (sec). Whole cell lysates (WCL) prepared at the indicated times were
resolved on 4 – 12% SDS-PAGE gels and western blotted with: (i) anti-
phosphotyrosine (p-Tyr); (iv) anti-Syk-phosphotyrosine 525/526 (Syk-p-Tyr525/526)
antibodies. (ii) Longer exposure of the region of membrane (i) where FcR γ-chain
migrates (~12 kDa). (iii) Membrane (i) was re-blotted with an anti-actin antibody. (v)
Membrane (iv) was re-blotted with an anti-Syk antibody. Representative images are
shown (n = 2 separate experiments).
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Figure 7.9: Normal GPVI signalling in aggregated PTP-1B-deficient platelets
(C57BL/6 background). Washed platelets (2 × 108/ml) pooled from three wild-type
(WT) and three PTP-1B-deficient (PTP-1B KO) mice on a C57BL/6 background were
stimulated with 5 µg/ml collagen-related peptide (CRP) in the presence of 2 U/ml
apyrase and 10 µM indomethacin for 30, 60, 120 and 240 seconds (sec). Whole cell
lysates (WCL) prepared at the indicated times were resolved on 4 – 12% SDS-PAGE
gels and western blotted with: (i) anti-phosphotyrosine (p-Tyr); (iv) anti-Syk-
phosphotyrosine 525/526 (Syk-p-Tyr525/526) antibodies. (ii) Longer exposure of the
region of membrane (i) where FcR γ-chain migrates (~12 kDa). (iii) Membrane (i) was
re-blotted with an anti-actin antibody. (v) Membrane (iv) was re-blotted with an anti-
Syk antibody. Representative images are shown (n = 2 separate experiments).
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7.3.1.6  Integrin αIIbβ3 signalling in PTP-1B-deficient platelets on a C57BL/6 
background 
The main finding of the study by Arias-Salgado et. al. is that PTP-1B is essential for initiating 
outside-in integrin αIIbβ3 signalling by dephosphorylating the inhibitory site of αIIbβ3-
associated Src, which activates the kinase.  These findings are based on observations made 
using PTP-1B-deficient platelets (Ex 1 deleted on a mixed C57BL/6-129SvJ background) 
(Arias-Salgado et al. 2005).  To test this finding, we investigated outside-in integrin αIIbβ3 
signalling in fibrinogen spread PTP-1B-deficient platelets (Ex 5/6 deleted on a C57BL/6 
background).  Whole cell phosphorylation was found to be virtually identical in BSA non-
adherent and fibrinogen-adherent WT and mutant platelets (Figure 7.10).  Further, the SFKs 
Src, Fyn and Lyn were all found to be phosphorylated to the same extent at their activation 
and inhibitory sites in non-adherent and adherent WT and mutant platelets (Figure 7.11).  
Contrary to the findings reported by Arias-Salgado et. al., our findings suggest that PTP-1B is 
not required for initiating outside-in integrin αIIbβ3 signalling.  This contradiction may 
reflect differences in the mouse models used by the two groups or differences in the 
experimental protocols. 
 The only potential biochemical difference in integrin signalling identified between 
WT and mutant platelets was in the phosphorylation and interacting proteins associated with 
the signalling molecules Syk and PLCγ2.  Both Syk and PLCγ2 lie downstream of Src in the 
αIIbβ3 signalling pathway, and both were found to be marginally hyper-phosphorylated in 
fibrinogen adherent mutant platelets compared with WT platelets (Figures 7.12 and 7.13).  In 
addition, differences were observed in both Syk and PLCγ2 co-associated phosphoproteins 
before and/or after adhesion to fibrinogen. 
 Taken together, these findings demonstrate that PTP-1B is not essential for initiating 
integrin αIIbβ3 signalling, but it may be involved in regulating signalling further downstream. 
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Figure 7.10: Normal integrin αIIbβ3 signalling in fibrinogen-adherent PTP-1B-
deficient platelets (C57BL/6 background). Washed platelets (5 × 108/ml) pooled
from five wild-type and five PTP-1B-deficient (KO) platelets on a C57BL/6
background were placed on BSA- and fibrinogen-coated surfaces for 45 minutes at
37°C. (i) Whole cell lysates (WCLs) prepared of BSA-non-adherent and fibrinogen-
adherent platelets were resolved on 4 – 12% SDS-PAGE gels and western blotted
with an anti-phosphotyrosine antibody (p-Tyr). (ii and iii) Membrane (i) was
stripped and re-blotted with an anti-PLCγ2 antibody, then stripped and re-blotted a
second time with an anti-PTP-1B antibody. Results are representative of 2 separate
experiments.
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Figure 7.11: Normal Src family kinase (SFK) phosphorylation in BSA non-
adherent and fibrinogen adherent PTP-1B-deficient platelets (C57BL/6
background). Washed platelets (5 × 108/ml) pooled from five wild-type and five
PTP-1B-deficient (KO) platelets on a C57BL/6 background were placed on BSA- and
fibrinogen-coated surfaces for 45 minutes at 37°C. Whole cell lysates (WCLs)
prepared of BSA non-adherent and fibrinogen adherent platelets were resolved on 4 –
12% SDS-PAGE gels and western blotted with: (i) an anti-SFK activation loop
phosphotyrosine antibody (SFK activation p-Tyr); (ii) an anti-Src inhibitory p-Tyr
antibody; (iii) an anti-Fyn inhibitory p-Tyr antibody; and (iv) an anti-Lyn inhibitory p-
Tyr antibody. Membranes (i – iv) were stripped and re-blotted with an anti-Src pan,
and-Fyn pan and anti-Lyn pan antibodies, respectively. Results are representative of 2
separate experiments.
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Figure 7.12: PLCγ2 phosphorylation and interacting proteins in BSA non-
adherent and fibrinogen adherent PTP-1B-deficient platelets (C57BL/6
background). Washed platelets (5 × 108/ml) pooled from five wild-type and five
PTP-1B-deficient (KO) platelets on a C57BL/6 background were placed on BSA- and
fibrinogen-coated surfaces for 45 minutes at 37°C. PLCγ2 was immunoprecipitated
(IP) from whole cell lysates (WCLs) prepared of BSA non-adherent and fibrinogen
adherent platelets. IPs were resolved on 4 – 12% SDS-PAGE gels and western blotted
with an anti-phosphotyrosine antibody (p-Tyr) then stripped and re-blotted with an
anti-PLCγ2 antibody. Blot representative of 2 experiments.
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Figure 7.13: Syk phosphorylation and interacting proteins in BSA non-adherent
and fibrinogen adherent PTP-1B-deficient platelets (C57BL/6 background).
Washed platelets (5 × 108/ml) pooled from five wild-type and five PTP-1B-deficient
(KO) platelets on a C57BL/6 background were placed on BSA- and fibrinogen-coated
surfaces for 45 minutes at 37°C. Syk was immunoprecipitated (IP) from whole cell
lysates (WCLs) prepared of BSA non-adherent and fibrinogen adherent platelets. IPs
were resolved on 4 – 12% SDS-PAGE gels and western blotted with an anti-
phosphotyrosine antibody (p-Tyr) then stripped and re-blotted with an anti-Syk
antibody.
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7.3.2  TC-PTP expression and functional characterization in platelets 
TC-PTP and PTP-1B are structurally similar PTPs, sharing 74 % sequence homology in their 
catalytic domains (Romsicki et al. 2003; Doody et al. 2009).  They also display similar 
enzyme kinetics (Iversen et al. 2002; Romsicki et al. 2003).  We therefore hypothesized that 
TC-PTP may compensate in the absence of PTP-1B.  In this section I confirmed expression of 
TC-PTP in mouse and human platelets, and analyzed GPVI-mediated functional responses in 
TC-PTP-deficient platelets. 
 
 
7.3.2.1  TC-PTP is expressed in human and mouse platelets 
 
Whole cell lysates prepared from human and WT mouse platelets were immunoblotted with 
an anti-TC-PTP antibody.  Jurkat T cells and mouse thymocytes, which express high levels of 
TC-PTP, were used as positive controls.  Faint bands migrating at the correct size for TC-PTP 
(45 kDa), were observed in both the human and mouse platelet (Figure 7.14A).  Two C-
terminal end splice variants of TC-PTP (45 and 48 kDa) are known to be expressed in various 
cell types.  Each has distinctly different subcellular localizations and substrate preferences.  
The 45 kDa variant of TC-PTP tends to associate with proteins at the plasma membrane 
whereas the 48 kDa variant is localized to the endoplasmic reticulum (Tiganis et al. 1998; 
Tiganis et al. 1999).  Our data suggests the 45 kDa splice variant is expressed in human and 
mouse platelets. 
 
7.3.2.2  TC-PTP-deficient platelets have impaired P-selectin expression in response to 
CRP and thrombin 
I next investigated the functional responses of TC-PTP-deficient platelets.  TC-PTP-deficient 
mice exhibit an assortment of developmental defects and die within weeks of birth, making it 
difficult to collect sufficient amounts of blood for aggregation studies.  Due to the poor 
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platelet recovery from mutant mice, flow cytometry was used to measure P-selectin 
expression on the surface of CRP- and thrombin-activated TC-PTP-deficient platelets.  TC-
PTP-deficient mice exhibited severely reduced levels of P-selectin on their surface in 
response to high doses of both CRP and thrombin (10 µg/ml and 1 U/ml, respectively) 
compared with litter-matched wild-type platelets (Figure 7.14B).  Surface expression of GPVI 
was also severely reduced in resting TC-PTP-deficient platelets, whereas expression of the 
integrin αIIbβ3 was normal (Figure 7.15) 
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Figure 7.14. TC-PTP-deficient platelets exhibit decreased P-selectin expression
in response to synthetic collagen peptide and thrombin. (A) Whole cell lysates
prepared of washed human and mouse platelets, Jurkat T cells and mouse thymocytes
were western blotted with an anti-TC-PTP antibody. (B) Washed platelets obtained
from wild-type (WT) and TC-PTP-deficient (TC-PTP-/-) mice were stimulated with 10
µg/ml of the GPVI-specific agonist collagen-related peptide (CRP) or 1 U/ml of
thrombin. Surface expression of P-selectin was measured using FITC-conjugated
anti-mouse P-selectin antibody and is directly proportional to the amount of α-granule
secretion. Results are representative of 2 mice of each genotype.
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Figure 7.15. TC-PTP-deficient platelets do not express GPVI on their surface,
but express normal levels of the integrin αIIbβ3. Resting, washed platelets from
wild-type (WT) and TC-PTP-deficient (TC-PTP-/-) mice were stained with either
FITC-conjugated anti-mouse GPVI antibody or FITC-conjugated anti-mouse αIIbβ3
antibody. Results are representative of 3 mice of each genotype.
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7.4 Discussion 
 
In this chapter I demonstrate that PTP-1B plays little or no role in regulating GPVI or integrin 
αIIbβ3 signalling in platelets.  However, this conclusion is complicated by strain variation 
which alters the platelet phenotype of PTP-1B-deficient mouse models.  Platelets from PTP-
1B-deficient mice on a Balb/c background exhibit minor CRP-mediated aggregation and 
secretion defects, whereas platelets from PTP-1B-deficient mice on a C57BL/6 background 
aggregated normally to CRP with a reduction in secretion.  Neither PTP-1B mouse model 
exhibited any overt phosphorylation defects to CRP or fibrinogen, demonstrating that CD148 
and PTP-1B have fundamentally different functions in platelets.  I also demonstrate for the 
first time that the structurally related PTP, TC-PTP, is expressed in human and mouse 
platelets at relatively low levels and that platelets from TC-PTP-deficient mice have severely 
reduced P-selectin expression in response to CRP and thrombin stimulation.  The cause of the 
CRP-mediated defect is likely the almost complete absence of GPVI on the surface of TC-
PTP-deficient platelets.  TC-PTP-deficient mice also appear to be severely thrombocytopenic, 
suggesting that TC-PTP is involved in platelet formation. 
 We chose to investigate the functional role of PTP-1B in platelets in parallel with 
CD148 because we hypothesized that these two structurally distinct phosphatases have 
redundant functions in platelets.  This is based on the fact that the functional and biochemical 
defects exhibited by CD148-deficient platelets were partial and could be overcome with high 
doses of agonists (Chapters 4 and 5).  CD45 is the main RPTP that regulates immune receptor 
function in B and T cells, however they also express CD148 which has been shown to have 
some redundant functions with CD45 (Zhu et al. 2008).  Since we could not conclusively 
identify another RPTP in platelets, we speculated that a non-transmembrane PTP could 
perform this function.  The most obvious candidate was PTP-1B because it was recently 
shown to be an important positive regulator of Src downstream of the integrin αIIbβ3 (Arias-
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Salgado et al. 2005).  Interestingly, PTP-1B selectively regulates Src downstream of αIIbβ3, 
but not Fyn and Lyn downstream of GPVI, which was different to what we were observing in 
CD148-deficient platelets.   We speculated that this may be due to masking resulting from use 
of high concentration of the powerful GPVI agonist convulxin (Arias-Salgado et al. 2005).  
Further, convulxin is not GPVI-specific, but also binds to and activates GPIb-IX-V on 
platelets (Kanaji et al. 2003). 
 Collectively, results presented in this chapter demonstrate that PTP-1B and CD148 
have fundamentally different roles in platelets.  Functional defects observed in both PTP-1B-
deficient mouse models were minor compared to those observed in CD148-deficient platelets 
(Chapter 4).  Moreover, there were no major phosphorylation defects in PTP-1B-deficient 
platelets, whereas dramatic defects were observed in CD148-deficient platelets (Chapter 5).  It 
should be pointed out that both the PTP-1B- and CD148-deficient mouse models were on a 
C57BL/6 background, eliminating the possibility of strain variation between the two models. 
One of the most interesting findings of this chapter that demonstrates the different 
biochemical functions of CD148 and PTP-1B in platelets was that SFK activity was normal in 
resting PTP-1B-deficient platelets, whereas it was significantly reduced in CD148-deficient 
platelets.  SFK activity was indirectly measured as phosphorylation of the SFK activation 
loop, which is a trans-autophosphorylation event, and phosphorylation of the FcR γ-chain, 
which is also mediated by SFKs.  These findings demonstrate that CD148 is critical for 
maintaining a pool of active SFKs in platelets, which keeps platelets primed, so that they can 
respond rapidly when they come into contact with ECM proteins at sites of vascular injury. 
We suspect the reason for the discrepancy between our findings and those previously 
reported by Arias-Salgado et. al. on the functional role of PTP-1B in platelets reflects strain 
variation and the effects of modifier loci on the PTP-1B-deficient mouse models studied by 
the two groups.  Strain variation may be compounded by differences in experimental 
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conditions.  We studied PTP-1B Ex5/6 KO mice on either a Balb/c or a C57BL/6 background, 
whereas Arias-Salgado et. al. studied PTP-1B Ex1 KO mice on a mixed C57BL/6-129SvJ 
mice.  Neither the PTP-1B Ex5/6 KO mouse nor the PTP-1B Ex1 KO mouse express 
truncated forms of PTP-1B and the metabolism phenotypes previously reported in these mice 
were very similar.  Therefore, it seems unlikely that either mouse model accidentally acquired 
other mutations besides ablation of the PTP-1B gene during generation.  However, the 
possibility exists that the models drifted apart with time due to naturally occurring mutations.  
Another possibility for the different findings between ours and the Arias-Salgado groups is 
differences in experimental protocols. 
Better understanding the functional role of PTP-1B in platelets will require identifying 
its substrates and interacting proteins.  Some of the known substrates expressed in platelets 
are Src and the adaptor protein Dok-1, which is also involved in regulating outside-in integrin 
αIIbβ3 signalling (Calderwood et al. 2003).  Another important question that needs to be 
addressed is how PTP-1B translocates from the outer surface of the ER to the plasma 
membrane following caplain-mediated cleavage.  Further, how does PTP-1B dock to or near 
GPVI and αIIbβ3?  One hypothesis is that Dok-1 and -2 may mediate docking of PTP-1B to 
the β3-subunit (Arias-Salgado et al. 2005).  Recent work has demonstrated that PTP-1B is 
targeted to newly formed cell-matrix adhesion complexes (Hernandez et al. 2006).  Live cell 
imaging has also been used to investigate trafficking of PTP-1B to the plasma membrane 
(Yudushkin et al. 2007). 
Although structurally similar, TC-PTP and PTP-1B have distinct physiological 
functions, as knockout mouse models exhibit dramatically different phenotypes (You-Ten et 
al. 1997; Elchebly et al. 1999; Doody et al. 2009).  PTP-1B-deficient mice live to adulthood, 
but have dramatic glucose and fat metabolism defects, whereas TC-PTP-deficient mice die 3 
– 5 weeks after birth of erythropoietic and lymphopoietic deficits, indicating a critical role for 
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TC-PTP in bone marrow maturation (You-Ten et al. 1997).  The two phosphatases have also 
been implicated in regulating different components of the insulin signalling pathway (Dube et 
al. 2005). 
Our hypothesis that TC-PTP compensates for the lack of PTP-1B or CD148 in 
platelets does not appear to be correct.  Preliminary findings presented in this chapter suggest 
that TC-PTP plays a role in platelet formation, which correlates with other haematopoietic 
defects previously reported in TC-PTP-deficient mice (Doody et al. 2009).  Our flow 
cytometry data demonstrated that platelets isolated from these mice were unresponsive to 
CRP and thrombin agonists.  The reduced responsiveness to CRP is likely due to the very low 
levels of GPVI expressed in TC-PTP-deficient platelets.  Interestingly, αIIbβ3 levels were 
normal in mutant platelets, demonstrating that TC-PTP does not regulate expression of all 
surface proteins.  The lack of GPVI expression may be due to a defective in development, 
trafficking or shedding. 
  In summary, PTP-1B plays little role GPVI or integrin αIIbβ3 signalling in platelets, 
that is influenced by modifier loci.  PTP-1B has little or no role in regulating SFK activity in 
resting or activated platelets, whereas CD148 is a global regulator of SFK activity in platelets.  
TC-PTP and PTP-1B also appear to have fundamentally different roles in platelets.  One of 
the main functions of TC-PTP appears to be in platelet development.  Interestingly, CD148, 
PTP-1B and TC-PTP all positively regulate surface expression of GPVI on platelets however, 
we suspect this is through different mechanisms. 
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8.1  Summary of findings 
The main objective of this thesis was to investigate the functional role of CD148 in platelets.  
Findings from this thesis establish CD148 as a key regulator of platelet responsiveness to 
collagen and fibrinogen.  I also demonstrate that CD148 plays a minor role in regulating 
platelet responsiveness to thrombin and TxA2.  We believe the molecular mechanism 
underlying how CD148 regulates platelet responsiveness to such a diverse array of agonists is 
through regulation of SFK activity.  We demonstrate that CD148 is a global regulator of SFKs 
in platelets, maintaining a pool of primed/active SFKs in resting platelets.  Subsequent ligand 
mediated cross-linking of the collagen activation receptor GPVI and the fibrinogen receptor 
αIIbβ3 triggers receptor signalling.  Although no other RPTPs were identified in platelets, I 
identified the non-transmembrane TC-PTP in platelets for the first time and work was 
initiated to investigate functional redundancy between CD148, PTP-1B and TC-PTP in 
platelets.  I focused on PTP-1B as recent work by the Shattil group demonstrated that that 
PTP-1B is essential for activating Src kinase specifically downstream of the integrin αIIbβ3 
(Obergfell et al. 2002; Arias-Salgado et al. 2003; Arias-Salgado et al. 2005).  However, my 
results demonstrate that unlike CD148, PTP-1B does not maintain a pool of active SFKs in 
platelets and it is not involved in initiating GPVI or integrin αIIbβ3 signalling in platelets.  
PTP-1B plays a minor role relative to CD148 in regulating GPVI-mediated platelet 
aggregation and secretion, and αIIbβ3 signalling, however these functions are strain-
dependent, suggesting that modifier loci influence its activity.  We speculate that the 
discrepancies between our findings and those of the Shattil group are due to strain variation of 
PTP-1B-deficient mouse models.  TC-PTP appears to play a developmental role in platelets.  
Therefore, I conclude that CD148, PTP-1B and TC-PTP have distinct functional roles in 
platelets. 
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8.2 Functional roles of CD148 in platelets 
In this thesis, I demonstrated that CD148 positively regulates several important platelet 
functional responses, including aggregation, secretion and spreading.  The most dramatic 
defects observed in CD148-deficient platelets were downstream of GPVI and the integrin 
αIIbβ3, both of which are tyrosine kinase-linked receptors.  Minor defects were also detected 
to thrombin and TxA2, which signal through the G protein-coupled receptors PAR-4 and TP 
in mouse platelets, respectively.  ADP-mediated responses were however normal. 
 Platelet aggregation and ATP secretion of CD148-deficient platelets were abolished to 
the GPVI-specific agonist CRP at the concentrations tested.  Platelet spreading on collagen 
was also attenuated, as was platelet adhesion to collagen under physiological flow conditions 
(Senis et al. 2009).  These defects cannot be explained by reduced GPVI expression alone as 
FcR γ-chain heterozygous-deficient platelets, which express comparable levels of GPVI to 
CD148-deficient platelets, respond better to CRP and collagen (Senis et al. 2009).  This result 
provided strong evidence that CD148-deficient platelets had a concomitant signalling defect.  
The reduction in surface levels of GPVI may be due to a reduction in expression, reduced 
trafficking or enhanced shedding from the platelet surface.  This change in surface expression 
appeared to be specific to GPVI, as α2β1 and αIIbβ3 levels were normal (Senis et al. 2009). 
 Platelet adhesion and spreading on fibrinogen is mediate by the integrin αIIbβ3.  The 
molecular mechanism involves αIIbβ3 clustering, leading to outside-in integrin signalling 
(Shattil et al. 2004).  Platelets placed on a fibrinogen-coated surface initially extend filopodia, 
which become firmly attached to the fibrinogen.  The spaces between filopodia subsequently 
fill in with lamellipodia.  CD148-deficient platelets took longer and extended fewer filopodia 
than WT platelets (Senis et al. 2009).  Moreover, filopodia did not remain firmly attached to 
the surface, compared with WT platelets.  As a result, CD148-deficient platelets could not 
maintain filopodia extensions, and therefore did not form lamellipodia that WT platelets 
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eventually partially developed on fibrinogen (Senis et al. 2009).  Since CD148-deficient 
platelets expressed normal levels of αIIbβ3 on their surface, these findings suggested that 
outside-in integrin αIIbβ3 signalling was abrogated. 
 The defects described above in CD148-deficient platelets contribute to a mild bleeding 
tendency, delayed thrombus formation and thrombus instability in vivo (Senis et al. 2009).  
These findings demonstrate a novel and vital role of CD148 in mediating haemostasis and 
thrombus formation in vivo (Senis et al. 2009).  However, it should be noted that because 
CD148 is also expressed in endothelial cells, these defects may be partly due to defective 
endothelial cell function.  The lack of evidence for a severe bleeding disorder in CD148 
mutant mice makes it a potentially promising anti-thrombotic drug target.  Structural and 
functional features of CD148 also lend it to drug targeting, including its large extracellular 
domain that could be targeted by small molecule inhibitors without the need to cross the 
plasma membrane. 
 
8.3  CD148 regulates global SFK activity in platelets 
SFKs are essential for initiating and propagating signalling from several major platelet 
tyrosine kinase-linked receptors.  They also contribute to signalling downstream of a number 
of stimulatory GPCRs (Harper et al. 2006; Minuz et al. 2006).  SFK activity is tightly 
regulated by tyrosine phosphorylation and two intramolecular interactions, that maintain the 
kinases in an inactive conformation (Xu et al. 1997; Xu et al. 1999).  These weak interactions 
can be disrupted through inter-molecular interactions or by dephosphorylation of the 
inhibitory site of SFKs.  One of the main findings of this thesis was that global SFK activity, 
as detected using phospho-specific antibodies, was significantly reduced in both resting and 
activated CD148-deficient platelets compared with WT platelets.  We hypothesize that the 
pool of active SFKs in resting WT platelets is required to initiate a rapid and maximal 
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response following contact with ECM proteins at a site of vessel injury.  Without this pool of 
active SFKs, clustering of GPVI and αIIbβ3 does not trigger sufficiently rapid or strong 
activatory signals (Figure 8.1).  This model would predict that there is a small amount of basal 
signalling from GPVI and αIIbβ3 receptors in resting WT platelets. Recent work 
demonstrates that this is the case for GPVI signalling (Mori et al. 2008).  Residual signalling 
from GPVI and αIIbβ3 in CD148-deficient platelets may be due to other PTPs compensating 
in the absence of CD148 or to activation of SFKs through inter-molecular interactions with 
proline-rich and phosphotyrosine-containing proteins.   
We believe the global reduction in SFK activity in CD148-deficient platelets also 
explains the reduced responsiveness of CD148-deficient platelets to thrombin and TxA2.  This 
is because both the PAR-4 and TP receptors have a minor Src signalling component 
(Offermanns 2006).  We speculate the reason for the normal ADP response of CD148-
deficient platelets is because ADP signals through two receptors one of which has no SFK 
component.  The Gq-coupled P2Y1 receptor, is responsible for shape change and initiation of 
aggregation and has a small SFK component; whereas the Gi-coupled P2Y12 receptor, which 
is required for sustain platelet aggregation does not signal through SFKs (Gachet 2006).  I 
also demonstrate that the normal ADP response partially masks the reduced collagen 
responsiveness of CD148-deficient platelets.  
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Figure 8.1: CD148 maintains a pool of active SFKs in platelets that are essential for 
initiating GPVI signalling. (A) SFKs are maintained in a primed/active state by 
dephosphorylation of their inhibitory C-terminal tyrosine (Y1) by CD148. SFKs then become 
fully active by trans-autophosphorylation of the tyrosine residue in the active loop (Y2). (B) 
The pool of activated SFKs is required to initiate a strong activatory signal following GPVI 
clustering. This model also holds true for αIIbβ3 signalling. 
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Findings from this study support the hypothesis that SFKs are direct substrates of 
CD148 (Senis et al. 2009).  Here I show that CD148 interacts with and dephosphorylates both 
the activation and inhibitory sites of Fyn, Lyn and Src.  Interestingly, the in vitro data 
demonstrates that recombinant CD148 marginally favours dephosphorylating the activation 
sites of Fyn, Lyn and Src rather than their inhibitory sites.  Of the three inhibitory site 
phospho-peptides tested, CD148 had a marginal preference for the Lyn-derived phospho-
peptide.  These in vitro findings appear paradoxical to our platelet findings as the net effect of 
deleting CD148 from platelets reduces responsiveness to collagen and fibrinogen.  To unify 
these findings, we hypothesize that CD148 initially activates SFKs, by dephosphorylating 
their C-terminal inhibitory tyrosine and subsequently attenuates their activity by 
dephosphorylating their activation loop tyrosine.  In this way, CD148 both positively and 
negatively regulates SFK activity.  Co-ordinated increased phosphorylation of the inhibitory 
sites of SFK, by Csk or its related kinase Ctk/Chk, effectively inhibit prolonged SFK-
mediated signalling.  The proposed model is illustrated in Figure 8.2.  CD45 is thought to 
regulate Lck and Fyn downstream of the TCR via a similar mechanism (Hermiston et al. 
2003).  Therefore, the activation status of SFKs is tightly regulated by the opposing activities 
of CD148 and Csk. 
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Figure 8.2: Model of how CD148 modulates SFK activity. CD148 initially activates SFKs, 
by dephosphorylating their C-terminal inhibitory tyrosine (Y1) (left of figure) and 
subsequently attenuates their activity by dephosphorylating their activation loop tyrosine (Y2) 
(right of figure). Co-ordinated increased phosphorylation of the inhibitory sites of SFK, by 
Csk or its related kinase Ctk/Chk, effectively inhibit prolonged SFK-mediated signalling . 
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8.4 Physiological substrates of CD148 in platelets 
Other potential physiological substrates of CD148 include: the tyrosine kinase-linked 
receptors Met and PDGFβ, the adapter proteins LAT and Gab1, the adherens junction protein 
p120catenin, PLCγ1 and more recently the p85 subunit of PI 3-kinase, although the latter is 
not tyrosine phosphorylated in platelets (Gibbins et al. 1998; Kovalenko et al. 2000; Baker et 
al. 2001; Holsinger et al. 2002; Palka et al. 2003; Tsuboi et al. 2008).  Interestingly, LAT, 
PLCγ1 and PI 3-kinase all lie downstream of SFKs in the GPVI signalling cascade, therefore 
CD148 may be regulating multiple points of the GPVI signalling pathway (Pasquet et al. 
1999; Pasquet et al. 1999; Suzuki-Inoue et al. 2003; Watanabe et al. 2003). 
Using a substrate trapping-pull down approach in conjunction with mass spectrometry, 
protein bands with molecular weights of 160, 90, 60 and 43 (doublet) kDa were isolated from 
pervanadate stimulated platelet lysates.  Identification of proteins in the broad band at 90 kDa 
was complicated by the co-migrating recombinant MBP-CD148 fusion protein.  The intensity 
and large size of this band may be due to several, highly phosphorylated, co-migrating 
proteins.  It may also be due to the MBP-CD148 trapping mutant being hyper-phosphorylated 
by trapped SFKs.  We suspect the 60 kDa band may be SFKs.  The 43 kDa band was 
particularly prominent and warrants further investigation. 
The identity of the 160 kDa protein pulled down from platelet lysate with the MBP-
CD148 trapping mutant was determined to be non-muscle myosin heavy chain IIa (Swiss-Prot 
no: P35579), whereas the 60 and 43 kDa bands remain unknown.  Non-muscle myosin heavy 
chain IIa is a novel and unexpected candidate substrate that requires further validation by 
other means.  It was recently shown to be phosphorylated at Tyr-754 and Tyr-1,408, however, 
the functional consequences of phosphorylating these sites is not known (Rikova et al. 2007).  
Interestingly, the latter of these tyrosine residues is within a consensus ITIM, what has been 
shown to bind Shp1 (Baba et al. 2003).  Indentifying non-muscle myosin heavy chain IIa as a 
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potential substrate of CD148 is an interesting finding as defects in the gene encoding this 
protein, namely MYH9, cause May-Hegglin anomaly, characterized by thrombocytopenia, 
giant platelets (Chen et al. 2007; Althaus et al. 2009). 
 
8.5  Regulation of CD148 activity 
Regulation of CD148 activity and localization in the platelet plasma membrane are now 
critical to understanding how CD148 regulates platelet function.  A question that arises from 
our proposed mechanism is how ~2,800 copies of CD148 molecules can maintain the entire 
platelet pool of SFKs in an active conformation.  We believe the explanation partly lies in the 
high catalytic activity of PTPs, which have kcat values up to three orders of magnitude greater 
than those of protein tyrosine kinases (Zhang 2003).  We also hypothesize that expression of 
low levels of CD148 relative to SFKs may serve to have more of an activatory role rather than 
an inhibitory role.  This hypothesis is largely based on recent work by McNeill et. al. 
investigating the effects of expressing various amounts of CD45 in transgenic mice  (McNeill 
et al. 2007).  They showed that expression of a low amount of CD45 (3 – 10%) is required to 
dephosphorylate the inhibitory site of Lck (Tyr-505) and allow T cell receptor signalling to 
occur.  Conversely, expression of higher levels of CD45, as seen in wild-type T cells are 
required to attenuate TCR signalling by dephosphorylating the activation loop tyrosine of Lck 
(Tyr-394).  It has also been suggested that net activation of an SFK by CD45 and other RPTPs 
requires a degree of separation between the RPTP and the SFK to promote dephosphorylation 
of the C-terminal tail whilst simultaneously allowing autophosphorylation of the activation 
loop tyrosine (Roach et al. 1997; Thomas et al. 1999; Johnson et al. 2000). Conversely, a high 
amount of a RPTP or close proximity to a SFK will have a net inhibitory effect on SFK 
activity by dephosphorylating the activation loop tyrosine.  The fact that CD148 is membrane 
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localised and has a relatively low copy number in platelets may explain why it has a positive 
regulatory role on SFKs rather than an inhibitory one. 
The ligand for CD148 is presently not known.  Very few ligands for RPTPs have been 
identified to date.  The most well established ligands for RPTPs are quite diverse and include: 
homophilic interactions of RPTPµ, pleitrophin for PTPλ and heparin sulphate and collagen 
for RPTPσ (Maeda et al. 1998; Aricescu et al. 2002; Sajnani-Perez et al. 2003; Ulbricht et al. 
2003; Fox et al. 2005).  The first study of CD148 demonstrated that cell-cell contact causes an 
increase in its surface expression and activity, suggesting that its ligand may be a counter 
receptor on an adjacent cell (Ostman et al. 1994).  Another report suggested that its ligand 
may be an extracellular matrix protein.  Sorby et. al. demonstrated that cells ectopically 
expressing CD148 exhibited increased CD148 catalytic activity when placed on Matrigel 
(Sorby et al. 2001).  This hypothesis is supported by the fact that the extracellular domain of 
CD148 contains eight fibronectin type III repeats found in a variety of receptors and 
extracellular matrix proteins.  An Arg-Gly-Asp (RGD) module within the FNIII domain 
conveys cell adhesion properties to proteins (Main et al. 1992).  A recent biophysical study by 
Matozo et. al. suggests that dimerization of CD148 catalytic domains would auto-inhibit, 
according to the inhibitory wedge model defined in PTPα (Matozo et al. 2006).  However, a 
recent large-scale structural study of all classical PTP catalytic domains argues strongly 
against the long-held inhibitory wedge model (Barr et al. 2009).  Another possibility is that 
CD148 does not have a ligand, but rather moves freely about the cell surface due to 
electrostatic forces or steric hindrance according to the size-exclusion model (Lin et al. 2003; 
Choudhuri et al. 2005).  This can be tested in a cell line model using mutant forms of CD148 
lacking specific regions of the extracellular domain or containing point mutations disrupting 
glycosylation sites. 
 
Chapter 8  General Discussion 
214 
8.6  Redundancy between CD148 and other platelet PTPs 
Residual GPVI and αIIbβ3 signalling in CD148-deficient platelets raises the possibility that 
one or more PTPs partially compensating in its absence.  Attempts to identify other RPTPs 
expressed in platelets were either negative or inconclusive.  Recent evidence suggests that 
megakaryocytes express low levels of CD45; PTPRO is expressed in human and mouse 
megakaryocytes; and RPTPσ may be expressed in human platelets (Taniguchi et al. 1999; 
Matsumura-Takeda et al. 2007; Senis et al. 2007).  However, I could neither detect CD45 in 
human and mouse platelets nor conclusively demonstrate expression of PTPRO and RPTPσ 
on human and mouse platelets.  This may be due to low levels of expression of these RPTPs 
in platelets, as well as questionable quality of the antibodies used for detection. 
Since I did not conclusively detect another RPTP in platelets, as is the case in most 
other haematopoietic cell lines that express CD45 and CD148 (with the exception of 
erythrocytes), we speculated that perhaps a non-transmembrane PTP may have redundant 
functions with CD148 in platelets.  The primary candidate was PTP-1B as recent evidence 
showed that PTP-1B dephosphorylates and activates Src downstream of αIIbβ3 (Obergfell et 
al. 2002; Arias-Salgado et al. 2003; Arias-Salgado et al. 2005).  Other candidates include the 
SH2 domain-containing PTPs, Shp1 and Shp2, as they have been previously shown to 
regulate proximal ITAM receptor signalling events in immune cells (Shi et al. 2000; Zhang et 
al. 2000).  Shp1 has also been shown to interact with Src in platelets and to positively regulate 
Src activation by preferentially dephosphorylating inhibitory Tyr-529 (Somani et al. 1997). 
 Findings presented in this thesis demonstrate that CD148 and PTP-1B have distinct 
functions in platelets.  CD148 is essential for maintaining a pool of active SFKs in platelets, 
whereas PTP-1B plays little or no role in activating SFKs in resting or activated platelets.  
This may be due to redundancy with another PTP.  We suspect the reason for the discrepancy 
between our findings and those of the Shattil group, regarding the function of PTP-1B in 
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GPVI and αIIbβ3 signalling, is strain variation of the mouse models.  Another possibility is 
that another phosphatase compensates in the absence of PTP-1B, which is why we 
investigated TC-PTP in platelets.  Although structurally similar, TC-PTP and PTP-1B appear 
to have distinct functional roles in platelets.  Severely reduced platelet counts and GPVI 
expression in platelets from TC-PTP-deficient mice suggest that TC-PTP may be involved in 
platelet development (You-Ten et al. 1997).  Collectively, these findings demonstrate that 
PTPs have distinct functional roles in platelets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Appendix 
243 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Confirmation of MBP.CD148 fusion protein expression  
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